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ABSTRACT
Methionine is a glutathione precursor and has been shown to be
effective in preventing liver damage after paracetamol overdosage.
Sterling Winthrop have linked paracetamol and N-acetyl-D-L-methionine
as the N-acetyl-D-L-methionine ester of paracetamol in an attempt to
make a safer form of paracetamol. As part of this compound's
development the disposition of paracetamol N-acetyl-D-L-methionate
was studied firstly in healthy subjects and then in patients with
chronic renal failure. Each study was conducted as a double blind
crossover clinical trial where each volunteer received 1 g of an
effervescent formulation of paracetamol as (1) paracetamol (1 g) and
(2) paracetamol N-acetyl-D-L-methionate (2.146 g).
Existing HPLC methods for measurement of paracetamol and its metabo¬
lites in plasma and urine were validated and used. In addition, a
method was developed for measurement of paracetamol N-acetyl-D-L-
methionate in plasma using solid phase extraction and analysis by
HPLC with u.v. detection. Using these methods the stability of
paracetamol N-acetyl-D-L-methionate was determined and the rate of
hydrolysis in aqueous samples was shown to be accelerated as pH and
temperature increased. The rate of hydrolysis in plasma and whole
blood at 37°C was much greater, particularly in whole blood.
Following administration of 1 g of paracetamol to healthy subjects,
paracetamol was rapidly absorbed, distributed and extensively metabo¬
lised. The major metabolites were the glucuronide and sulphate con¬
jugates of paracetamol with the capacity for sulphation probably
reduced because of saturation of the pathway. A minor fraction of
the dose was metabolised to a reactive intermediate which was then
conjugated with glutathione and metabolised to form the cysteine and
mercapturic acid conjugates of paracetamol. Elimination of paraceta¬
mol was consistent with glomerular filtration and passive reabsorp-
tion of paracetamol and active secretion of the sulphate and glucur-
onide conjugates. The total 24 h urinary recovery of paracetamol was
essentially complete. This group provided control data consistent
with other reports in the literature.
Following administration of 2.146 g of paracetamol N-acetyl-D-L-
methionate to healthy subjects the parent compound was rapidly hydro-
lysed by ubiquitous esterases and the peak plasma paracetamol concen¬
tration was reduced and delayed. There was a corresponding delay in
the appearance of paracetamol metabolites. The relative bioavaila¬
bility of paracetamol however, was not altered and paracetamol
absorption was essentially complete following administration of para¬
cetamol in this form. The extent of paracetamol metabolism was the
same as that obtained after administration of paracetamol alone and
the amount recovered in urine as the glutathione derived conjugates
was not increased even although methionine is a glutathione precur¬
sor. Sulphate conjugation was however significantly increased
following administration of paracetamol N-acetyl-D-L-methionate.
This may be explained by methionine providing a source of inorganic
sulphate thus preventing its depletion or alternatively that the
paracetamol sulphate pathway was less readily saturated as paraceta¬
mol was released more slowly. The increase in sulphate conjugation
was at the expense of glucuronide conjugation. Elimination of
paracetamol and its metabolites was not altered following administra¬
tion of paracetamol N-acetyl-D-L-methionate.
Following administration of 1 g of paracetamol to 7 non-dialysis and
5 haemodialysis patients with chronic renal failure absorption of
paracetamol was normal, however, there was gross cumulation of meta¬
bolites and the late elimination phase of the parent compound was
also impaired compared to healthy subjects. Elimination of metabo¬
lites in the haemodialysis patients was negligible. Cysteine and
mercapturic acid conjugates of paracetamol were present at low con¬
centrations in plasma and were eliminated at similar rates in the
non-dialysis patients. In the haemodialysis patients elimination of
mercapturic acid was negligible, whereas cysteine concentrations
decreased over the period 8-24 h. The cysteine conjugate was, there¬
fore, removed by a route other than urinary excretion. It may be
that at the high metabolite concentrations attained in renal failure
patients, the cysteine conjugate and possibly the other metabolites
of paracetamol may undergo limited enterohepatic circulation with
subsequent reabsorption of the parent compound, thus explaining the
abnormal late elimination phase of paracetamol. Nietabolism of para¬
cetamol, however, was not altered in patients with chronic renal
failure with the fractional urinary recovery of paracetamol and its
metabolites in non-dialysis patients similar to that obtained in
healthy subjects. The capacity for active tubular transport was
reduced to a greater extent than passive reabsorption and the total
24 h urinary recovery of paracetamol was reduced in the non-dialysis
patients. On long term paracetamol therapy plasma paracetamol con¬
centrations would probably be higher than in the present study and
there would be gross cumulation of paracetamol metabolites. Multiple
dose studies, therefore, require to be performed.
Following on, the disposition of paracetamol N-acetyl-D-L-methionate
in patients with chronic renal failure was compared with the disposi¬
tion of paracetamol administered alone to the same renal failure
patients. The appearance of paracetamol was delayed and the peak
plasma paracetamol concentrations reduced following administration of
paracetamol N-acetyl-D-L-methionate. All other pharmacokinetic vari¬
ables for paracetamol N-acetyl-D-L-methionate were, however, not
significantly different from those obtained after administration of
paracetamol alone to the same patients. Therefore, the relative
bioavailability, metabolism and elimination of paracetamol adminis¬
tered in this form were not altered in patients with chronic renal
failure. In particular the portion of the dose metabolised to form
the cysteine and mercapturic acid conjugates remained unchanged.
Unlike in healthy subjects, sulphate conjugation was not increased
following administration of paracetamol N-acetyl-D-L-methionate in
non-dialysis patients. As inorganic sulphate is retained in these
patients it is probable that depletion of inorganic sulphate
following administration of paracetamol alone was prevented, thus
avoiding saturation of the sulphate pathway.
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In the late 19th century, the antipyretic properties of aniline deri¬
vatives were investigated following the chance discovery that aceta-
nilide lowered body temperature in patients with fever. Acetanilide










It is probable that paracetamol was first used clinically in 1893 by
von Mering (Smith, 1958). At this time, however, paracetamol was not
considered a suitable substitute for acetanilide or phenacetin. The
observation that acetanilide and phenacetin also had analgesic
properties resulted in their use continuing well into the 20th
century.
It was investigation into the metabolic fate of acetanilide and
phenacetin by Brodie and Axel rod in the late 1940's that brought
about the re-emergence of paracetamol. These investigations showed
that acetanilide (Brodie and Axelrod, 1948) and phenacetin (Brodie
and Axelrod, 1949) were both predominantly metabolised to paracetamol
and excreted in conjugated form in man. At the same time, parace¬
tamol was shown to have similar analgesic potency to acetanilide
(Flinn and Brodie, 1948). It was therefore concluded that the anti¬
pyretic and analgesic properties of acetanilide and phenacetin were
mainly due to their conversion to paracetamol. A further advantage
of paracetamol was that unlike acetanilide and phenacetin, it did not
cause methaemoglobinemia.
Paracetamol was marketed in Great Britain in 1956. Acceptance was
initially slow and in 1963 it was included in the British Pharmaco¬
poeia. Clinical studies showed paracetamol to be well tolerated with
antipyretic and analgesic activities similar to aspirin (Beaver,
1965).
Since 1963, there has been a marked increase in the use of parace¬
tamol with a corresponding decline in the use of aspirin (Spooner
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and Harvey, 1976). In April 1985, paracetamol was included in the
limited list of analgesics for mild to moderate pain drawn up by the
Department of Health.
Paracetamol is a very safe and effective antipyretic and analgesic
agent when taken in therapeutic doses. When taken in overdose,
however, paracetamol can cause severe and occasionally fatal liver
damage. The first cases of liver damage caused by paracetamol
overdosage were reported more than 20 years ago (Davidson and
Eastham, 1966; Thomson and Prescott, 1966). With the increasing
availability of paracetamol, further reports were soon to follow.
The mechanism by which paracetamol causes hepatotoxicity was dis¬
covered by Mitchell and his colleagues (Jollow et al, 1973; Mitchell
et al, 1973 a; b; Potter et al, 1973). A minor proportion of a dose
of paracetamol is converted to a reactive intermediate by cytochrome
P-450 mixed function oxidase. The reactive intermediate is then
conjugated with glutathione and excreted in the urine as cysteine and
mercapturic acid conjugates. In overdose, however, glutathione
becomes depleted and the reactive metabolite is free to covalently
bind to the vital hepatic macromolecules causing cell death.
The results of Mitchell's work provided a rational approach to the
treatment of paracetamol toxicity. Prescott and Critchley (1983)
have reviewed the treatment of paracetamol poisoning and described
the successful use of glutathione precursors and other sulphydryl
compounds.
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Chemical data for paracetamol are shown in Appendix 1.1.
b) Pharmacology
Paracetamol is a well tolerated mild analgesic and antipyretic in
both adults and children with only weak anti-inflammatory properties
(Beaver, 1965). It is particularly suited for the relief of moderate
pain intensity such as headache, musculoskeletal pain and dysmenorhea
(British National Formulary, 1989).
Algesia, pyrexia and inflammation are thought to be mediated by
prostaglandins, and it is the ability of antipyretic analgesics to
inhibit prostaglandin biosynthesis that gives them their effect.
Different pharmacological potencies and properties within the anti¬
pyretic analgesic drug group may be explained by the prostaglandin
producing enzyme systems from different tissues, possessing different
sensitivities towards these drugs (Ferreira and Vane, 1974; Flower,
1974).
Although this explanation may provide part of the answer, the
mechanisms that cause pain, fever and inflammation are not fully
understood, nor are the pharmacological actions of any of the anti¬
pyretic analgesics. This area of research is therefore inconclusive
with a great number of conflicting publications appearing in the
literature. This is particularly the case for aniline derivatives
(Brune, 1983). The pharmacological properties and efficacy of
paracetamol are, therefore, more easily assessed through clinical
trials.
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Studies assessing the analgesic efficacy of paracetamol have been
reviewed (Beaver, 1965; Cooper, 1981; Mehlisch, 1983) and the overall
conclusion is that paracetamol is significantly better than placebo
and equianalgesic and equipotent to aspirin. Examples of investiga¬
tions substantiating these findings include studies in cancer pain
(Wallenstein and Houde, 1954) and oral surgery pain models (Cooper,
1981).
Studies of the efficacy of paracetamol and aspirin in lowering body
temperature have also been reviewed (Lovejoy, 1978). Compared to
placebo, paracetamol and aspirin demonstrate significant and similar
antipyretic effects. Temperature declined from 0.5 h following
paracetamol administration with a duration of action of approximately
3 h. Maximum reductions in temperature were in the order of 2.7%
(Colgan and Mintz, 1957) and 2.9% (Steele et al, 1972).
Paracetamol has little or no anti-inflammatory activity in the treat¬
ment of rheumatoid arthritis (Batterman and Grossman, 1955; Hajnal et
al, 1959). Paracetamol does, however, exhert anti-inflammatory
effects against post traumatic inflammation. Following surgical
removal of bilateral wisdom teeth, paracetamol reduced post operative
swelling on the third day by 29% compared to placebo in addition to
reducing local hyperpyrexia and pain (Skjelbred and Lokken, 1979). It
may be, therefore, that paracetamol has a clinical use for some types
of inflammation not associated with arthritis (Cooper, 1981).
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c) Absorption, Distribution, Metabolism and Excretion
Absorption: Paracetamol is usually taken orally and it is absorbed
from the upper gastro-intestinal tract by passive diffusion. Trans¬
port across the mucosal membrane is dependent on paracetamol being in
a lipid soluble, unionised state at physiological pH. It is a weak
organic acid (pKa 9.5), which is predominantly unionised in biologi¬
cal fluids and therefore available for gastro-intestinal absorption.
Other conditions such as mucosal blood supply and surface area may
also affect absorption (Prescott, 1974).
The primary sites of absorption have been investigated using animal
models (Weikel and Lish, 1959; Josting et al, 1976; Bagnal et al,
1979; Pang et al, 1986). Methodological differences and variable
physiological conditions have, however, led to variation in results.
It is probable that the gastro-intestinal tract is capable of absor¬
bing paracetamol over most of its length, but the upper small intes¬
tine is the optimum site and as much as 76% can be absorbed in 30 min
(Josting et al, 1976). These findings are supported by studies in
man where the rate of gastric emptying was shown to influence the
rate of absorption (Heading et al, 1973).
Paracetamol was administered orally as a solution to 8 healthy
subjects at a dose level of 20 mg.kg"1 following an overnight fast
(Prescott, 1980). Under these optimal conditions, absorption was
rapid with the mean peak plasma concentration at 30 min. Paracetamol
absorption may be greatly influenced by formulation and there is also
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considerable individual variation (McGilveray et al, 1971; Prescott,
1974; Ritcher and Smith, 1974; Ameer et al, 1983).
The effect of age, weight, sex, posture, drugs and disease on parace¬
tamol absorption has been reviewed (Forrest et al, 1983). The most
influential factor is the rate of gastric emptying. Food, drugs and
disease states which reduce gastric emptying consequently reduce the
rate of paracetamol absorption and vice versa, however, the total
amount absorbed is unaltered. Binding agents such as activated
charcoal and cholystyramine reduce the total amount of paracetamol
absorbed.
Distribution: Following absorption, paracetamol is rapidly distri¬
buted throughout most tissues and body fluids.
Two hours after the administration of 2.7 g of phenacetin to a dog,
paracetamol was more or less equally distributed between tissue water
and plasma water (Brodie and Axelrod, 1949). These results were
subsequently confirmed in a similar study where 5 dogs each received
300 mg.kg"1 of paracetamol orally (Gwilt et al, 1963). In neither
study was there an accumulation of paracetamol in any of the tissues
investigated. Low paracetamol concentrations were observed in fat
and cerebrospinal fluid and the mean whole blood to plasma ratio at
45 min was 1.06. There is no appreciable binding of paracetamol to
erythrocytes nor to plasma proteins at concentrations less than
60 ug.mr1. The extent of plasma protein binding at 280 pig.ml"1 was
15-21% (Gazzard etal, 1973). The glucuronide and sulphate
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conjugates of paracetamol also do not bind to plasma proteins
(Lowenthal et al, 1976).
Metabolism: Most drugs are primarily dependent on metabolism for
their elimination and are converted in the liver to polar metabolites
which are more readily excreted by the kidney.
A potential site for drug metabolism is the gastro-intestinal tract.
Intestinal metabolism of paracetamol has been observed in rats
(Josting et al, 1976; Pang et al, 1986) and man (Rogers et al, 1987).
Glucuronide and sulphate conjugates have been detected, but only in
insignificant quantities. In addition, following oral and intrave¬
nous administration of paracetamol in man, the percentage urinary
recovery of paracetamol and its metabolites was similar (Clements et
al, 1984). These findings suggest the gastro-intestinal tract is an
insignificant site for paracetamol metabolism.
From the small intestine, paracetamol passes to the systemic circu¬
lation via the portal vein and the liver. The oral bioavailability
of paracetamol in man is 70-80% (Rawlins et al, 1977; Perucca and
Richens, 1979; Clements et al, 1984). Quantitative urinary recov¬
eries and minimal intestinal metabolism indicate that bioavailability
is limited by first pass metabolism by the liver. The first pass
metabolism of paracetamol is said to be dose dependent (Rawlins et
al, 1977) with an oral bioavailability of 63% after 0.5 g and 89%
after 1.0 g. However, these findings have not been confirmed in more
recent studies (Clements etal, 1984).
10
The major route of paracetamol metabolism is by conjugation at the
hydroxyl group. Glucuronyl and sulphotransferases in the presence of
their uridine diphosphoglucuronic acid (UDPGA) and 31-phosphoadeno-
sine-5'-phosphosulphate (PAPS) cofactors form the glucuronide and
sulphate conjugates of paracetamol respectively. Unlike the glucur¬
onide pathway sulphate conjugation exhibits dose dependent saturation
within the therapeutic dose range (Prescott, 1984). In addition, the
capacity for sulphation is probably dependent on the availability of
inorganic sulphate (Levy, 1986) a precursor of PAPS.
A minor fraction of paracetamol is metabolised to form a reactive
intermediate metabolite which is probably N-acetyl-p-benzoquinone
imine (Miner and Kissinger, 1979; Dahlin et al, 1984). The exact
mechanism by which the intermediate is formed is unclear (Potter and
Hinson, 1986). It is normally recovered by conjugation with reduced
glutathione.
The ability to inactivate the intermediate by conjugation with
hepatic glutathione is dose dependent. Following overdosage,
glutathione becomes depleted leaving the reactive intermediate free
to bind to vital hepatic macromolecules causing cell death. With
therapeutic doses, however, glutathione deactivates the reactive
intermediate forming a paracetamol gluthathione conjugate (Mitchell
et al, 1973b, 1974; Potter et al, 1974). This is converted to the
cysteine conjugate of paracetamol by loss of glutamyl and glycine
moieties catalysed by glutamyl transferase and dipeptidase respec¬
tively. The cysteine conjugate may then be acetylated by N-acetyl
transferase to form the mercapturic acid conjugate of paracetamol.
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Other minor metabolites accounting for approximately IX of a thera¬
peutic dose have been identified in man. These include conjugates of
3-hydroxy and 3-methoxyparacetamol (Andrews et al, 1976) and 3-thio-
methylparacetamol (Klutch et al, 1978). Following overdosage, 3-
methoxyparacetamol has also been identified (Knox and Jurand, 1977,
1978).
After a therapeutic dose of paracetamol the 24 h urinary recovery is
about 85-95X in healthy subjects. The glucuronide, sulphate,
cysteine and mercapturic acid conjugates and parent compound account
for approximately 55, 30, 4, 4 and 4X respectively (Prescott, 1980).
The proposed metabolic pathway for paracetamol in man is shown in
Figure 1.1.
As indicated earlier, paracetamol metabolism is dose dependent. The
effect of dose on paracetamol metabolism has been demonstrated by
investigating the urinary metabolite profiles of overdose patients on
supportive therapy who did not develop severe liver damage. In this
group there was less sulphate and more glucuronide conjugation with
no significant change in the proportions of cysteine and mercapturic
acid conjugates produced compared to healthy subjects receiving
therapeutic doses. In a similar group of patients where severe liver
damage did develop, there was an increase in cysteine and mercaptu-
rate conjugation, reflecting an increased proportion of paracetamol
being converted to the toxic intermediate. This increase was at the
expense of glucuronide conjugation (Prescott, 1980, 1983; Forrest et
al, 1982).
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Paracetamol metabolism is also age dependent as young children less
able to conjugate phenolic drugs with glucuronic acid, compensate by
predominantly converting them to the sulphate conjugate (Levy et al,
1975; Notarianni et al, 1987).
In patients with severe liver disease receiving therapeutic doses of
paracetamol the plasma paracetamol to glucuronide and sulphate ratio
is greater than in healthy subjects. The 24 h urinary metabolite
profiles, however, were not significantly different from those
obtained from healthy subjects (Forrest et al, 1979). In patients
with Gilbert's Syndrome the ability to conjugate paracetamol with
glucuronic acid was impaired (Douglas et al, 1978). These findings,
however, have not been confirmed recently (Ullrich et al, 1987).
The influence of alcohol on paracetamol metabolism has been reviewed
(Seeff et al, 1986). Chronic and acute use of alcohol appears to
increase and decrease respectively the proportion of paracetamol
metabolised to the reactive intermediate.
Drugs which induce microsomal enzymes alter paracetamol metabolism.
Compared to healthy subjects, patients receiving anticonvulsants or
rifampicin exhibited enhanced glucuronide conjugation with no signi¬
ficant change in sulphate conjugation. Urinary excretion of cysteine
and mercapturic acid conjugates were similar in each group (Prescott
et al, 1981).
Inter-individual variation in paracetamol metabolism was greater than
intra-individual variation (Caldwell etal, 1980; Clements etal,
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1984). The contribution to inter-individual variation by sulphate
and glucuronide conjugation was much less than that of the cysteine
and mercapturic acid pathway (Critchley et al, 1986).
The influence of genetic factors on paracetamol metabolism has been
investigated in healthy twins. The data suggests that unidentified
environmental conditions account for inter-individual variations in
paracetamol metabolism, rather than genetic factors (Nash et al,
1984). The investigators, however, only concentrated on the sulphate
and glucuronide conjugation of paracetamol and omitted to consider
its conversion to the cysteine and mercapturic acid conjugates.
Ethnic studies of paracetamol metabolism have shown that the frac¬
tional recovery of the cysteine and mercapturic acid conjugates is
less in Africans than in Caucasians. This may be due to genetic or
environmental factors such as dietary differences, particularly
protein intake (Critchley et al, 1986).
Excretion: Paracetamol and its conjugates are excreted rapidly in
man. Unchanged drug appears to be filtered at the glomerulus
followed by passive reabsorption producing a low renal clearance
which is dependent on the urine flow rate. The renal clearance of
the conjugates of paracetamol is greater than the glomerular filtra¬
tion rate and independent of the urine flow rate indicating active
renal tubular secretion with negligible reabsorption. The excretion
of paracetamol and its conjugates is independent of urinary pH
(Prescott and Wright, 1973). These findings have also been observed
in the dog (Duggin and Mudge, 1975).
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The renal clearance of paracetamol sulphate has been shown to
decrease as plasma concentration increases and is, therefore, dose
dependent (Clements et al, 1984; Morris and Levy, 1984).
Investigation of the biliary excretion of paracetamol in man is
difficult. Following 1 g of oral paracetamol only the glucuronide
and cysteine conjugates representing 0.1 and 0.6$ of the dose respec¬
tively were recovered in bile after 12 h. This, however, represents
19.4$ of the total excretion of the cysteine conjugate. Taking into
account the limitations of the experiment the biliary recovery
reported is maybe an underestimate (Jayasinghe et al, 1986). Earlier
studies of the biliary excretion of paracetamol in man proved incon¬
clusive (Siegers et al, 1984).
d) Toxicity and Overdosage
As no preclinical toxicity studies were performed with paracetamol,
it was not until paracetamol had gained in popularity that its
hepatotoxic properties following acute overdosage were discovered.
Reports of paracetamol hepatotoxicity in cats (Eder, 1964) and rats
(Boyd and Bereczky, 1966) were soon followed by reports of severe and
fatal liver damage following paracetamol overdosage in man (Davidson
and Eastham, 1966; Thomson and Prescott, 1966). Since then the
incidence of paracetamol overdosage has gradually increased. In
Edinburgh the number of annual admissions to the Regional Poisoning
Treatment Centre increased from 15 in 1967 to a peak of 309 in 1979.
In 1983, 13$ of overdose admissions involved paracetamol (Prescott,
1983).
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The mechanism of paracetamol hepatotoxocity was discovered by
Mitchell and colleagues in 1973. Initial work in rats and mice
demonstrated that pretreatment with compounds which stimulated the
cytochrome P-450 mixed function oxidase system potentiated hepatic
necrosis, whereas pretreatment with inhibitors of this enzyme system
reduced liver necrosis. It was, therefore, proposed that necrosis
was mediated by a toxic metabolite and not by paracetamol itself
(Mitchell et al, 1973a). Further experiments using [^H]-paracetamol
demonstrated that necrosis was caused by covalent binding of a reac¬
tive intermediate metabolite to vital hepatic macromolecules and that
the degree of covalent binding was proportional to the severity of
necrosis (Jollow et al, 1973). In vitro studies confirmed the
covalent binding of a metabolite generated by cytochrome P-450 mixed
function oxidase to microsomal proteins (Potter et al_, 1973).
Finally, the fundamental role of glutathione in protecting against
paracetamol induced hepatic necrosis was demonstrated. Mice pre-
treated with diethylmaleate (which depletes hepatic glutathione)
potentiated hepatic necrosis, whereas treatment with cysteine, a
glutathione precursor, prevented hepatic damage. Administration of
paracetamol caused dose-dependent depletion of hepatic glutathione.
Furthermore, hepatic necrosis was potentiated by treatments which
depleted glutathione while treatments that maintained glutathione
concentrations protected against liver damage. Covalent binding of
the reactive metabolite did not occur until glutathione was depleted
by about 70? (Mitchell et al, 1973b). Marked species differences in
susceptibility to hepatotoxicity of paracetamol were correlated
directly with the extent of hepatic glutathione depletion (Davis
et al, 1974). The protective role of glutathione in man was
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confirmed where an increase in the urinary excretion of glutathione
derived metabolites was observed following increasing doses of para¬
cetamol. It was also estimated that approximately 10 to 15 g of
paracetamol would be required to deplete glutathione levels (Mitchell
et al, 1974) to a critical level. There is marked individual vari¬
ation in susceptibility to paracetamol toxicity in man (Prescott and
Critchley, 1983).
Following paracetamol overdosage, consciousness is not impaired and
there are no specific symptoms apart from nausea and vomitting. How¬
ever, from 24-36 h there may be abdominal pain and hepatic tenderness
which persists for 2 to 3 days (Prescott, 1983). It is not until 12
to 36 h after ingestion that biochemical evidence of acute hepatic
injury becomes apparent. This is characterised by gross elevation of
plasma aspartate and alanine aminotransferase (AST and ALT), mild
hyperbilirubenemia and a prolonged prothrombin time (Proudfoot and
Wright, 1970; Prescott et al, 1971; Clark et al, 1973a). In patients
who recover, liver function returns to normal within 7 to 20 days.
Severely poisoned patients may develop hepatic failure on the third
to sixth day with deepening jaundice, deterioration of consciousness
which is often followed by death (Canalese et al, 1981). Liver
biopsies and post mortem studies reveal extensive centrilobular
hepatic necrosis with little or no inflammatory reaction (Davidson
and Eastham, 1966; Clark et al, 1973b; James et al, 1975; Portmann et
al, 1975). Other complications of severe paracetamol overdosage
include haematological abnormalities, renal failure, pancreatitis and
cardiotoxicity. These have been reviewed in detail (Prescott,
1983).
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Initial clinical assessment of the severity of paracetamol poisoning
is difficult as there are no early symptoms and no reliance can be
placed on the number of tablets claimed to be taken by the patient
(Prescott, 1978). The most reliable early indication of liver damage
is probably prolongation of the plasma paracetamol elimination half
life. Hepatic damage is to be expected if the half life exceeds 4 h
(Prescott et al, 1971). However, it is not practicable to measure
the half life therefore a 'treatment line1 joining a semi logarithmic
plot of 200 mg.litre"1 at 4 h to 30 mg.litre"1 at 15 h is used as an
index of the severity of poisoning. Severe liver damage as defined
by plasma AST or ALT activity exceeding 1000 U.litre"1 occurs in about
60% of patients with plasma paracetamol concentrations above this
line. Patients with plasma paracetamol concentrations below this
line are unlikely to develop liver damage. Patients with plasma
concentrations above a similar parallel line joining 300 mg.litre"1 at
4 h and 45 mg.litre"1 at 15 h are at high risk with a 90% chance of
severe liver damage. Values obtained earlier than 4 h after inges¬
tion are unreliable as absorption may still be continuing (Prescott,
1983).
Paracetamol absorption following overdosage may be reduced by gastric
lavage or induction of emesis within 4 h of ingestion. These
measures are indicated in patients suspected of ingesting 100 mg.kg"1
or more of paracetamol (Prescott, 1983). Activated charcoal or
cholestyramine may also reduce absorption of paracetamol if taken
within 1 h of ingestion (Dordoni et al, 1973). Haemoperfusion and
haemodialysis have no place in the treatment of paracetamol poisoning
(Prescott, 1983). Forced diuresis does not enhance paracetamol
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elimination and the renal clearance of paracetamol is independent of
urinary pH (Prescott and Wright, 1973).
Mitchell's work provided a rational approach to the treatment of
paracetamol toxicity. As glutathione itself does not penetrate
hepatocytes it was proposed that administration of sulphydryl
compounds which are glutathione precursors may protect against
paracetamol toxicity (Mitchell et al, 1974). Successful treatment of
severe paracetamol overdosage with intravenous cysteamine was first
described in 1974 (Prescott et al). Further reports of successful
treatment using cysteamine followed (Hughes et al, 1976; James, 1976;
Prescott et al, 1976; Hamlyn et al, 1981). The mechanism by which
cysteamine acts is by preventing hepatic glutathione depletion and
possibly inhibition of the metabolic activation of paracetamol
(Buckpitt et a_U 1979). Unfortunately cysteamine also produces
unpleasant gastro-intestinal and central nervous system side effects
therefore alternative treatments were sought.
Orally methionine is also effective and it has no serious side
effects (Crome et al, 1976; Hamlyn et al, 1981; Vale et al, 1981).
Its use for the treatment of paracetamol toxicity will be dealt with
in detail in Section 2 of this chapter.
N-Acetylcysteine is another sulphydryl compound which is effective in
animals (Piperno and Berssenbruegge, 1976) and its success in the
treatment of paracetamol poisoning in man was reported by Prescott et
al, 1977, 1979. N-Acetylcysteine administered within 10 h of
paracetamol ingestion as a total intravenous dose of 300 mg.kg"1 over
20
20 h is effective in preventing liver damage, renal failure and death
and it is currently the treatment of choice (Prescott, 1983; Prescott
and Critchley, 1983). There is no evidence that treatment beyond 15
h is beneficial and oral administration of N-acetylcysteine may be
unreliable as vomitting may impair its absorption (Prescott, 1981).
N-Acetylcysteine primarily protects by stimulating hepatic gluta¬
thione synthesis. It greatly increases the concentrations of circu¬
lating cysteine, but glutathione synthesis is not actually increased
unless the glutathione pool is stressed as would occur after parace¬
tamol overdosage (Burgunder et al, 1989). N-Acetylcysteine may also
conjugate directly with the reactive intermediate (Buckpitt et al,
1979) and stimulates sulphate conjugation (Prescott, 1980). These
latter actions however, are unlikely to be relevant to the protective
properties of N-acetylcysteine.
hi Id allergic reactions to N-acetyl cysteine have been reported and
these include mild skin manifestations and occasional bronchospasm
and hypotension. These reactions usually occur within 20-60 min
after starting the infusion (Walton et al, 1979; hant et al, 1984).
Dimercaptol and D-penicillanamine have little or no protective action





Paracetamol is a safe and effective analgesic and antipyretic agent
when taken in therapeutic doses. When taken in overdose, however,
paracetamol can cause severe and occasionally fatal liver damage.
Treatment of paracetamol poisoning with sulphydryl compounds and
glutathione precursors is very effective if these are administered
within 10 h of ingestion (Prescott and Critchley, 1983).
One such treatment is 2.5 g of oral methionine repeated at 4 h
intervals up to a total dose of 10 g. This regime has been shown to
be effective in preventing severe liver damage and death after
paracetamol overdosage with no serious side effects (Crome et al,
1976; Hamyln et al, 1981; Vale et al, 1981). Methionine adminis¬
tered intravenously or as a large oral dose may cause nausea and
vomitting. Following intravenous administration drowsiness and
irritability may also be encountered. Possible interactions include
the reversal of levodopa effectiveness in parkinsonism and super¬
imposed symptoms of intoxication in schizophrenic patients being
treated with monoamine oxidase inhibitors (Martindale, 1982). The
observation that methionine may exacerbate existing liver disease
(Phear et al, 1956) is of particular importance as late administra¬
tion of methionine following paracetamol overdosage may be harmful.
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Methionine is a glutathione precursor as it is metabolised to
cysteine via the transsulphuration pathway (Cooper, 1983). Cysteine
is then incorporated into glutathione (Figure 1.2) enabling gluta¬
thione levels to be maintained following paracetamol overdosage
(Miners et al, 1984; Pratt and Ioannides, 1985; Warrander et al,
1985). This is probably the main mechanism by which methionine
exherts its protective effect as it does not bind directly to the
reactive intermediate of paracetamol (Buckpitt et al, 1979; Huggett
and Blair, 1983).
An alternative transaminative pathway of methionine catabolism also
exists, but little is known of its importance (Benevenga, 1985). In
addition, methionine exists in 2 isomeric forms designated -D and -L.
L-methionine is an essential amino acid and is more readily utilised
than the -D form in man (Stegink et al, 1986).
Even with effective methods of treatment, the number of deaths
attributed to paracetamol poisoning in England and Wales has risen
steadily since 1966 with 176 deaths due to paracetamol alone reported
in 1984. Although this figure is probably an overestimate (Meredith
et al, 1986) mortalities arising from paracetamol overdosage continue
to be a serious problem.
Delay in initial presentation to hospital is probably the major
reason why death following paracetamol overdosage still occurs (Read
et al, 1986). A possible method of prevention would, therefore, be
to incorporate methionine into paracetamol tablets. This would
enable the rapid onset of action of the antidote and the dose of
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FIGURE 1.2 The Role of Methionine in Glutathione Biosynthesis












































methionine would automatically increase with the amount of
paracetamol ingestea.
This concept was first described by McLean and Day in 1975. They
showed that oral administration of 0.3 g.kg"1 of methionine (30%) with
1 g.kg"1 paracetamol prevented liver damage in rats. Fifteen percent
and 10% provided some protection while 5% was ineffective. Similar¬
ly, oral administration of a paracetamol and methionine (4:1 w/w)
mixture at increasing doses showed that most rats survived a dose of
paracetamol of 7.5 g.kg"1 whereas the LD^q of paracetamol alone is
about 2 g.kg"1 (McLean and Day, 1975).
More recently the analgesic effect and acute toxicity (LD^q) of
orally administered paracetamol and L-methionine (5:1 w/w) has been
studied in animals. The analgesic effect of paracetamol was not
altered by the addition of methionine in rats, however, the addition
of methionine did reduce the acute toxicity of paracetamol by 50% in
non-fasted, fasted and phenobarbitone pretreated mice (Neuvonen
et al, 1985).
The same investigators administered oral paracetamol (1.5 g) and L-
methionine (0.3 g) to 10 healthy human subjects. Methionine did not
affect the pharmacokinetics of paracetamol. In addition, peak plasma
concentrations of methionine were observed at 30 min and were 3 to 4
times higher than after 1.5 g paracetamol alone. It was, therefore,
concluded that the addition of L-methionine to paracetamol tablets
should increase safety of paracetamol without loss of pharmacological
activity (Neuvonen et al, 1985).
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Currently, the only commercially available application of this
concept is 'Pameton1, which was introduced in December 1986. It
contains paracetamol (500 mg) and D-L-methionine (250 mg) and is
particularly expensive (14.79 for 60 tablets compared to 45p for 60
paracetamol tablets). Pameton is available without prescription, but
is not included in the limited list for National Health Service
prescription in general practice (Drug and Therapeutic Bulletin,
1987).
Sterling Winthrop have now developed paracetamol N-acetyl-D-L-
methionate in which paracetamol is linked by an ester bond to N-
acetyl-D-L-methionine. This compound is tasteless and is hydrolysed
in vivo to yield paracetamol and methionine in equimolar quantities.
At present it is not available commercially.
Chemical data for paracetamol N-acetyl-D-L-methionate are shown in
Appendix 1.2
b) Pharmacology
The analgesic activity of paracetamol N-acetyl-D-L-methionate and
paracetamol have been compared using the Randal1-Selitto test in rats
(SWRD Report 205032, 1978). Inflammation was induced in the rear
right foot by a subplanter injection of 0.1 ml of a 20% bakers yeast
suspension in saline. The test compound was administered 2.5 h after
the injection and the reaction threshold to pressure measured in both
hind paws at timed intervals.
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At doses ranging from 0.25-0.50 mmol.kg"1, paracetamol N-acetyl-D-L-
methionate was slightly, but consistently more effective than
paracetamol in increasing the pain threshold of the inflamed paw. At
higher doses of 0.7-2.0 mmol.kg"1 there were no quantitative differ¬
ences in analgesic activity between the 2 compounds.
The peak analgesic effect of paracetamol N-acetyl-D-L-methionate was
reached within 1-3 h and was maintained for 5-5.5 h after oral admin¬
istration. Compared with paracetamol, paracetamol N-acetyl-D-L-
methionate had a slower onset of action but a longer dose dependent
duration of analgesia. An equimolar mixture of paracetamol N-acetyl-
D-L-methionate and paracetamol combined the early onset of action of
paracetamol with the prolonged duration of effect of paracetamol N-
acetyl-D-L-methionate.
Similar comparative studies were also undertaken using the mouse
writhing test (SWRD Report 205032, 1978). Writhing was induced by
intraperitoneal administration of 3.5 mg.kg"1 acetylcholine chloride
in saline and the ability of the test drugs to inhibit the reaction
was tested at intervals following oral administration. Responses
during the period 25-120 seconds following the injection were
recorded and the results expressed as the percentage protection from
writhing. At doses over the range of 0.25-2.8 mmol.kg"1 paracetamol,
paracetamol N-acetyl-D-L-methionate and the equimolar combination had
similar analgesic activity and duration of effect. With repeated
administration of paracetamol N-acetyl-D-L-methionate or paracetamol
over 4 days there was no evidence of tolerance to either compound in
this test (SWRD Report 205032, 1978).
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The comparative analgesic efficacy of the equimolar combination of
(1) paracetamol N-acetyl-D-L-methionate and paracetamol and (2)
paracetamol alone was investigated in patients following dental
surgery (Skoglund and Skjelbred, 1984). Twenty seven patients
received the equimolar combination equivalent of 2 g of paracetamol 3
and 9 h after operation and the equivalent of 1 g of paracetamol at
0800 and 1600 h on the following 2 days. Another group of 26
patients received 1 g of paracetamol 3, 6, 9 and 12 h after operation
on the day of surgery and 0.5 g at 0800, 1200, 1600 and 2000 h on the
following 2 days.
An analgesic effect was demonstrated within 0.5 h of administration
in both groups, but it was not possible to assess the duration of
effect. Following the first dose the equimolar combination was more
effective than paracetamol alone over the period 0.5-3.0 h.
In a similar study using the same dosage regime the equimolar combin¬
ation reduced pain significantly more than placebo during the first
day (Skoglund, 1986).
The antipyretic activity of paracetamol N-acetyl-D-L-methionate was
studied in rats with hyperthermia induced by subcutaneous injection
of dried yeast. Oral paracetamol N-acetyl-D-L-methionate and
paracetamol (0.5 and 1.0 mmol.kg"1) had a dose dependent antipyretic
activity for 4 h after medication. Initially, paracetamol N-acetyl-
D-L-methionate was less effective than paracetamol (SWRD Report
203236, 1977). Oral paracetamol (100 mg.kg"1) and mixtures in which
28
10, 20 and 40% of the total paracetamol dose was replaced by
equimolar quantities of paracetamol N-acetyl-D-L-methionate all had
similar antipyretic activity in hyperthermic rats (SWRD Report
203490).
The equimolar combination of paracetamol N-acetyl-D-L-methionate and
paracetamol was no better than placebo at reducing post operative
swelling in 30 patients following bilateral oral surgery (Skoglund,
1986).
c) Absorption, Distribution, Metabolism and Excretion
Absorption: Peak plasma paracetamol concentrations following oral
administration of paracetamol N-acetyl-D-L-methionate in mice and
rats were delayed and lower compared to those obtained following an
equivalent equimolar dose of paracetamol (SWRD Reports 305212 and
305213, 1978).
Eight healthy subjects received 2 g of oral paracetamol as (1) para¬
cetamol, (2) paracetamol and N-acetyl-D-L-methionine, (3) paracetamol
and paracetamol N-acetyl-D-L-methionate, and (4) paracetamol N-
acetyl-D-L-methionate. Mean peak plasma paracetamol concentrations
were 26.6, 21.1, 17.3 and 13.3 v^ml"1 respectively and the mean time
to peak plasma paracetamol concentration for paracetamol N-acetyl-D-
L-methionate was 2 h compared to 0.5 h for the other formulations
(SWRD Report 305510, 1978).
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The mechanism and site of paracetamol N-acetyl-D-L-methionate absorp¬
tion is not known.
Distribution: No information is available concerning the distribu¬
tion of paracetamol N-acetyl-D-L-methionate.
Metabolism: Paracetamol N-acetyl-D-L-methionate is hydrolysed in
vivo to paracetamol and N-acetyl-D-L-methionine. Esterase enzymes
are ubiquitous. Orally administered ester prodrugs are mainly
hydrolysed by intestinal, hepatic and plasma esterases (Williams,
1985).
Attempts to measure paracetamol N-acetyl-D-L-methionate in biological
fluids have been unsuccessful. Using a non-specific enzymatic method
and reverse phase high performance liquid chromatography paracetamol
N-acetyl-D-L-methionate could not be detected in the plasma of mice
(SWRD Report 305213, 1978), rats (SWRD Report 305212, 1978) or man
(SWRD Report 304655, 1977; SWRD Report 305510, 1978).
Paracetamol N-acetyl-D-L-methionate was administered orally to 4
beagle dogs at 675 mg.kg"1 daily for 29 days. The mean difference
between serum 'total paracetamol' (paracetamol and its glucuronide
and sulphate conjugates, paracetamol metabolites and paracetamol N-
acetyl-D-L-methionate) and 'enzymatic paracetamol' (paracetamol and
its glucuronide and sulphate conjugates) was 11 pig.ml"1 at 4 h on
Day 29. The precise form which accounts for this difference was,
however, not identified (SWRD Report 304686, 1977).
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The plasma concentrations of paracetamol and its glucuronide and
sulphate conjugates following administration of 2 g of paracetamol
and the equivalent dose of paracetamol N-acetyl-D-L-methionate were
investigated in healthy volunteers. Peak concentrations of
paracetamol conjugates occurred 1 h after the peak concentration of
paracetamol following administration of paracetamol and 2 h after
paracetamol N-acetyl-D-L-methionate. The glucuronide and sulphate
conjugates were formed at similar rates and in similar quantities for
each formulation. The elimination kinetics of paracetamol and its
conjugates were also similar (SWRD Report 305510, 1978).
As methionine is a precursor of glutathione the effect of paracetamol
N-acetyl-D-L-methionate administration on hepatic glutathione was
investigated. Paracetamol N-acetyl-D-L-methionate was administered
to mice at a dose level equivalent to 400 mg.kg^ of paracetamol.
There was less depletion of hepatic glutathione than with the equiv¬
alent paracetamol dose (Skoglund et al, 1986). The maximum reduction
with paracetamol N-acetyl-D-L-methionate was 54% at 1 h and this
would probably protect against liver damage as this does not occur
until glutathione is reduced to 20-30% of normal (Mitchell et al,
1973b). At 16 h hepatic glutathione concentrations were signifi¬
cantly greater than in control mice.
Similarly, enhanced glutathione synthesis was reported following
administration of an equimolar combination of paracetamol and para¬
cetamol N-acetyl-D-L-methionate equivalent to 400 and 800 mg.kg"1 of
paracetamol in mice (Skoglund et al, 1988).
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Excretion: The excretion of paracetamol following administration of
paracetamol N-acetyl-D-L-methionate was investigated in man following
doses equivalent to 2 g of paracetamol. The mean 24 h total urinary
recovery of paracetamol and metabolites was 62% for paracetamol N-
acetyl-D-L-methionate and 74% for paracetamol. The fractional
recovery of paracetamol and its glucuronide, sulphate, cysteine and
mercapturic acid conjugates were similar to that with paracetamol
(SWRD Report 305510, 1978).
d) Toxicology
Paracetamol administered orally to mice at 400 mg.kg"1 produced a
transitory rise in plasma ALAT (alanine aminotransferase) activity
but this did not occur with the equivalent dose as paracetamol N-
acetyl-D-L-methionate (Skoglund et al, 1986). Similar findings were
reported with paracetamol in doses of 400 and 800 mg.kg"1 administered
to mice as the equimolar combination of paracetamol and paracetamol
N-acetyl-D-L-methionate (Skoglund et al, 1988).
The Oral LD^q (7 days) was determined following administration of
paracetamol, paracetamol N-acetyl-D-L-methionate (PNAM) and mixtures
of both in mice. The LD^q values were expressed as paracetamol
equivalents:
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! Compound LDca 7 Days 1
(mg.kg"1) i
1 Paracetamol 690 1
I Paracetamol:PNAM (450:100 w/w) 800 1
1 Paracetamol:PNAM (400:200 w/w) 930 1
1 Paracetamol:PNAM (300:400 w/w) 1500 1
I Paracetamol N-acetyl-D-L-methionate >4000 1
Slow absorption of paracetamol N-acetyl-D-L-methionate probably
contributes to its low acute toxicity in addition to the protective
action of the methionine (SWRD Report 403238, 1977).
Six month chronic toxicity studies of paracetamol N-acetyl-D-L-
methionate were performed in rats and dogs. Thirty rats were given
oral paracetamol N-acetyl-D-L-methionate at doses of 130, 390 and
1170 mg.kg"1. Paracetamol N-acetyl-D-L-methionate was well tolerated
and weight gain, food consumption, blood pressure and behaviour were
normal. At the highest dose the fur was sticky and unclean, and
water consumption was increased. After 6 months there was an
increase in the erythrocyte sedimentation rate and lymphocyte count
in males and a decrease in the reticulocyte, platelet and lymphocyte
counts in females. Urine analysis showed no notable abnormalities
and clinical biochemical tests were normal, except for an elevated
cholesterol level in females at the highest dose. At the same dose
level there was an increase in the liver weight in females, but
microscopic examination showed no changes attributable to the drug
(SWRD Report 505300, 1978).
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Six dogs were given daily for 6 months paracetamol N-acetyl-D-L-
methionate at 108 and 215 mg.kg"1 and 8 dogs at 430 mg.kg"1. It was
well tolerated and weight gain, biochemistry, urine analysis, optical
tests, and tests of kidney and adrenal function and behaviour were
all normal. At 430 mg.kg'1 there was a decrease in red blood cells
and haematocrit, and an increase in reticulocytes. There was a
slight biliary pigmentation of the Kupffer cells in the liver at the
highest dose level. No microscopic changes were observed (SWRD
Report 505263, 1978).
No serious toxic effects attributable to paracetamol N-acetyl-D-L-
methionate were found in either acute or chronic toxicity studies
(Investigators Handbook, SWRD).
The teratogenicity of paracetamol N-acetyl-D-L-methionate was studied
in mice, rats and rabbits. Rats and mice received oral paracetamol
N-acetyl-D-L-methionate daily at 130, 390 and 1170 mg.kg"1 from Days
6-15 of gestation and rabbits daily at 130, 260 and 520 mg.kg"1 from
Days 6-18 of gestation. At the highest dose in rats (but not in mice
or rabbits) there was an increase in the number of foetuses with 14
ribs and an extra lumbar vertebra (SWRD Report 607474, 1980).
In further studies in rats paracetamol N-acetyl-D-L-methionate was
administered at 130, 260 and 1170 mg.kg"1 daily to males for 63 days
and to females for 14 days prior to mating. No effect on spermato¬
genesis or oogenesis were observed. Treatment was continued during
pregnancy and no gross malformations were observed at 15 days of
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gestation. At 21 days the number of foetuses with 14 ribs and an
extra lumbar vertebrae was again increased. Dams were treated until
21 days post partum with no adverse effects on maternal lactation.
There were no adverse effects from weaning to maturity in the second
generation and fertility and reproductive performance at sexual
maturity were normal. Pregnancy in dams of the second generation
was normal at each dose and the progeny of the second generation were
also normal (SWRD Report 605307, 1978).
Paracetamol N-acetyl-D-L-methionate was devoid of mutagenic activity
in 6 strains of Salmonella typhimurium (Investigators Handbook,
SWRD).
A single oral dose of 859.5 mg.kg"1 of N-acetyl-D-L-methionine
administered in mice produced no histological damage to the liver or




In an attempt to make a safer form of paracetamol Sterling Winthrop
have linked paracetamol and N-acetyl-D-L-methionine as the N-acetyl-
D-L-methionine ester of paracetamol. The objective of this study is
to complement existing pharmacological and toxicity data on paraceta¬
mol N-acetyl-D-L-methionate by studying in detail its disposition in
healthy subjects and patients with chronic renal failure. This will
provide previously unpublished data in addition to furthering the
development of this compound.
Firstly, existing methods for measurement of paracetamol and its
metabolites in plasma and urine require to be validated in addition
to development of a method for measurement of paracetamol N-acetyl-D-
L-methionate. Having established suitable analytical methods the
study of the disposition of paracetamol N-acetyl-D-L-methionate in
healthy subjects will be undertaken in a double blind cross-over
clinical trial. Each healthy subject will receive 1 g of paracetamol
as (1) paracetamol and (2) paracetamol N-acetyl-D-L-methionate. The
data generated from healthy subjects receiving paracetamol alone will
provide control data with which the disposition of paracetamol
following administration of paracetamol N-acetyl-D-L-methionate can
be compared.
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Following on, the same double blind cross-over clinical trial will
then be performed in patients with chronic renal failure. The data
generated from chronic renal failure patients following administra¬
tion of 1 g of paracetamol alone will be compared with that obtained
following administration of 1 g of paracetamol to healthy subjects.
This will provide more detailed information of the disposition of
paracetamol in patients with chronic renal failure than previously
reported. The data obtained after administration of paracetamol N-
acetyl-D-L-methionate in patients with chronic renal failure will
then be compared with that obtained after administration of paraceta¬
mol alone to the same patients. This will provide information as to
the disposition of paracetamol N-acetyl-D-L-methionate in patients






ESTIMATION OF PARACETAMOL AND ITS METABOLITES IN PLASMA AND
URINE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
a) Introduction
Many methods have been described for the estimation of paracetamol.
These can be divided into 2 main areas of interest.
i) The Estimation of Paracetamol Concentrations in Plasma
These methods are generally used to aid diagnosis and management of
overdose patients and therefore require to be specific, accurate and
rapid. Early techniques, however, utilised non specific procedures
whereby paracetamol was hydrolysed directly with acid to p-amino-
phenol. These methods over-estimate free paracetamol, as its conju¬
gates were also hydrolysed to p-aminophenol (Stewart et al, 1979).
Techniques where conjugates do not interfere include, u.v. spectro¬
photometry following solvent extraction (Routh et al, 1968) and
phenolic ring nitration (Glynn and Kendal, 1975). These methods are
however, susceptible to interference from unrelated compounds.
More recently, a paracetamol enzyme assay kit has been developed.
This new approach uses a bacterial acyl amidase which specifically
converts free paracetamol to p-aminophenol with quantitation by a
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previously developed colorimetric techniaue. This method correlates
well with existing methods (Widdop, 1984).
ii) The Estimation of Paracetamol and its Metabolites in Biological
Fluids
These methods require to be sensitive in addition to being specifc
and accurate and are generally used to measure therapeutic concen¬
trations for research purposes. Methods include gel filtration
(Jagenburg et al, 1968), gas-liquid chromatography (Prescott, 1971),
ion exchange chromatography (Mrochek et al, 1974), and thin layer
chromatography (Andrews et al, 1976).
Significant progress has been made since the introduction of High
Performance Liquid Chromatography (HPLC). Separation of paracetamol
and its major metabolites was achieved by Knox and Jurand in 1979
using a reverse phase support, however, quantitation was not
attempted. Reverse phase HPLC utilises a polar mobile phase with a
non-polar support. Polar components have a higher affinity for the
eluent than for the support, and so are eluted first. Reverse phase
HPLC therefore, is a very useful technique for the separation and
quantitation of drugs and their metabolites. Estimation of paraceta¬
mol and its metabolites in urine (Howie et al, 1977; Adrianssens,
1980) and plasma (Adrianssens and Prescott, 1978) by HPLC provides a
sensitive, specific, accurate and rapid technique with minimal sample
preparation. The procedures used throughout this work for the esti-
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mation of paracetamol and its metabolites are based on the methods of
Howie et al, and Adrianssens et al.
b) High Performance Liquid Chromatography Assays for the Estimation
of Paracetamol and its Metabolites in Plasma and Urine
i) Materials
Paracetamol, paracetamol glucuronide, paracetamol sulphate, para¬
cetamol cysteine and paracetamol mercapturic acid for reference
standards, were kindly donated by Sterling-Winthrop Research and
Development Division, Alnwick, England.
Potassium dihydrogen orthophosphate, formic acid, iso-propyl alcohol,
and acetic acid were supplied by BDH Chemicals Limited, Poole,
England, 60% perchloric acid and ethyl acetate were obtained from
Fisons Scientific Apparatus, Loughborough, England, and helium from
The British Oxygen Company.
The internal standard used was N-propionyl-4-aminophenol (NPA). It
was synthesised from 4-aminophenol and propionic anhydride (BDH
Chemicals Limited), as described by Adrianssens (1980), with













4-aminophenol propionic N-propionyl- propionic
anhydride 4-aminophenol acid
All other reagents used were of analytical grade,
ii) Instrumentation
The HPLC system consisted of an Altex 110A pump which delivered the
mobile phase (degassed with helium prior to use) via a filter to the
system.
The mobile phase then passed to an Altex 210 Manual Sample Injection
Valve, and samples were injected into the loop via a needle port
using a blunt 22 gauge Hamilton syringe. A Waters Intelligent Sample
Processor 710B (WISP), an automatic sample injection module, was also
used.
Prior to passing through the analytical column, the solvent was
passed through a metal filter and a Waters Guard-PAK precolumn
containing the same packing material as the column.
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The columns used were 8 mm x 10 cm Waters Radial-PAK cartridges
containing a reverse phase, 5 or 10 y, C18 bonded spherical silica
support. The cartridge was housed in a Waters RCM-100 Radial
Compression Module (Figure 2.1).
From the column, the eluate then passed into a ultraviolet (u.v.)
absorbance detector (Perkin-Elmer Model LC-75 spectrophotometric
detector or the Waters Series 441 absorbance detector).
The u.v. detector output was passed to a Hewlett-Packard 3390A Single
Channel Plotting/Reporting Integrator to produce the chromatogram and
peak areas. The HPLC system is shown in Figure 2.2.
iii) Collection and Storage of Samples
Prior to analysis, all samples were stored at -20°C. Blood samples
were collected into 10 ml heparinised tubes, centrifuged for 10' min
at 1400 x g and the plasma separated for storage. Urine volumes and
pH were recorded and a 50 ml aliquot stored. Paracetamol and para¬
cetamol conjugates are stable under these conditions for a period of
years (Adrianssens, 1980).
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FIGURE 2.1 Copied from the Operators Manual for the Waters Radial Compression
Separation System
















For the estimation of plasma paracetamol, paracetamol glucuronide and
paracetamol sulphate a Radial-PAK, C18, 5 pi cartridge was used under
the following chromatographic conditions:
Mobile Phase: 0.05 M potassium dihydrogen orthophosphate
containing 0.1% formic acid:isopropanol
(295:5 v/v)
Flow Rate: 3 ml.min"1
Pressure: 1000 psi
Detector Wavelength: 254 nm
Preparation of Standards and Test Samples for Plasma Assay
For estimating therapeutic concentrations of paracetamol and its
metabolites, spiked plasma standards containing 5 and 25 pig.ml"1 of
paracetamol were prepared and run in duplicate with the test samples.
To 0.5 ml of plasma in a plastic tube, 50 pil of 30 mg% NPA in 30% w/v
aqueous perchloric acid was added with continuous mixing (Whirlimix,
Jencons) to precipitate the plasma proteins. The tubes were centri-
fuged for 10 min at 1400 x g and up to 30 pil of the clear supernatant
injected directly into the HPLC system.
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Calculation of Results for Plasma Assay
Concentrations were calculated in paracetamol equivalents from the
peak area ratios of paracetamol and paracetamol conjugates to the
internal standard (NPA). The ratios were then multiplied by a factor
(F) representing the reciprocal of the slope of the regression line
for the standards, to give the paracetamol concentration in pig.ml'1.
The calculation of the factor (F) is shown in Appendix 2.1.
As only authentic paracetamol standards were used, values obtained
are only accurate for paracetamol. The molar extinction coefficients
of glucuronide and sulphate conjugates of paracetamol are not the
same as paracetamol and correction factors of 0.835 and 1.027




Where: Pa, Ga, Sa and NPAa are the peak areas for paracetamol,
glucuronide, sulphate and internal standard respectively. F is the
factor representing the reciprocal of the slope of the regression
line for the standards. For the mean value of F obtained see
Appendix 2.1.
Paracetamol = ——— x F x 1.000 =
NPAa
Glucuronide = — x F x 0.835 =
NPAa
Sulphate = —^— x F x 1.027 =
NPAa
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Results of Plasma Assay
Chromatograms for drug-free plasma and from plasma obtained 45 min
following a dose of 1 g of paracetamol are shown in Figure 2.3. The
retention times of paracetamol glucuronide, paracetamol sulphate,
paracetamol and internal standard (NPA) were 2.7, 4.2, 6.3 and
12.0 min respectively. The system also separates the cysteine
(5.3 min) and mercapturic acid (15.0 min) conjugates of paracetamol,
but these metabolites were rarely detectable except after overdosage.
A chromatogram of plasma obtained 15.25 h after a paracetamol over¬
dose is shown in Figure 2.4. The limit of detection of each compound
is less than 1 pig.ml"1 and there is no interference from commonly used
drugs (Adrianssens, 1980).
Validation of Plasma Assay
As authentic metabolite standards were not available in quantity, the
accuracy of the assay could not be assessed. The accuracy has, how¬
ever, been demonstrated previously whereby measured concentrations
were within 6% of weighed-in values over a wide range of concen¬
trations (Adrianssens, 1980). The linearity and the precision for
the plasma assay was determined by repeated analysis of serially
diluted overdose samples.
Plasma Paracetamol: Serial dilutions of a stock solution of para¬
cetamol in blank plasma (Blood Transfusion Service) were prepared
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FIGURE 2.3 Chromatograms Obtained from:
A Drug free plasma (30 pi; 0.05 AUFS)
B Plasma obtained 45 mln following a dose of 1 g of paracetamol (30 pi; 0.05 AUFS)
The peaks are: 6.2 pg.ml"1 paracetamol glucuronide (G)
3.4 pg.ml"1 paracetamol sulphate (S)
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FIGURE 2.4 Chromatogram Obtained from Plasma Taken 15.25 h After Paracetamol
Overdosage
The peaks are: 183.1 jig.ml"1 paracetamol glucuronide (G)
40.4 jig.ml"1 paracetamol sulphate (S)
19.3 jig.ml"1 paracetamol cysteine (C)
104.5 jig.ml"1 paracetamol (P)








to give concentrations ranging from 5-50 pig.ml"1. Samples were
assayed as described, and analysed 5 times over a period of 2 days.
The results are shown in Table 2.1 and Figure 2.5. The coefficients
of variation ranged from 1.4-3.1% while the calibration plot was
linear and passed through the origin.
Plasma Paracetamol Metabolites: Plasma obtained from an overdose
patient was serially diluted with blank plasma to give concentrations
of paracetamol, paracetamol glucuronide and paracetamol sulphate
ranging from 9.9-118.5, 6.2-75.3 and 1.1-13.6 pig.ml"1 respectively.
Each sample was assayed 5 times over a period of 2 days.
The results are shown in Tables 2.2(i-iii) and Figure 2.6. The
coefficients of variation for the determination of paracetamol and
paracetamol glucuronide were within 5% over the range of concen¬
trations investigated. The precision for paracetamol sulphate, how¬
ever, ranged from 6.5-13.6%. This result is explained by the very
much lower concentrations of the paracetamol sulphate conjugate. The
paracetamol sulphate peak is also subject to interference at low
concentrations. The calibration plots were linear for paracetamol
and its glucuronide and sulphate conjugates.
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TABLE 2.1 Precision of Plasma Paracetamol HPLC Assay (5-50 jig-ml-1)
| Paracetamol | Peak Area Ratio 1 I I
[Concentration| (Paracetamol /NPA) 1 Mean + SD | Coefficient of |
! < y.g -mi-1) | Run 1 | Run 2 Run 3 | Run 4| Run 5 | | V ar i at i on ( %) |
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0.765 + 0.01 1
I I
I 1 -5 I
I I

























FIGURE 2.5 Linearity of HPLC Plasma Assay; Calibration Plot of the Mean Peak Area
Ratio Obtained Following Repeated Analysis (n = 5) of Plasma Containing
Paracetamol Concentrations In the Range 5-50 ug.ml"1
Paracetamol Concentration (ug.ml"*)
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TABLE 2.2(1 ) Precision of Plasma HPLC Assay - Paracetamol
1 | Paracetamol Concentration | 1
S Sample 1 (pg. ml "*) I Mean + SD | Coefficient of I
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TABLE 2.2(11 ) Precision of Plasma HPLC Assay - Paracetamol G1ucuronIde
j Paracetamol Glucuronlde 1 1
I Sample | Concentration (pg.ml"1) 1 Mean + SD | Coefficient of I
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FIGURE 2.6 Linearity of HPLC Plasma Paracetamol Metabolite Assay: Calibration Plot of
the Mean Paracetamol (P), Glucuronlde (G) and Sulphate (S) Concentrations





For the estimation of paracetamol, paracetamol glucuronide, para¬
cetamol sulphate, paracetamol mercapturic acid and paracetamol











Preparation of Standards and Test Samples for Urine Assay
For estimating paracetamol and its metabolites in urine, aqueous
standard solution of paracetamol (1 mg.ml"1) and NPA (2 mg.ml"1) were
prepared. Three standards were set up by combining the paracetamol
and NPA solutions in the following proportions: 1:1, 1:2 and 2:1
(v/v). These standards were then run with the test samples.
The urine was mixed with NPA standard in different proportions accor¬
ding to the concentration of paracetamol and its metabolites present.
The ratios of urine to NPA solution ranged from 1:1 to 20:1 for
samples obtained after a therapeutic paracetamol dose. Volumes up
to 10 jil were injected directly into the HPLC system.
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Calculation of Results for Urine Assay
As described for the plasma assay the factor (F) representing the
reciprocal of the slope of the regression line for the standards was
calculated (see Appendix 2.1). Concentrations of paracetamol and its
conjugates were calculated as described on Page 46, using correction
factors of 0.945 and 0.909 for paracetamol sulphate and paracetamol
glucuronide conjugates respectively. No correction factor was used
for paracetamol cysteine and paracetamol mercapturic acid
conjugates (Adriaenssens, 1980).
Paracetamol = — x F x NPAv x
NPAa Uv
Cysteine = _— x F x NPAv x
NPAa Uv
Mercapturate = ——— x F x NPAv x
NPAa Uv
Sulphate = — x F x NPAv x
NPAa Uv
Glucuronide = — x F x NPAv x
NPAa Uv
(Note: mg.ml"1
1.000 = paracetamol concentration
(mg.ml"1)
1.000 = paracetamol equivalents
(mg.ml"1)
1.000 = paracetamol equivalents
(mg.ml"1)
0.945 = paracetamol equivalents
(mg.ml"1)
0.909 = paracetamol equivalents
(mg.ml"1)
x 1000 = ug.ml"1)
Where: Pa, Ca, Ma, Sa, Ga and NPAa are the peak areas for paraceta¬
mol, cysteine, mercapturic acid, sulphate, glucuronide and internal
standard respectively. F is the factor representing the reciprocal
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of the slope of the regression line for the standards. NPAa and Uv
are the volume of internal standard and urine present in the sample
mixture respectively. For the mean value of F obtained see
Appendix 2.1.
Results of Urine Assay
Chromatograms obtained from drug free urine and from urine collected
2-4 h following a dose of 1 g of paracetamol are shown in Figure 2.7.
The retention times of paracetamol sulphate, paracetamol glucuronide,
paracetamol, internal standard (NPA), paracetamol cysteine and para¬
cetamol mercapturic acid were 0.9, 2.1, 4.8, 9.7, 11.1 and 12.5 min
respectively. The order of elution of the cysteine and mercapturic
acid conjugates was reversed compared to the original method. The
limit of detection for the assay was dependent on the presence of
interfering peaks from endogenous material present in the urine.
Validation of Urine Assay
Urinary Paracetamol: A stock solution of paracetamol in blank urine
was serially diluted to give concentrations ranging from 25-
500 pig.ml"1. Samples were assayed as described and analysed 5 times
over a period of 2 days.
The results are shown in Table 2.3 and Figure 2.8. The coefficient
of variation was less than 3% for concentrations in the range 50-
500 lig.ml"1. At 25 pig.ml"1 the coefficient of variation was \2%. The
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FIGURE 2.7 Chromatograms Obtained from:
A Drug free urine (5 y|; 0.2 AUFS)
B Urine collected 2-4 h following a dose of 1 g of paracetamol (3 yI; 0.2 AUFS)
The peaks are: 674 yg.ml"1 paracetamol sulphate (S)
952 yg.ml"1 paracetamol glucuronlde (G)
65 yg.ml"1 paracetamol (P)
66 yg.ml"1 paracetamol cysteine (C)
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TABLE 2.5 Precision of Urine Paracetamol HPLC Assay - (25-600 VLg.ml"1)
| Paracetamol | Peak Area Ratio I I I
[Concentration J (Paracetamol/NPA) I Mean + SD | Coefficient of |
| (jig-ml"1) j Run 1 | Run 2 | Run 3| Run 4| Run 5 | I Variation (?) |











1 50 | 0.11 2 | 0.108
I I I










































| 400 | 0.818| 0.762
I I I





















FIGURE 2.8 Linearity of HPLC Urine Paracetamol Assay: Calibration Plot of the Mean
Peak Area Ratio Obtained Following Repeated Analysis (n = 5) of Urine
Containing Paracetamol Concentrations In the Range 50-500 ug.ml-1
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plot of mean peak area ratio against concentration was linear and
passed through the origin.
Urinary Paracetamol Metabolites: Urine obtained from an overdose
patient was serially diluted with distilled water to give concen¬
trations of paracetamol, paracetamol glucuronide, paracetamol
sulphate, paracetamol cysteine and paracetamol mercapturic acid
ranging from 53-3383, 210-13078, 21-1309, 4-289 and 4-242 pig.ml"1
respectively. Each sample was analysed 5 times over a period of 2
days.
The results are shown in Tables 2.4(i-iii) and 2.5(i-ii) and Figures
2.9 and 2.10.
The coefficients of variation for the determination of paracetamol,
paracetamol glucuronide, paracetamol sulphate and paracetamol
cysteine ranged from 1.6-7.0, 1.1-5.5, 1.1-6.7 and 0-17.7% respect¬
ively. In each case the greater variation in the range was assoc¬
iated with the lowest concentration. The calibration plots were
linear for paracetamol and its glucuronide, sulphate and cysteine
conjugates.
The coefficient of variation for the determination of paracetamol
mercapturate ranged from 2.5-10.6%. At concentrations below
60 pig.ml"1 the coefficient of variation exceeded 5% and there was a
corresponding loss of linearity at the lowest concentrations.
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TABLE 2.4 (I ) Precision of Urine HPLC Assay - Paracetamol
I Paracetamol Concentration \ 1 1
| Sample I (pg. ml "*) I Mean + SO | Coefficient of |
































































































































TABLE 2.4(11) Precision of Urine HPLC Assay - Paracetamol GIucuronide
| Paracetamol Gl ucuron1de I I I
j Sample ! Concentration (pg. ml "*) I Mean + SD | Coefficient of |











































































































TABLE 2.4 (11! ) Precision of Urine HPLC Assay - Paracetamol Sulphate
1 Paracetamol Su phate I I I
| Sample 1 Concentration (pg.ml"1) I Mean + SD | Coefficient of |














































































































































FIGURE 2.9 Linearity of HPLC Urine Paracetamol Metabolite Assay: Calibration Plot of
the Mean Paracetamol (P), Glucuronide (G) and Sulphate (S) Concentrations






TABLE 2.5(I ) Precision of Urine HPLC Assay - Paracetamol Cysteine
I Paracetamol Cystelne I I I
| Sample I Concentration (ug. ml "*) I Mean + SD | Coefficient of |
































































































































TABLE 2.5(1!) Precision of Urine HPLC Assay - Paracetamol Mercapturic Acid
| Sample
| Paracetamol Mercapturic Acid |
j Concentration (pg.ml"1) j Mean + SD
I
| Coefficient of
































































































































FIGURE 2.10 Linearity of HPLC Urine Paracetamol Metabolite Assay: Calibration Plot of
the Mean Cysteine (C) and Mercapturlc Acid (M) Concentrations Obtained
Following Repeated Analysis (n = 5) of Serially Diluted Overdose Urine
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c) Discussion and Summary
The ability to measure drugs and their metabolites has been signifi¬
cantly enhanced by the advent of HPLC. Methods based on established
HPLC assays for measuring paracetamol and its metabolites in plasma
and urine, using N-propionyl-4-aminophenol (NPA) as the internal
standard have been described. Standard HPLC equipment and materials
were used in conjunction with radially compressed columns.
For paracetamol and metabolite concentrations in the therapeutic
range in plasma and urine, the chromatograms obtained were similar to
those described in the original method. By introducing radially
compressed cartridges, the order of elution of the cysteine and
mercapturic acid conjugates was reversed when compared to the
original urine assay. A relatively short run time, minimal sample
preparation and calibration using only paracetamol standards enabled
rapid analysis.
Validation of both plasma and urine assays was carried out using




ESTIMATION OF PARACETAMOL N-ACETYL-D-METHIONATE IN PLASMA BY
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
a) Introduction
A reverse phase HPLC method for the simultaneous determination of
paracetamol and paracetamol N-acetyl-D-L-methionate in plasma has
previously been described (SWRD Report 16/77, 1977). The method used
N-butyryl-p-aminophenol as the internal standard with a mobile phase
of methanol :water, 40:60 v/v at a flow rate of 2 ml.min"1, detection
was by u.v. at 254 nm. Aliquots of plasma (2 ml) were washed with
iso-octane prior to extraction into ether. The ether extract was
then evaporated to dryness, reconstituted in methanol and 25 pil
injected into the HPLC system. The range of concentration for both
paracetamol and paracetamol N-acetyl-D-L-methionate was 0.5-
10.0 yg.ml"1.
The disadvantages of this method included the elution of paracetamol
very close to the solvent front, a lengthy extraction process and
loss of precision at lower concentrations.
Attempts to increase the retention time of paracetamol while main¬
taining the quality of chromatography required for accurate deter-
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mination of paracetamol N-acetyl-D-L-methionate under isocratic
conditions were unsuccessful. Therefore, an HPLC method and
extraction technique for measuring plasma paracetamol N-acetyl-D-L-
methionate alone was developed.
b) Development of a High Performance Liquid Chromatography Assay
for the Estimation of Paracetamol N-acetyl-D-L-methionate in
Plasma
i) Materials
Paracetamol N-acetyl-D-L-methionate was kindly donated by Sterling-
Winthrop Research and Development Division, Alnwick, England.
Acet-p-toluidide was supplied by BDH Chemicals Limited, Poole,
England, acetonitrile and methanol were obtained from Fisons
Scientific Apparatus, Loughborough, and helium from The British
Oxygen Company.
Other reagents were of analytical grade.
ii) Instrumentation
The HPLC equipment for measuring paracetamol N-acetyl-D-L-methionate
was as described on Pages 41-42, for measuring paracetamol.
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Paracetamol N-acetyl-D-L-methionate was extracted from plasma using
'Bond E1 ut' (Analytichem International) solid phase extraction
columns. The columns consisted of a polypropylene tube of 1 ml
capacity with a Luer fitting at one end containing 100 mg of end
capped, 40 u C18 bonded silica between 2 porous polypropylene frits
(20 u). A diagram of a 'Bond Elut' solid phase extraction column is
shown in Figure 2.11.
Samples can be prepared as follows: methanol is passed through the
column to wet the sorbent bed followed by a conditioning flush of
distilled water or buffer. The sample is then passed through the
column. According to the principles of reverse phase HPLC, lipid
soluble components are retained by the non-polar support, whereas
polar material passes straight through. Potentially interfering
material may, however, also be retained but can be removed by
flushing the column with distilled water, buffer or solvent. The
component of interest is then selectively eluted from the column with
300-500 pil of an appropriate solvent. The extract is collected, and
either concentrated or injected directly into the chromatograph
(Figure 2.11).
This procedure provides a fast, simple sample preparation with
selective retention of the component of interest and economy of
solvent.
'Bond Elut' columns used with a 'Vac Elut' (Analytichem
International) processing station enabled up to 10 extractions to be
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FIGURE 2.11 Diagram of a 'Bond Elut' Solid Phase Extraction Column and the Procedure
Used for Its Use
A Sample applied to conditioned column
B Cleaning step to elute off Interfering (I) material












processed at one time. The 'Vac Elut' comprised of a solvent
resistant basin with a detachable moulded cover which received the
Luer tips of the 'Bond Elut' columns. A drain in the base of the
basin was fitted with a vacuum guage and release ring. The vacuum
controller/release was connected to a glass side armed flask which in
turn was linked to a vacuum pump (Mi 11ipore Corporation). A diagram
representing the 'Bond Elut'/'Vac E1 u' system is shown in
Figure 2.12.
This system was capable of undertaking all the steps previously des¬
cribed for 'Bond Elut' extraction. The vacuum applied was generally
between 10 and 20 inches of mercury and the vaccuum release ring en¬
abled rapid application or release of the vacuum whenever appropri¬
ate. When the eluent was not required, liquids applied to the column
passed directly through the 'Vac Elut' into the collection flask for
disposal. When the eluent was to be collected, the vacuum was
released and the lid removed. A stainless steel rack containing
appropriately positioned glass collection vials was then placed into
the basin, the lid was replaced and the eluting solvent added to the
column. On re-application of the vacuum, the solvent passed through
the column and into the collection vials positioned below.
iii) Chromatographic Conditions
Detection
Solutions of paracetamol N-acetyl-D-L-methionate and acet-p-toluidide
(internal standard) were scanned from 210-260 nm using a Pye Unicam
FIGURE2.12'BoneElut/VacElut'Separ tionSystem
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SP1750 dual beam u.v. spectrophotometer (Figure 2.13). The absorb-
ance maxima for paracetamol N-acetyl-D-L-methionate and act-p-
toluidide was approximately 243 nm, however, fixed wavelength
detectors (254 nm) were used.
Mobile Phase
The flow rate was 1.5 ml.min"1 and the separation using different
proportions of acetonitrile to water is shown in Figure 2.14.
Results
The optimum chromatographic conditions were as follows:
Mobile Phase: Acetonitrile:water (35:65 v/v)
Flow Rate: 1.5 ml .min"1
Pressure: 1000 psi
Wavelength: 254 nm
Under these conditions the retention time of paracetamol N-acetyl-D-
L-methionate and acet-p-toluidide were 4.0 and 6.2 min respectively
(Figure 2.15).
The chromatography is simple and fast with sharp, well resolved
peaks. The number of theoretical plates (N = 5.54 R/VIk, where R is
the peak retention time and is the peak width at half height) was
2200 for paracetamol N-acetyl-D-L-methionate and 2300 for acet-p-
toluidide using a 5 n radial compression cartridge.
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FIGURE 2.13 Ultraviolet Scan of 10 tig.ml "* Paracetamol N-acety l-D-L-methlonate ( )
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FIGURE 2.14 The Retention Times of the Solvent Front (SF), Paracetamol N-Acetyl-D-
L-methlonate (PNAM) and Acet-p-toIuIdide (APT) Obtained Using Different
Proportions of Acetonitrile to Water 1n the Mob Ile Phase at a Flow Rate of
1.5 ml .mln"1
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FIGURE 2.15 Chromatogram Obtained from an Aqueous Mix of Paracetamol









iv) Extraction from Aqueous Solutions
Determination of Optimal Extraction Conditions
'Bond Elut' (C18) columns were first conditioned with 1 ml of
methanol followed by distilled water (2x1 ml). A 1 ml aliquot
containing aqueous paracetamol N-acetyl-D-L-methionate (10 ug.ml^)
and acet-p-toluidide (5 ug.mT1) was then passed through the column,
followed by a 1 ml distilled water wash. The eluents from each step
were collected and analysed by HPLC using the method described in
(iii). By comparing the peak areas obtained for paracetamol N-
acetyl-D-L-methionate and acet-p-toluidide with that of the non
extracted mixture, the percentage recovery of each component could be
calculated. It was observed that all the paracetamol N-acetyl-D-
methionate and acet-p-toluidide was retained on the column after the
distilled water wash. To determine the optimal strength of methanol
for sample clean up and elution of the compounds, 1 ml washes of 15,
20, 25 and 30% methanol in water were passed through followed by
2 x 200 pi 1 of 100% methanol. The percentage recoveries of para¬
cetamol N-acetyl-D-L-methionate and acet-p-toluidide in each fraction
were calculated and the results are shown in Table 2.6. A 25%
methanol wash followed by elution with 300 yl of 100% methanol
appeared to provide a suitable extraction method. However, repeated
extractions revealed that small percentages of acet-p-toluidide were
detected in the eluent following the 25% methanol wash. This was
prevented by using a 20% methanol wash, followed by elution with
300 pil of 100% methanol. The final procedure is summarised as
follows:
























































1. Column Conditioned: a) 1 ml methanol
b) 2 x 1 ml distilled water
2. Aqueous Mixture Applied to Column (1 ml)
3. Sample Clean Up: a) 1 ml distilled water
b) 1 ml 20% methanol
4. Selective Elution: 300 yl lOOifc methanol
Assessment of Extraction Procedure Using Aqueous Paracetamol
N-acetyl-D-L-methionate Solutions (Upper Range 2-10 pig.ml"1)
Aqueous solutions of paracetamol N-acetyl-D-L-methionate (2-10 pig.
ml"1) and acet-p-toluidide (2.5 pig.ml"1) were extracted 4 times at
each paracetamol N-acetyl-D-L-methionate concentration. The peak
areas and peak area ratios were compared to the appropriate non-ex¬
tracted aqueous mixture.
Recovery: The apparent mean percentage recovery of paracetamol N-
acetyl-D-L-methionate and acet-p-toluidide ranged from 109-118% with
coefficients of variation of less than 9% (Table 2.7). The spuri¬
ously high recoveries were attributed to evaporation of the final
methanol extract in the 'Vac Elut' processing station, since methanol
solutions containing the compound placed under vacuum for 1 min also
showed an increase in peak area of up to 28% compared to solutions
left on the bench.
Aqueous solutions containing paracetamol N-acetyl-D-l-methionate
(10 pig.ml"1) and acet-p-toluidide (5 pig.ml^1) were extracted 4 times.



































































































The percentage recoveries for each component in the first methanol
elution were again high (108-116%). However, neither component was
detected in the 20% methanol wash nor the second methanol elution
(Table 2.8). It was therefore reasonable to assume that the recover¬
ies of both paracetamol N-acetyl-D-L-methionate and acet-p-toluidide
were probably quantitative with the spuriously high recoveries
obtained due to evaporation of the final methanol extract.
Peak Area Ratios: Mean peak area ratios with and without extraction
varied by less than 3% (Table 2.9). The calibration plot was linear
following 'Bond E1ut1 extraction and passed through the origin
(Figure 2.16). The coefficient of variation for the peak area ratios
following 4 'Bond E1ut' extractions at each concentration was less
than 2%.
Assessment of Extraction Procedure Using Aqueous Paracetamol
N-acetyl-D-L-methionate Solution (Lower Range 0.2-1.0 pig.ml"1)
Aqueous solutions containing paracetamol N-acetyl-D-L-methionate
(0.2-1.0 pig.mlH) and acet-p-toluidide (0.25 pig.ml"1) were prepared and
extracted as above.
The results are shown in Table 2.10 and Figure 2.17. The percentage
recoveries of paracetamol N-acetyl-D-L-methionate and acet-p-
toluidide were again quantitative. The coefficient of variation for
the peak area ratios of paracetamol N-acetyl-D-L-methionate/acet-p-
toluidide following 4 'Bond E1ut' extractions at paracetamol N-
acetyl-D-L-methionate concentrations in the range 0.4-1.0 pg.ml"1 was
less than 2%. At 0.2 pig.ml"1 it was 6.5%. The calibration plot was
linear.
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TABLE 2.8 The Percentage of 10 ytg Paracetamol N-acety l-D-L-methtonate (PNAM) and
5 ug Acet-p-toluidide (APT) Recovered In Bond EIut Fractions Following
Application of Aqueous Sarrples
' Run


















































































































FIGURE 2.16 Mean Paracetamol N-Acetyl-D-L-methlonate/Acet-p-toluldlde Peak Area Ratios
Obtained from Aqueous Solutions Extracted Using 'Bond Elut' Columns
(n = 4)« Paracetamol N-Acetyl-D-L-methlonate Concentrations Ranged from
2-10 ug.ml-1. The concentration of Acet-p-toluldlde was 2.5 ug.ml"* In Each
Samp I e
2.5
1 , I ——7




























































2.17 Mean Paracetamol N-Acetyl-D-L-methlonate/Acet-p-toluldide Peak Area Ratios
Obtained from Aqueous Solutions Extracted Using 'Bond Elut' Columns
(n = 4). Paracetanol N-AcetyI-D-L-msthlonate Concentrations Ranged from
0.2-1.0 ytg.inl"1. The Concentration of Acet-p-toluidlde was 0.25 ug.ml"1 In
Each Sample
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v) Extraction from Plasma
Determination of Optimal Extraction Conditions
The extraction of plasma spiked with paracetamol N-acetyl-D-L-methi-
onate, revealed rapid hydrolysis of the compound. Plasma was
therefore spiked and analysed immediately to minimise this loss.
A small percentage (<6%) of paracetamol N-acetyl-D-L-methionate and
acet-p-toluidide was found to be retained after elution with 300 y. 1
of 100% methanol. Recovery was quantitative when the elution volume
was increased to 350 y 1. The optimum extraction regime for plasma
was found to be as follows:
1. Column Conditioned: a) 1 ml methanol
b) 2 x 1 ml distilled water
2. Plasma Sample Applied to Column (1 ml)
3. Sample Clean Up: a) 1 ml distilled water
b) 1 ml 20% methanol
4. Selective Elution: 350 y1 100% methanol
Assessment of Extraction Procedure Using Plasma Containing
Paracetamol N-acetyl-D-L-methionate (Upper Range 2-10 pig.ml"1)
The extraction of plasma and equivalent aqueous solutions were
compared. Stock aqueous solutions of paracetamol N-acetyl-D-L-methi¬
onate (1 mg.ml"1) and acet-p-toluidide (25 pig.ml"1) were prepared. An
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aqueous solution of 10 pg.ml"1 paracetamol N-acetyl-D-L-methionate was
made by diluting 100 pi 1 of the stock solution in 10 ml of distilled
water. Duplicate extractions were made after mixing 1 ml aliquots
with 100 pi 1 of the 25 pig.ml"1 acet-p-toluidide (internal standard)
solution in plastic tubes. The extracts were then analysed directly
by HPLC. The same procedure was then carried out using blank plasma.
Four aliquots of spiked plasma (10 pig.ml"1) were extracted immedi¬
ately. The 20% methanol wash in addition to the eluates after
application of 2 x 350 pi of methanol were analysed by HPLC.
Aqueous and plasma samples containing paracetamol N-acetyl-D-L-methi-
onate at 2, 4, 6 and 8 pg.ml"1 were prepared similarly and run through
the procedure. Only the first 350 pi methanol elution was analysed
at these concentrations.
Recovery: By comparing the peak areas of paracetamol N-acetyl-D-L-
methionate and acet-p-toluidide obtained from the plasma and aqueous
extracts the percentage recovery of each from plasma was calculated.
The recovery of paracetamol N-acetyl-D-L-methionate (10 pg.ml"1) and
acet-p-toluidide in the first 350 pi methanol elution was in the
range 92-97%. Analysis of the other fractions showed neither para¬
cetamol N-acetyl-D-L-methionate nor acet-p-toluidide to be present
(Table 2.11).
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TABLE 2.11 The Percentage Paracetamol N-acetyt-D-L-roethlonate (PNAM) and Acet-p-
toluidide (APT) Recovered In Bond EIut Fractions Collected Following
Applications of a Spiked 10 pg.ml* PNAM Plasma Sample
' Run
| 20$ Methanol Wash
I
First 350 pi Methanol
EIutlon

















































Chromatograms obtained from the extract of aqueous and plasma samples
were similar. In each case, both peaks were well resolved and free
from any interference. Analysis of the 20% methanol wash following
application of a plasma sample (10 pig.ml"1) demonstrated the degree
of clean up achieved (Figure 2.18). This step was particularly use¬
ful as it removed a potentially interfering peak eluting close to the
paracetamol N-acetyl-D-L-methionate peak.
The mean percentage recovery of paracetamol N-acetyl-D-L-methionate
(2-10 pig.ml"1) and acet-p-toluidide ranged from 91-100% with the coef¬
ficient of variation for each component less than 5% (Table 2.12).
Peak Area Ratios: Peak area ratios of paracetamol N-acetyl-D-L-
methionate/acet-p-toluidide obtained from aqueous and plasma sample
extractions are shown in Table 2.13. Comparing the mean peak area
ratios of paracetamol N-acetyl-D-L-methionate/acet-p-toluidide fol¬
lowing plasma extraction, with that following aqueous extraction
demonstrated that no significant change to the proportions of the 2
components was taking place. The coefficients of variation for 4
plasma extractions at each concentration was less than 5%.
Assessment of Extraction Procedure Using Plasma Containing




were carried out with spiked plasma
-D-L-methionate in the concentration





FIGURE 2»18 Chromatograms of;
A Aqueous paracetamol N-ace+y l-D-L-me+h lonate (10 pg.ml"1) 'Bond Elut' extract (20 pi;
0.04 AUFS)
B 20$ Methanol wash following extraction of plasma containing 10 pig.ml"1 paracetamol N-
acetyI-D-L-methlonate (20 pi; 0.02 AUFS)
C Plasma containing paracetamol N-acety I -D-L-meth lonate (10 pig.ml"1), 'Bond Elut'
extract (20 pi; 0.04 AUFS)
PNAM
PNAM


















































































































































































(0.1 mg.ml"1) and acet-p-toluidide (2.5 yg.ni"!"1) were prepared and used
as before.
The mean percentage recoveries of paracetamol N-acetyl-D-L-methionate
and acet-p-toluidide from plasma ranged from 94-101%, with coeffic¬
ients of variation of less than 5% in the range 0.4-1.0 yg.ml"1. At
0.2 yg.ml^1 the coefficient of variation for paracetamol N-acetyl-D-L-
methionate was 6.1% (Table 2.14).
Peak area ratios of paracetamol N-acetyl-D-L-methionate/acet-p-tolui-
dide obtained from aqueous and plasma extracts were within 5% of each
other, and the coefficient of variation following 4 plasma extract¬
ions was less than 4% (Table 2.15).
Chromatograms obtained from blank plasma and plasma containing
0.2 yg.ml"1 paracetamol N-acetyl-D-L-methionate are shown in
Figure 2.19.
At plasma paracetamol N-acetyl-D-L-methionate concentrations as low
as 0.2 yg.ml"1 peaks were easily detected and well resolved with
minimal interference.
vi) Validation of the Assay for the Estimation of Paracetamol
N-acetyl-D-L-methionate in Plasma
As paracetamol N-acetyl-D-L-methionate is unstable in plasma, it was
not feasible to calibrate the assay using plasma standards. Pre¬
viously in v) it was shown that spiked plasma samples extracted
















































































































































































FIGURE 2.19 Chromatograms of 'Bond Elut' Extractions Containing:
A Blank plasma (30 pi; 0.01 AUFS)








immediately, gave comparable results to those obtained with equiv¬
alent aqueous samples. Aqueous standards were therefore used to
calibrate the assay.
Precision and Linearity (5-25 pig.ml"1)
An aqueous solution was serially diluted to provide paracetamol N-
acetyl-D-L-methionate concentrations in the range 5-25 pig.ml"1. The
concentration of acet-p-toluidide (internal standard) was 50 pig.ml"1.
Prior to extraction, 100 pil of internal standard solution was mixed
with the test sample (1 ml). Each concentration in the range was
analysed 5 times on 5 separate occasions.
The results are shown in Table 2.16 and Figure 2.20. Coefficients of
variation ranged from 0.6-1.7%. The plot of mean peak area ratio
against concentration was linear and passed through the origin.
Precision and Linearity (0.1-1.0 pig.ml"1)
An aqueous solution was serially diluted to give paracetamol N-
acetyl-D-L-methionate concentrations in the range 0.1-1.0 pig.ml"1 and
the concentration of acet-p-toluidide (internal standard) was
2.5 pig.ml"1. Prior to extraction, 100 pi 1 of internal standard
solution was mixed with the test sample (1 ml). Each concentration
in the range was analysed 5 times over a period of 2 days.
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TABLE 2.16 Precision of Paracetamol N-acetyl-D-L-roethlonate Assay -
Aqueous Standards 5-25 ug.ml'1
| Paracetamol Peak Area Ratio PNAM/APT j
|N-acetyl-D-L- 1 | Coefficient of |
| methlonate 1 1 Mean + SD 1 Variation ]
(Concentration Run 1 | Run 2 | Run 3 | Run 4| Run 5| 1 <*> i
j (ug.rnl"1) 1 1




0.507 + 0.004 1 0.7 j
1 io 1 .026 | 1.029| 1.033|
1 1
1 .01 9 | 1.035 |
I I
1 .028 + 0.006 1 0.6 |
1 15 1.555] 1 .548 | 1 .532 |
I I
1.538 | 1 .574|
1 1
1 .549 + 0.016 1 1*1 1




2.080 + 0.031 | 1 .5 |




2.580 + 0.043 I 1 '1 1
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FIGURE 2.20 Linearity of Paracetamol N-Acetyl-D-L-methlonate HPLC Assay: Calibration
Plot of the Mean Peak Area Ratio Obtained Following Repeated Analysis
(n = 5) of Aqueous Solutions Containing Paracetamol N-Acetyl-D-L-
meth lonate In the Range 5-25 yLg.ml'1
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The results are shown in Table 2.17 and Figure 2.21. Coefficients of
variation ranged from 0.7-2.6% for paracetamol N-acetyl-D-L-methio-
nate concentrations in the range 0.2-1.0 ug.ml"1. At 0.1 pig.ml"1 it
was 6.6%. The plot of mean peak area ratio against concentration was
linear and passed through the origin.
Quantitation
For plasma concentrations in the range 5-25 ug.ml"1, aqueous standards
of 5 and 25 ug.ml"1 were prepared and processed in duplicate with the
samples. From the paracetamol N-acetyl-D-L-methionate/acet-p-tolui-
dide peak area ratios for the standards, a factor (F) representing
the reciprocal of the slope of the regression line for the standards
was calculated. The factor multiplied by the paracetamol N-acetyl-D-
L-methionate/acet-p-toluidide peak area ratio for an unknown sample
provided the paracetamol N-acetyl-D-L-methionate concentration in
ug.ml"1. The method of calculation of the factor (F) and the mean
value obtained is shown in Appendix 2.1.
Accuracy (0.1, 1.0 and 10.0 ug.ml"1)
Aqueous solutions of paracetamol N-acetyl-D-L-methionate at concen¬
trations of 0.1, 1.0 and 10.0 ug.ml"1 were run through the procedure 5
times. The percentage accuracy was determined by dividing the calcu¬
lated concentration by the actual concentration.
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The results are shown in Table 2.18. At 1.0 and 10 ug.ml"1, there was
good agreement between calculated and actual concentrations. At
0.1 iig.mT1 the percentage accuracy ranged from 90.5-106.3% with a
coefficient of variation 6.5$.
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TABLE 2.17 Precision of Paracetamol N-acetyl-D-L-methionate Assay - Aqueous Standards
0.1-1 .0 ug-ml "*
| Paracetamol Peak Area Ratio PNAM/APT | 1 1
|N-ace+yl-D-L- I | Coefficient of |
| me+hlona+e 1 1 1 1 I Mean + SD | V ar 1 at 1 on |
[Concentration Run 1 | Run 2| Run 31 Run 4 | Run 5 | 1 1
! (iig.ml"1) 1 1 1 1 I 1 1
| 0.1
1 1 1
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FIGURE 2.21 Linearity of Paracetamol N-Acetyl-D-L-methlonate HPLC Assay: Calibration
Plot of the Mean Peak Area Ratio Obtained Following Repeated Analysis
(n = 5) of Aqueous Solutions Containing Paracetarol N-Acetyl-D-L-
methlonate Concentrations In the Range 0.1-1.0 yig»ml ^
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c) Discussion and Summary
An HPLC method and extraction technique for the estimation of para¬
cetamol N-acetyl-D-L-methionate in plasma has been described. The
chromatographic system used acet-p-toluidide as the internal standard
with a mobile phase of acetonitrilerwater 35:65 v/v at a flow rate of
1.5 ml.min"1, detection was by u.v. at 254 nm. The chromatography was
simple and fast with sharp, well resolved peaks.
The extraction of paracetamol N-acetyl-D-L-methionate from plasma was
carried out using 'Bond E1ut1 C18 solid phase extraction columns. The
method was developed using aqueous solutions and adapted for extrac¬
tion from plasma. Plasma samples (1 ml) containing the internal
standard were passed through a pre-conditioned column. The column
was then washed using 1 ml aliquots of distilled water and 20%
methanol. Quantitative recoveries of paracetamol N-acetyl-D-L-methi¬
onate and internal standard were obtained by selective elution from
the column using 350 y. 1 of 100% methanol. Plasma paracetamol N-
acetyl-D-L-methionate levels as low as 0.1 pig.ml4 were detected with
minimal interference. Sample preparation was rapid and easy to
perform.




STABILITY OF PARACETAMOL N-ACETYL-D-L-METHIONATE
a) Introduction
Paracetamol N-acetyl-D-L-methionate is an ester prodrug where para¬
cetamol is chemically linked by an ester bond to N-acetyl-D-L-methi-
onine. Little is known regarding its stability, and the effects of
pH and temperature were investigated. Using both the paracetamol N-
acetyl-D-L-methionate and paracetamol HPLC assays, the disappearance
of paracetamol N-acetyl-D-L-methionate and the simultaneous
appearance of paracetamol was monitored.
Many ester prodrugs are hydrolysed by ubiquitous esterases (Sinkula
and Yalkowsky; 1975 and Williams, 1985). The rate of paracetamol N-
acetyl-D-L-methionate hydrolysis in the presence of simulated gastric
and intestinal fluid, hog liver esterase and serum has previously
been studied (SWRD Report 303944, 1977). Hydrolysis was slow in the
presence of simulated gastric and intestinal fluid, negligible with
hog liver esterase and rapid in the presence of serum. The stability
of paracetamol N-acetyl-D-L-methionate in human blood samples,
however, was not investigated. Its stability in plasma and whole
blood was therefore studied.
Ill
b) Assessment of Paracetamol N-acetyl-D-L-methionate Stabi1ity
Methods
The stability of paracetamol N-acetyl-D-L-methionate at 20 pig.ml"1 was
investigated. Paracetamol N-acetyl-D-L-methionate concentrations
were estimated using the HPLC method developed (Section 2).
Complete hydrolysis of 20 tig paracetamol N-acetyl-D-L-methionate
yields 9.4 jig of paracetamol. The plasma paracetamol HPLC assay was
therefore adapted to estimate paracetamol concentrations in the range
0.5-10 ug.ml"1. Peaks were quantitated by measuring peak heights.
Process controls to assess the hydrolysis of paracetamol N-acetyl-D-
L-methionate during sample preparation for the estimation of para¬
cetamol were carried out. Hydrolysis to paracetamol did not occur if
samples were analysed within 20 min after the addition of perchloric
acid.
Hydrolysis of Paracetamol N-acetyl-D-L-methionate in Acetate Buffer,
pH 4.0 at 0, 20 and 37°C
Duplicate solutions of paracetamol N-acetyl-D-L-methionate (20 pig.
ml"1) in 0.1 N acetate buffer, pH 4.0 were left to stand in ice (0°C),
at room temperature (20°C) and in a heated water bath (37°C). A1i-
quots were taken from each solution and simultaneous estimations
112
of paracetamol N-acetyl-D-L-methionate and paracetamol were made at
0, 2, 4, 24 and 51 h.
The results are shown in Table 2.19 and Figure 2.22. The semilog
plot of mean paracetamol N-acetyl-D-L-methionate concentration
against time gave a linear response indicative of a first order
process. The half life decreased as temperature increased, being
greater than 100 h at 0 and 20°C and 72 h at 37°C.
The total paracetamol N-acetyl-D-L-methionate equivalents plus para¬
cetamol N-acetyl-D-L-methionate in each sample in every case was
close to 20 pig.ml"1 and there was good agreement between the duplicate
samples.
Hydrolysis of Paracetamol N-acetyl-D-L-methionate in Distilled Water,
pH 6.1 at 0, 20 and 37°C
Duplicate solutions of paracetamol N-acetyl-D-L-methionate (20 pig.
ml"1) in distilled water, pH 6.1 were left to stand at 0, 20 and 37°C.
Aliquots were taken from each solution and simultaneous estimations
of paracetamol N-acetyl-D-L-methionate and paracetamol were made at
0, 2, 4, 24 and 96 h.
The results are shown in Table 2.20 and Figure 2.23. The semilog
plot of mean paracetamol N-acetyl-D-L-methionate concentration
against time was linear with the half life at 0 and 20°C greater than
100 h and 40 h at 37°C. All the paracetamol N-acetyl-D-L-methionate































































































































































































































FIGURE 2.22 Stability of Aqueous Paracetamol N-Acetyl-D-L-methlonate (20 pg.ml'1,
pH 4.0) at 0, 20 and 37°C
Results expressed as mean (n = 2) paracetamol N-acetyl-D-L-methlonate concentration
(pg.ml*)
20.0- - 0°C (ti>100 h)
:§20°C (ti>100 h)




































































































































































































































ND=otdetected*asparac tamolN-acetyl- -L-m thlonate
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FIGURE 2.23 Stability of Aqueous Paracetamol N-Acetyl-D-L-methlonate (20 ug.ml"1,
pH 6.1) at 0, 20 and 57"C
Results expressed as mean (n = 2) paracetamol N-acetyl-D-L-methlonate concentration
Cpg.ml*)
20.0 0°C (ti>100 h)
20°C (ti>100 h)








was accounted for in each sample and there was good agreement between
duplicate samples.
Hydrolysis of Paracetamol N-acetyl-D-L-methionate in Phosphate
Buffer, pH 7.4 at 0, 20 and 37°C
Duplicate solutions of paracetamol N-acetyl-D-L-methionate (20 pig.
ml"1) in 0.07 M phosphate buffer, pH 7.4 were left to stand at 0, 20
and 37°C. Aliquots were taken from each solution and simultaneous
estimations of paracetamol N-acetyl-D-L-methionate and paracetamol
were made at 0, 2, 4, 6 and 24 h.
The results are shown in Table 2.21 and Figure 2.24. The semilog
plot of mean paracetamol N-acetyl-D-L-methionate concentration
against time was linear with the half lives at 0, 20 and 37°C being
95.0, 6.2 and 1.3 h respectively. At 24 h the values obtained for
paracetamol N-acetyl-D-L-methionate and paracetamol in each sample at
20°C deviated from linearity. This may be explained by a fall in
room temperature overnight. All the paracetamol N-acetyl-D-L-methi¬
onate was accounted for in each sample and there was good agreement
between duplicate samples.
The hydrolysis of paracetamol N-acetyl-D-L-methionate at pH 7.4





where Poo = Paracetamol concentration at infinity
Pt = Paracetamol concentration at time (t)
At each temperature, the process was linear and the half lives were
similar to those obtained for the disappearance of paracetamol N-
acetyl-D-L-methionate (Figure 2.25).
Hydrolysis of Paracetamol N-acetyl-D-L-methionate in Tris Buffer,
pH 8.0 at 0, 20 and 37°C
Duplicate solutions of paracetamol N-acetyl-D-L-methionate (20 pig.
ml"1) in 0.2 M Tris buffer, pH 8.0 were left to stand at 0, 20 and
37°C. Aliquots were taken from each solution and simultaneous
estimations of paracetamol N-acetyl-D-L-methionate and paracetamol
were made at 0, 1, 2 and 4 h.
The results are shown in Table 2.22 and Figures 2.26 and 2.27. The
semilog plot of mean paracetamol N-acetyl-D-L-methionate concen¬
tration against time was linear with the half lives at 0, 20 and 37°C
being 5.0, 1.4 and 0.6 h respectively. Similar results were obtained
from the semilog plot for the rate of appearance of paracetamol. All
the paracetamol N-acetyl-D-L-methionate was accounted for in each
sample and there was good agreement between duplicate samples. At
pH 10.0 the hydrolysis of paracetamol N-acetyl-D-L-methionate was
almost instantaneous.





























































































































































































































FIGURE 2.24 Stability of Aqueous Paracetamol N-Acetyl-D-L-methtonate (20 pg.ml'1,
pH 7.4) at 0, 20 and 37"C
Results expressed as mean (n = 2) paracetamol N-acetyl-D-L-methlonate concentration
(U9«ml*)
0°C (ti 95 h)




FIGURE 2.25 Stability of Aqueous Paracetamol N-Acetyl-D-L-methlonate (20 Hg.ml"1,
pH 7.4) at 0, 20 and 37"C
Results expressed as the mean appearance of paracetamol (n = 2)
















































































































































FIGURE 2.26 Stability of Aqueous Paracetamol N-Acetyl-D-L-methlonate (20 ug.ml'S
pH 8.0) at 0, 20 and 37°C




FIGURE 2.27 Stability of Aqueous Paracetamol N-Acetyl-D-L-methlonate (20 ug.ml'S
pH 8.0) at 0, 20 and 37"C
Results expressed as the mean appearance of paracetamol (n = 2)
Time (h)
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Hydrolysis of Paracetamol N-acetyl-D-L-methionate in Plasma at 37°C
Four freshly prepared plasma samples containing 20 yg.ml"1 paracetamol
N-acetyl-D-L-methionate were incubated at 37°C. Aliquots were taken
for the simultaneous estimation of paracetamol N-acetyl-D-L-methi¬
onate and paracetamol at 0, 15, 30, 45 and 60 min. The experiment
was repeated 4 times.
The results are shown in Table 2.23 (i-iii) and Figures 2.28 and
2.29. The semilog plot of mean paracetamol N-acetyl-D-L-methionate
concentration against time was linear and the mean half life was
24 min. Similar results were obtained from the semilog plot of the
rate of appearance of paracetamol. All the paracetamol N-acetyl-D-L-
methionate was accounted for in each sample and there was good
agreement between replicate samples.
Hydrolysis of Paracetamol N-acetyl-D-L-methionate in Whole Blood at
37°C
Fresh whole blood taken into 1ithium-heparin tubes and containing
20 ug.ml"1 paracetamol N-acetyl-D-L-methionate was incubated at 37°C.
Three samples were prepared and analysed at intervals of 1, 2, 3, 4
and 5 min. Paracetamol N-acetyl-D-L-methionate was estimated by ad¬
apting the 'Bond Elut1 extraction method (Page 91).
With whole blood the 'Bond Elut' columns were susceptible to blockage
and sample clean up was inferior. However, the peaks were free from
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TABLE 2.23(1 ) Stability of Paracetamol N-acetyI-D-L-methI onate (20 ug.ml"1) In Plasma







































































3.3 + 0.8 I
TABLE 2.23 (11 ) Stability of Paracetamol N-acety I -D-L-meth lonate (20 ug.ml-1) In Plasma
at 37°C - Paracetamol Estimation
Paracetamol
Concentration (Ug.ml "*)
| T1 me | I I I Mean + SD |












0.7 | ND |







3.3 | 3.1 +_ 0.3 j







5.6 | 5.3 + 0.5 |







7.1 j 6.8 + 0.5 |







8.0 | 7.8 + 0.5 |
ND = Not detected
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TABLE 2.23 (i i 1 ) Stability of Paracetamol N-acety l-D-L-methlonate (20 ug.ml"1) In








j T i me
| Cmins) 1
I I





Mean + SD |
1 0 18.9
I I





19.6 + 0.5 |
1 15 19.6
1 1





19.8 + 0.4 |
I 30 19.4
1 1





19.9 + 0.6 j
| 45 21 .0
I I





20.0 + 1 .1 |
j 60 20.6
I I





20.0 + 0.5 |
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FIGURE 2«28 Stability of Paracetamol N-Acetyl-D-L-methlonate (20 In Plasma at
37 "C




FIGURE 2.29 Stability of Paracetamol N-Acety l-D-L-meth lonate (20 yig.ml'1) In Plasma at
37 °C
Results expressed as the mean appearance of paracetamol (n = 4)
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interference and the recovery of acet-p-toluidide was greater than
80%. Recovery of paracetamol N-acetyl-D-L-methionate was always
slightly less probably due to hydrolysis. This method was used to
provide an indication of the rate of paracetamol N-acetyl-D-L-methi¬
onate hydrolysis in whole blood at 37°C. Paracetamol was not esti¬
mated.
The results are shown in Table 2.24 and Figure 2.30. The semilog
plot of mean paracetamol N-acetyl-D-L-methionate concentration
against time was linear with a half life of 1.5 min.
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FIGURE 2.30 Stability of Paracetamol N-Acetyl-D-L-methlonate (20 ug.ml-1) In Whole Blood
at 37"C
Results expressed as mean (n = 3) paracetamol N-acetyl-D-L-methlonate concentration
(pg.ml "*)
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c) Discussion and Summary
The stability of aqueous paracetamol N-acetyl-D-L-methionate (20 pig.
ml"1) at different temperatures and pH was investigated. Stability
was assessed by the simultaneous estimation of the disappearance of
paracetamol N-acetyl-D-L-methionate and the appearance of paracetamol
by HPLC. All the paracetamol N-acetyl-D-L-methionate could be
accounted for as the parent compound and free paracetamol. The
process obeyed first order kinetics and the rate of hydrolysis was
accelerated by increased pH and temperature.
Similarly, the stability of paracetamol N-acetyl-D-L-methionate
(20 ug.ml^1) in plasma and whole blood at 37°C was investigated. The
rate of hydrolysis in these biological fluids was much greater,
especially in whole blood.
The results are summarised in Table 2.25.
TABLE 2.25 Summary of Results
Paracetamol N-acetyl-D-L-methlonate (20 ug.ml"1) Stability in Aqueous Solutions
Half Life (h)
[ Temperature
| (0°C) pH 4.0 | pH 6.1 |
I I















1 .3 | 0.6 |
Paracetamol N-acetyl-D-L-methlonate (20 pg.ml-1) Stability In Plasma and Whole Blood
| Temperature | | Ha 1f LIfe |



















Paracetamol Disposition in Healthy Male Subjects
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PARACETAMOL DISPOSITION IN HEALTHY MALE SUBJECTS
a) Introduction
Paracetamol metabolism in healthy subjects has been reported previ¬
ously (Davis et al, 1976; Adrienssens, 1980; Prescott, 1980; Forrest
et al, 1982; Critchley et al, 1986). In order to provide appropriate




Ten healthy males with a mean age of 28 + 6 years, body weight 72 +_
11 kg and height 174 + 6 cm were entered into the study. Each was
given a physical examination and screening tests for plasma bio¬
chemistry, haematology were performed together with urinalysis. The
results in all subjects were normal and each subject had a creatinine
clearance value greater than 100 ml.min"1.
Individual details of age, body weight and height are shown in Table
3.1 and mean plasma biochemistry and haematology screen data are
shown in Tables 3.2 and 3.3.
No other drugs were taken for one week and no alcohol for 3 days
prior to and during the study. None of the subjects regularly
consumed excessive quantities of alcohol and one subject smoked.
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| 1 I 30 | 66.8 171 |
I 2 I 27 | 56.8 165 1
| 3 I 25 | 73.2 177 |
I 4 I 33 | 77.1 175 |
I 5 j 20 j 64.2 171 |
I 6 j 29 j 66.6 168 |
| 7 I 32 | 88.0 179 j
I 8 I 39 | 87.0 180 j
I 9 I 23 | 77.8 181 |
I 10 I 23 | 60.9 170 |
| Mean + SD | 28.3 _+ 5.9 | 71.8 _+ 10.6 173.7 +_ 5.5 |
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+ = Department of Clinical Chemistry, Royal Infirmary, Edinburgh
142
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Informed consent was given by each subject and the study was approved
by the local Ethics Committee.
Drug Administration and Sampling
Subjects attended the University Department of Clinical Pharmacology
Patient Investigation Room in the morning after fasting overnight and
an in-dwelling cannula was inserted into a forearm vein. Sachets
containing 1 g of an effervescent formulation of paracetamol were
supplied by Sterling Winthrop, Alnwick. Each subject received the
contents of one sachet orally in 2:00 ml of water. The subjects then
remained recumbent for 3 h and lunch and supper were allowed at 4 and
8 h respectively. They received 200 ml of water every 2 h up to 12 h
and, thereafter, fluid and food intake were unrestricted.
10 ml venous blood samples were taken into heparinised tubes at 0,
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24 h
after dosing. The blood was centrifuged at 1400 x g for 10 min and
the plasma separated and stored at -20°C prior to analysis. Urine
samples were collected immediately before drug administration and
from 0-2, 2-4, 4-6, 6-8, 8-10, 10-12 and 12-24 h after dosing. The
total urine volume and pH were recorded and 50 ml aliquots were
stored at -20°C prior to analysis. Individual urine volumes and pH
values are shown in Appendix 3.9.
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Drug Analysis
Plasma concentrations of paracetamol, paracetamol sulphate and
paracetamol glucuronide, and urine concentrations of paracetamol,
paracetamol sulphate, paracetamol glucuronide, paracetamol cysteine
and paracetamol mercapturic acid were measured by HPLC as described
in Chapter II, Section 1. Metabolite concentrations are expressed as
paracetamol equivalents.
Data Analysis
i) Plasma Concentrations of Paracetamol and its Metabolites
Mean plasma concentrations of paracetamol and its sulphate and
glucuronide conjugates were plotted on a semi logarithmic graph
against time and individual peak plasma concentrations (Cmax) and
time to reach peak plasma concentration (Tmax) determined.
ii) Plasma Elimination Half Life
After absorption and distribution are complete the elimination of
paracetamol is a first order process (Nelson and Moriska, 1963). The
plasma concentration (Cp) at any time (t) can be determined from the





In Cp = In Co -kel.t
or
loq Cp = loq Co -kel.t
2.303
Therefore, a semi logarithmic plot of plasma concentration against
-kel
time exhibits a linear elimination phase with the slope = ^ ^
As the half life is defined as the time taken for the concentration
of drug in plasma to decline to half its original value, the above
equation can be rearranged to determine the elimination half life
(t*g):
/Cp\ -kel.t
log \Co/ = 2.303
fCp\
when log \£o7 = 0.5 and t = tk
log 0.5
then th = -kel = 0.301
2.303 Slope
The plasma elimination half life for paracetamol and the apparent
plasma elimination half life for paracetamol sulphate and paracetamol
glucuronide were determined for each subject as described above. The
slope was determined by direct linear regression from semilogarithmic
plots of plasma concentration against time, over the periods 2-8 h
for paracetamol, 3-8 h for paracetamol sulphate and 5-8 h for parace¬
tamol glucuronide. Formal model dependent curve fitting and compart-
mental analysis was not performed.
where : Co = plasma concentration at
zero time
kel = elimination rate constant
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The plasma paracetamol half life from 8-24 h was also determined as
described above.
iii) Recovery of Paracetamol and its Metabolites in Urine
The percentage of the dose recovered in urine in 24 h as paracetamol
and its sulphate, glucuronide, cysteine and mercapturic acid conju¬
gates was determined and the mean cummulative urinary recovery of
paracetamol and its metabolites plotted against time. The fractional
urinary recovery of paracetamol and its metabolites was also deter¬
mined in divided urine collections.
iv) Urinary Excretion
The urinary excretion rate (mg.h"1) of paracetamol and its metabolites
was determined for each of the divided urine collections up to 12 h.
The mean urinary excretion rate was plotted on a semi logarithmic
graph against time where the time taken was the midpoint of each
urine collection.
Plots of the log of urinary excretion rate of paracetamol and its
metabolites against time eventually become linear (Cummings et al,
1967). Therefore, the urinary elimination half life for paracetamol
and the apparent urinary elimination half life for its conjugates
were determined from the slopes of the linear elimination phase as
described in (ii). The slope was determined by linear regression
using data points from 0-8 h for paracetamol, 2-12 h for paracetamol
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sulphate and glucuronide and 4-12 h for paracetamol cysteine and
mercapturic acid.
v) Renal Clearance
The renal clearance is defined as the volume of plasma completely
cleared of drug as it passes through the kidney in unit time. The
renal clearance of paracetamol and its glucuronide and sulphate
conjugates was calculated using the following equation:
Renal Clearance = Amount excreted in urine
Area under the plasma concentration time curve
over the same time period
The area under the plasma concentration time curve was calculated by
the trapezoidal method. The renal clearances of paracetamol and its
sulphate and glucuronide conjugates were determined over the period
0-8 h after dosing.
vi) Statistical Analysis
Mean values +_ standard deviation (SD) are presented. The relation¬
ship between quantitative observations on each subject (bivariate
data) was determined by calculation of the correlation coefficient
(r). The correlation coefficient was tested for statistical signifi¬
cance using tabulated values (Geigy Scientific Tables, page 61).
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The Student t-test for paired data was used to test for statistical
significance.
c) Results
i) Plasma Concentrations of Paracetamol and its Sulphate and
Glucuronide Conjugates
Mean plasma concentrations of paracetamol and its sulphate and
glucuronide conjugates following oral administration of 1 g of
paracetamol to 10 healthy male subjects are shown in Table 3.4 and
Figure 3.1. Plasma concentrations of the cysteine and mercapturic
acid conjugates of paracetamol were below the limit of detection.
Individual values for peak concentration (Cmax), time to reach peak
concentration (Tmax) and apparent elimination half life are shown in
Tables 3.5 and 3.6 respectively. Plasma concentrations for each
subject are shown in Appendices 3.1-3.3
Paracetamol
Paracetamol absorption was rapid with a mean individual peak plasma
paracetamol concentration of 20.0 _+ 8.4 pig.ml"1 (range 12.9-40.7)
occurring at 0.35 _+ 0.17 h (range 0.25-0.75) after administration.
In most subjects the peak plasma paracetamol concentration occurred
at or before the time of the first sample at 15 min. Following
distribution, plasma paracetamol concentrations declined in a linear
fashion from 2-8 h when plotted against time on a semi logarithmic
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TABLE 3.4 Mean Plasma Concentrations of Paracetamol and Its Sulphate and GlucuronIde
Conjugates In 10 Healthy Male Subjects Following Ingestion of 1 g of
Paracetamol
| Time After | Plasma Concentration (pg.ml"1)
| Ingestion | Paracetamol | Paracetamo Sulphate |Paracetamol GIucuron1de|
1 (h> 1
1 1
(Mean + SD) | (Mean + SD) |
1 1
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FIGURE 3.1 Mean Plasma Concentrations of Paracetamol and Its Sulphate and Glucuronlde








TABLE 5.5 Peak Plasma Concentrations (Cmax) and Tims to Reach Peak Plasma
Concentrations (Tmax) of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 10 Healthy Male Subjects Following Ingestion of 1 g of
ParacetamoI
j Paracetamol j Paracetamo SuIphate Paracetamol GlucuronIde|
Subject j Cmax I Tmax j Cmax Tmax Cmax 1 Tmax i
























































































3.5 -_+ 0.7 1 .08 _+ 0.53 9.4 _+ 2.6 j2.00 _+ 0.441
152
TABLE 5.6 Apparent Plasma Elimination Half Life of Paracetamol and Its Sulphate and
Glucuronide Conjugates In 10 Healthy Male Subjects Following Ingestion of
1 g of Paracetamol
| Subject | Apparent Plasma Elimination Ha f Life (h)























































































































.0 _+ 0.3 |
Half 1ife ca1cu ated over: 2-8 h for paracetamol
3-8 h for paracetamol sulphate
5-12 h for paracetamol glucuronide
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graph. The mean elimination half life over this period was 2.3 +
0.3 h (range 1.9-2.7). From 8-24 h the paracetamol disappeared more
slowly with a mean half life of 5.4 +_ 2.4 h. Little or no parace¬
tamol was detected after 24 h.
Paracetamol Sulphate
Paracetamol sulphate was detected in plasma at 15 min and the mean
individual peak concentration was 3.5 +_ 0.7 yg.ml"1 (range 2.1-4.5) at
1.08 +_ 0.53 h (range 0.5-2.0). The mean concentrations of sulphate
conjugate were lower than those of the parent drug at all times and
the mean half life from 3-8 h was 3.2 _+ 0.4 h (range 2.8-3.9). Little
or no paracetamol sulphate was detected after 24 h.
Paracetamol Glucuronide
Plasma paracetamol glucuronide concentrations rose steadily after
15 min, exceeding the plasma concentrations of paracetamol in most
subjects after 1 to 2 h. The mean individual peak concentration was
9.4 +_ 2.6 ug.mT"1 (range 5.8-13.3) at 2.00 +_ 0.44 h (range 1.5-3.0)
and the mean half life from 5-12 h was 3.0 +_ 0.3 h (range 2.4-3.4).
The mean individual time to reach peak paracetamol glucuronide con¬
centration differed significantly from that of the sulphate conjugate
(t = 4.869, P<0.001). After 24 h only trace amounts of the glucuro¬
nide conjugate were detected in plasma in 6 of the 10 subjects.
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li) Urine Recovery of Paracetamol and its Sulphate, Glucuronide
Cysteine and Mercapturic Acid Conjugates
The percentages of the dose recovered in the urine in 24 h as para¬
cetamol and its metabolites are shown in Table 3.7 and the mean cumu¬
lative urinary recoveries in Figure 3.2. Individual urinary excre¬
tion data are shown in Appendices 3.4-3.8.
Most of the administered dose was recovered in urine as the sulphate
and glucuronide conjugates of paracetamol. In all subjects the 24 h
urinary recovery of the glucuronide conjugate was greater than that
of the sulphate conjugate. The mean 24 h urinary recovery of parace¬
tamol sulphate and paracetamol glucuronide was 23.7 +_ 4.5 (range
18.1-31.2) and 49.8 + 6.8% of the dose (range 39.2-63.7) respec¬
tively. Approximately half of the total glucuronide and sulphate
conjugates recovered was excreted within 4 h.
The mean 24 h urinary recovery of paracetamol was 3.6 +_ 1.5% of the
dose (range 1.5-6.0), of which approximately half was recovered after
2 h.
After 24 h, 5.6 +_ 2.5% of the dose was recovered as the cysteine and
mercapturic acid conjugates of paracetamol. The cysteine and mercap-
turic acid conjugates combined represented 1.8 +_ 0.8 after 4 h and
4.2 +_ 1.7% of the dose after 8 h. More mercapturic acid than
cysteine conjugate was recovered in all subjects. The mean 24 h
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TABLE 3.7 Percentage of Dose Recovered In Urine as Paracetamol and Its Sulphate,
Glucuronide, Cysteine and Mercapturic Acid Conjugates in 24 h Following
Ingestion of 1 g of Paracetamol in 10 Healthy Male Subjects
Percentage of Dose Recovered in Urine Over 24 h
|Subject |Paracetamol Cysteine +
|Number Paracetamol Paracetamol |Paracetamol Paracetamol |Mercapturic Mercapturic TotaIj
Su I phate |GIucuronide Cysteine | Ac! d Aci d
j 1 6.0 26.1 | 47.8 3.1 | 4.8 7.9 87.8 |
I 2 1 .5 18.7 | 51 .2 2.1 1 3.3 5.4 76.8 |
j 3 3.2 18.5 | 50.0 1.9 | 2.0 3.9 75.3 |
I 4 4.6 31 .2 | 39.2 4.4 1 5.1 9.5 84.5 |
I 5 2.7 18.1 | 54.0 2.1 | 3.0 5.1 79.9 |
I 6 2.7 23.6 | 53.4 1 .3 1 2-3 3.6 83.4 |
| 7 3.9 29.7 | 42.6 3.7 | 5.6 9.3 85.5 |
I 8 1 .6 23.9 | 50.3 0.8 1 1 »5 2.3 78.1 |
I 9 5.6 22.4 j 63.7 1 .0 I 3.4 4.4 96.1 |
I 10 3.7 24.3 | 45.7 2.1 | 2.8 4.9 78.6 |
| Mean 3.6 23.7 | 49.8 2.3 I 3.4 5.6 82.6 |
| + + + + + + + + |
I sF U5 475 | 6.8 i72 I 1~4 275 673 j
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FIGURE 3.2 Mean Cumulative Urinary Recovery of Paracetamol and its Metabolites up to
24 h in 10 Healthy Male Subjects Following Ingestion of 1 g of Paracetamol
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urinary recoveries of paracetamol cysteine and paracetamol mercap-
turic acid were 2.3 + 1.2 (range C.8-4.4) and 3.4 _+ 1.2% of the dose
(range 1.5-5.6) respectively.
The mean total amounts recovered in urine after 6, 12 and 24 h were
53.9%, 75.5% and 82.6% of the dose respectively.
iii) Fractional Excretion of Paracetamol and its Sulphate,
Glucuronide, Cysteine and Mercapturic Acid Conjugates
The mean percentages of total drug excreted in divided urine collec¬
tions as paracetamol and its metabolites following ingestion of 1 g
of paracetamol in 10 healthy male subjects are shown in Table 3.8 and
Figure 3.3. Individual data are shown in Appendices 3.4-3.8.
The glucuronide conjugate of paracetamol accounted for the greatest
proportion of the total excreted. Over the first 2 h the mean frac¬
tion excreted as the glucuronide conjugate was 54.8 + 8.4%, increas¬
ing to 62.4 +_ 7.1% by 4 h. For the next 12 h the mean fraction
excreted as the glucuronide conjugate remained constant, after which
it declined to 49.5 + 27.9% from 12 to 24 h.
The fraction excreted as paracetamol sulphate followed the opposite
pattern to that of the glucuronide conjugate, accounting for 32.9 +
6.6% up to 2 h, then falling to 27.1 + 4.7% by 4 h. The fraction
excreted as sulphate conjugate remained relatively constant until
12 h, after which it increased to 43.2 + 23.3% from 12 to 24 h.
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TABLE 5-8 Mean Percentage of Total Drug Excreted In Divided Urine Collections as
Paracetamol and Its Metabolites Following Ingestion of 1 g of Paracetamol
in 10 Healthy Male Subjects
| Time After
Mean Proportion Excreted (as Percentage of Total in Sample) + SD |
| Ingestion










| 0-2 9.6 +_ 2.8 | 32.9 +_ 6.6
I




| 1.8 + 1.1 |
I I
j 2-4 4.3 +_ 2.3 | 27.1 _+ 4.7
I




| 4.1 + 1 .4 |
I I
| 4-6 3.1 +1.8 j 24.8 _+ 4.7
I




| 5.0 + 2.2 |
I I
j 6-8 2.9 _+ 2.9 | 24.5 _+ 5.2
I




| 4.8 + 1.8 |
1 1
| 8-10 1 .2 _+ 2.1 | 26.6 _+ 5.3
I




| 4.9 + 1.9 |
1 1
| 10-12 0.3 +_ 1 .0 | 28.0 +_ 4.5
I




| 4.5 + 1.4 |
I I
| 12-24 - j 43.2 _+ 23.3
I




| 4.7 + 5.7 |
I I
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FIGURE 3«5 Changes In the Mean Proportional Urinary Excretion of Paracetamol and Its
Sulphate, Glucuronlde, Cysteine and Mercapturlc Acid Conjugates with Time
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Paracetamol accounted for 9.6 _+ 2.8% of the total excreted over the
first 2 h. Thereafter, the fraction excreted unchanged decreased.
After 10 h urinary concentrations of paracetamol were below the limit
of detection in most subjects.
The patterns of excretion of the cysteine and mercapturic acid conju¬
gates of paracetamol were similar with greater recovery as mercaptur-
ate than the cysteine conjugate. Over the first 2 h less than 2% of
the total was excreted as the cysteine or the mercapturate conjugate.
The fraction increased to 4.2 +_ 2.2 and 4.8 +_ 1.8% respectively by
8 h. Thereafter the fractional excretion of these metabolites gradu¬
ally declined.
iv) Urinary Excretion Rate of Paracetamol and its Sulphate,
Glucuronide, Cysteine and Mercapturic Acid Conjugates
The mean urinary excretion rates of paracetamol and its metabolites
in 10 healthy male subjects following ingestion of 1 g of paracetamol
are plotted on a semi logarithmic graph in Figure 3.4. The apparent
urinary elimination half life values of paracetamol and its metabo¬
lites calculated from plots of individual urinary excretion rates are
shown in Table 3.9. Individual data are shown in Appendices 3.4-
3.8.
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FIGURE 3.4 Mean Urinary Excretion Rates of Paracetamol and Its Metabolites In 10












TABLE 3.9 Apparent Urinary Elimination Half Life of Paracetamol and Its Metabolites In
10 Healthy Male Subjects Following Ingestion of 1 g of Paracetamol























































































(n = 9) |
+ = Accurate determination not possible due to fluctuation In excretion rate
Where enough data points were available, half life was calculated over:
0-8 h for paracetamol
2-12 h for paracetamol sulphate and paracetamol glucuronide
4-12 h for paracetamol cysteine and paracetamol mercapturlc acid
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Paracetamol
The mean urinary excretion rate of paracetamol was 8.6 +_ 4.0 mg.IT1
over the first 2 h and after 4 h the rate was less than that of its
metabolites. A plot of the log of the mean urinary excretion rate of
paracetamol against time was linear from 0-8 h and the mean urinary
elimination half life over this time was 2.4 + 0.6 h (range 1.8-
3.7).
Individual excretion rates fluctuated and accurate determination of
the apparent urinary elimination half life was not possible for
paracetamol in Subject 8 or for paracetamol and its metabolites in
Subject 3. The urinary half life for paracetamol was not determined
in Subject 2 as there were too few data points.
Paracetamol Sulphate
The mean urinary excretion rate of paracetamol sulphate peaked during
the first 4 h. Mean urinary excretion rates from 0-2 and 2-4 h were
28.2 + 10.4 and 28.3 +_ 5.9 mg.h"1 respectively and, thereafter, the
mean urinary excretion declined. Semilog plots of paracetamol
sulphate excretion rate against time were linear from 2 to 12 h. The
mean apparent urinary elimination half life for paracetamol sulphate
from 2-12 h was 3.3 +_ 0.5 h (range 2.4-4.0).
Individual paracetamol sulphate urinary excretion rates were gener¬
ally lower than those of the glucuronide conjugate throughout. In
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Subjects 4 and 7, however, the excretion rate of the sulphate conju¬
gate from 0-2 h was marginally higher than that of the glucuronide
conjugate.
Paracetamol Glucuronide
At each time point the mean urinary excretion rates of the glucuron¬
ide conjugate exceeded those of the parent drug and the other metabo¬
lites. The mean paracetamol glucuronide excretion rate increased
from 46.5 + 18.8 mg.h"1 over the first 2 h to peak at 66.2 + 10.5 mg.
h"1 from 2-4 h. Thereafter, a plot of log of the mean urinary excre¬
tion rate of the glucuronide conjugate against time was linear. The
mean urinary elimination half life from 2-12 h was 3.1 + 0.4 h
(range 2.6-3.6).
Paracetamol Cysteine and Mercapturic Acid
Mean urinary excretion rates of the cysteine and mercapturic acid
conjugates were initially low, increasing to 2.8 +_ 1.6 mg.h"1 from
4-6 h and 4.3 + 1.6 mg.h"1 from 2-4 h respectively. The mean urinary
excretion rates of the mercapturic conjugate were slightly higher
than those of the cysteine conjugate at each time point. The mean
apparent urinary elimination half life from 4-12 h was 3.2 _+ 1.0
(range 1.8-4.9) and 2.9 + 0.5 h (range 2.1-3.5) for the cysteine and
mercapturic acid conjugates respectively.
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v) Renal Clearances of Paracetamol arid its Sulphate and Glucuronide
Conjugates
The mean renal clearances of paracetamol, paracetamol sulphate and
paracetamol glucuronide calculated over 0-8 h were 15.2 +_ 7.0 (range
6.2-28.2), 180.5 + 31.6 (range 143.0-247.0) and 136.9 + 32.9 ml.min"1
(range 100.3-191.9) respectively. The paracetamol renal clearance
(0-8 h) was positively correlated with urine flow rate (r = 0.81,
P<0.01), but no such correlation existed for the sulphate or the
glucuronide conjugates. There was no significant correlation between
the 0-8 h renal clearance of paracetamol or its glucuronide or
sulphate conjugates and urinary pH.
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d) Piscussion
The absorption of paracetamol in healthy male subjects was rapid and
peak plasma concentration occurred in most subjects before the first
blood sample was taken at 0.25 h. Paracetamol is predominantly
unionised at physiological pH and is absorbed by passive diffusion
from the upper gastro-intestinal tract. As paracetamol was adminis¬
tered in solution and all subjects had fasted overnight, factors
likely to delay absorption were minimised. The mean peak plasma
paracetamol concentrations and the times to reach the peak were
comparable to those reported in other studies where 1 g of paraceta¬
mol was administered under similar conditions (McGilvary and Mattock,
1972; Rawlins et al, 1977; Perucca and Richens, 1979).
Following absorption, there is a distribution phase during which in
addition to elimination, paracetamol leaves the circulation to be
taken up by peripheral tissues. The distribution phase ends with
equilibrium between the tissues and the circulation and this occurred
at approximately 1.5 h. Paracetamol is distributed throughout most
tissues but not fat (Gwilt et al, 1963).
From about 2-8 h the fall in plasma paracetamol concentrations
represents removal of paracetamol by hepatic metabolism. The mean
plasma paracetamol elimination half life over this period was 2.3 _+
0.3 h (range 1.5-2.5) in good agreement with other published data
(Prescott, 1980; Forrest et al, 1982).
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A third phase from 8-24 h was also observed in which the mean half
life was 5.4 + 2.4 h. This is consistent with a 3 compartment model
and was similar to the value of 4.2 h observed after sampling for
12 h (Clements and Prescott, 1976).
Metabolism of paracetamol by the gastro-intestinal tract is insigni¬
ficant in man (Clements et al, 1984; Rogers et al, 1987), however,
once absorption has taken place paracetamol reaches the systemic
circulation via the portal vein and the liver. Paracetamol is exten¬
sively metabolised on its first pass through the liver and the amount
of parent drug reaching the systemic circulation is significantly
reduced. The oral bioavailability in man after 1 g of paracetamol is
892> (Rawlins et al, 1977; Perucca and Richens, 1979) and is indepen¬
dent of dose (Clements et al, 1984).
The extent and rate of paracetamol metabolism is reflected in the
mean recovery of only 3.6% of the dose unchanged in urine in 24 h,
7Z% of which was recovered in the first 4 h.
As expected, the mean elimination half life values of paracetamol in
urine and plasma were similar. The pattern of excretion of parace¬
tamol and its metabolites in the present study was comparable to that
reported in similar studies in healthy subjects (Adrienssens, 1980;
Prescott, 1980; Forrest et al, 1982).
The sulphate and glucuronide conjugates are the major metabolites of
paracetamol and their combined mean 24 h urinary recovery represented
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73.4% of the dose. The sulphate conjugate appeared more rapidly than
the other metabolites of paracetamol. At 0.25 h the mean plasma
paracetamol sulphate concentration was greater than that of any of
the other metabolites and the mean individual peak plasma concentra¬
tion occurred at 1.1 + 0.5 h. In addition, the fractional urinary
excretion of paracetamol sulphate and the maximum urinary excretion
rates were greatest at early time points. Sulphate conjugation is,
however, susceptible to dose dependent saturation within the thera¬
peutic dose range (Prescott, 1984), and in keeping with this the mean
paracetamol sulphate excretion rate was relatively constant over the
first 4 h. This has been reported previously and was thought to be
consistent with capacity limited formation of paracetamol sulphate
(Levy and Yamada, 1971). Following rapid absorption of paracetamol,
inorganic sulphate (a precursor of 3'-phosphoadenosine-5'-phosphosul-
phate) may become depleted, thus reducing the capacity for sulpha-
ti on.
Plasma paracetamol glucuronide concentrations were higher than those
of the parent drug after 1-2 h and they continued to rise after the
peak plasma paracetamol sulphate concentration had been attained.
The mean of the individual peak plasma paracetamol glucuronide
concentrations was 9.4 + 2.6 pig.ml"1 at 2 h.
The mean apparent plasma elimination half life values for paracetamol
sulphate and paracetamol glucuronide were greater than that for the
parent drug (3.2 + 0.4 and 3.0 + 0.3 h respectively). Similar values
were obtained for the mean urinary elimination half life for the
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sulphate and glucuronide conjugates of paracetamol. Comparable
findings and values were reported by Adrienssens (1980).
A minor fraction of paracetamol is metabolised to a reactive inter¬
mediate which is probably N-acetyl-p-benzoquinone-imine (Miner and
Kissinger, 1979). This reactive intermediate is normally deactivated
by conjugation with hepatic glutathione (Mitchell et al, 1973b, 1974)
and is metabolised further to form the cysteine and mercapturic acid
conjugates of paracetamol (Prescott, 1980). The plasma concentra¬
tions of these conjugates of paracetamol were below the limits of
detection but both were detected in the urine of most subjects within
2 h. The mean 24 h urinary recoveries of the cysteine and mercap¬
turic acid conjugates were 2.3 + 1.2 and 3.4 + 1.4% of the dose
respectively. The maximum excretion rates of these conjugates were
delayed relative to the other metabolites. The mean apparent urinary
elimination half life of the cysteine and mercapturic acid conjugates
were similar to those for sulphate and glucuronide conjugates.
In young healthy subjects approximately 85-95% of a therapeutic dose
of paracetamol is excreted in the urine within 24 h (Forrest et al,
1982). In the present study the mean total 24 h urinary recovery was
82.6 +_ 6.3% of the dose (range 75.3-96.1) which is slightly lower.
This is likely to be associated with collection of urine samples and
compliance with the protocol.
The inter-individual variation in paracetamol metabolism previously
reported (Caldwell et al, 1980; Clements et al, 1984; Critchley et
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al, 1986) was observed in the present study. In particular, Subjects
4 and 7 produced less paracetamol glucuronide and more paracetamol
sulphate, cysteine and mercapturic acid conjugates than the other
subjects. Factors such as age, alcohol, drugs and diet may influence
paracetamol metabolism.
The mean renal clearance of paracetamol was low (15.2 +_ 7.0 ml.min"1)
and positively correlated with urine flow rate but not urinary pH.
This is in keeping with filtration of paracetamol at the glomerulus
followed by passive reabsorption. The renal clearances of the
sulphate and glucuronide conjugates of paracetamol were greater than
the glomerular filtration rate (180.5 +_ 31.6 and 136.9 +_ 32.9 ml.min"1
respectively). The renal clearances of these metabolites were not
correlated with urine flow rate or pH suggesting active tubular
secretion with negligible reabsorption. These results are consistent
with other data obtained in healthy subjects where the mean renal
clearances of paracetamol, paracetamol sulphate and paracetamol glu¬
curonide were 13, 170 and 130 ml.min"1 respectively (Prescott, 1980;
Forrest etal, 1982; Morris and Levy, 1984).
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e) Summary
The absorption, distribution, metabolism and elimination of parace¬
tamol were studied in 10 healthy male subjects after oral administra¬
tion of 1 g of an effervescent formulation of paracetamol.
Paracetamol was rapidly absorbed, distributed and extensively metabo¬
lised with only 3.6% of the dose recovered unchanged in urine. The
mean individual peak plasma paracetamol concentration was 20 pig.ml"1
at 0.35 h and the mean elimination half life was 2.3 h. The major
metabolite of paracetamol was paracetamol glucuronide representing
49.8% of the dose with 23.7% of the dose excreted as paracetamol
sulphate. Conversion to paracetamol sulphate, was however, initially
more rapid. The capacity for sulphate conjugation was probably
reduced because of saturation of the pathway.
A minor fraction of the dose was recovered as the cysteine (2.3%) and
mercapturic acid (3.4%) conjugates of paracetamol. The appearance of
these metabolites in urine was initially slow. They represent the
proportion of the dose metabolised to the reactive intermediate which
is then conjugated with glutathione.
The renal clearance of paracetamol was 15.2 ml.min"1 with paracetamol
filtered freely at the glomerulus and then passively reabsorbed. The
glucuronide and sulphate conjugates were actively secreted by the
tubule as their clearances were greater than the normal glomerular
filtration rate, being 137 and 181 ml.min"1 respectively. The mean
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PARACETAMOL N-ACETYL-D-L-METHIONATE DISPOSITION IN
HEALTHY MALE SUBJECTS
a) Introduction
Oral administration of the glutathione precursor methionine, is an
effective method of preventing severe liver damage and death after
paracetamol overdosage (Crome et al, 1976; Hamlyn et al, 1981, Vale
et al, 1981). Initial delay in presentation to hospital probably
accounts for the increasing mortality rate attributed to paracetamol
poisoning, as to be effective, methionine must be given within 10 h
of paracetamol ingestion.
It was first suggested in 1975 by McLean and Day that the addition of
methionine to paracetamol tablets may make paracetamol safer when
taken in overdosage. These suggestions have been reiterated more
recently (Neuvonen et al, 1985). In late 1986, 'Pameton' which
contains paracetamol (500 mg) and D-L-methionine (250 mg) was intro¬
duced. However, it is expensive and was not included in the National
Health Service Limited List.
Continuing along these lines, Sterling Winthrop have linked paraceta¬
mol and N-acetyl-D-L-methionine as the N-acetyl-D-L-methionine ester
of paracetamol. This compound is tasteless and on hydrolysis yields
equimolar quantities of paracetamol and methionine.
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As part of the evaluation and development of this ester, healthy male
subjects received orally, 1 g of paracetamol as (1) paracetamol and
(2) paracetamol N-acetyl-D-L-methionate. At least one week was
allowed between each administration. This chapter describes the
disposition of paracetamol following administration of paracetamol N-
acetyl-D-L-methionate alone. Data obtained from healthy male




The same 10 healthy male subjects as previously described in Chapter
III with a mean age of 28 +_ 6 years and body weight 72 +_ 11 kg were
entered into the study. Screening tests for plasma biochemistry,
haematology, urinalysis and creatinine clearance were normal.
Individual details of age, body weight and height are shown in
Table 3.1 and mean plasma biochemistry and haematology screen data
are shown in Tables 3.2 and 3.3
No other drugs were taken for one week and no alcohol for 3 days
prior to and during the study. None of the subjects regularly con¬
sumed excessive quantities of alcohol and one subject smoked. In¬
formed consent was given by each subject and the study was approved
by the local Ethics Committee.
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Drug Administration and Sampling
Subjects attended the University Department of Clinical Pharmacology
Patient Investigation Room in the morning after fasting overnight,
and an in-dwelling cannula was inserted into a forearm vein. Sachets
containing 2.146 g of an effercescent formulation of paracetamol N-
acetyl-D-L-methionate (equivalent to 1 g paracetamol) were supplied
by Sterling Winthrop, Alnwick. Each subject received the contents of
one sachet orally in 200 ml of water. The subjects remained recum¬
bent for 3 h and lunch and supper were allowed at 4 and 8 h respect¬
ively. They received 200 ml of water every 2 h up to 12 h, and
thereafter fluid and food intake were unrestricted.
10 ml venous blood samples were taken into heparinised tubes at 0,
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24 h
after dosing. The blood was centrifuged at 1400 xg for 10 min and
the plasma separated and stored at -20°C prior to analysis. Urine
samples were collected immediately before drug administration and
from 0-2, 2-4, 4-6, 6-8, 8-10, 10-12 and 12-24 h after dosing. The
total urine volume and pH were recorded and 50 ml aliquots were
stored at -20°C prior to analysis. Individual urine volumes and pH
values are shown in Appendix 4.9.
Drug Analysis
In addition to measurement of plasma and urine concentrations of
paracetamol and its metabolites as described in Chapter II, Section 1
measurement of plasma concentrations of paracetamol N-acetyl-D-L-
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methionate was attempted by HPLC as described in Chapter II,
Section 2.
10 ml venous blood samples from 4 subjects were taken into cooled
heparinised tubes in ice (0°C) at times ranging from 0.75-3 h after
dosing. The blood was centrifuged at 1400 x g at 0°C for 10 min and
1 ml of plasma taken for immediate analysis. The time from taking
the sample to its injection into the HPLC was approximately 25 min.
Paracetamol N-acetyl-D-L-methionate undergoes rapid hydrolysis in
plasma and whole blood (Chapter II, Section 3) and the extent to
which this occurred during processing of samples was assessed by
measuring plasma paracetamol and paracetamol N-acetyl-D-L-methionate
concentrations in fresh whole blood spiked with paracetamol N-acetyl-
D-L-methionate (20ug.mr1). In addition fresh whole blood spiked
with 0.04, 0.4 and 4.0 yg.ml"1 of paracetamol N-acetyl-D-L-methionate
was processed as described, to determine the threshold for detection
of paracetamol N-acetyl-D-L-methionate.
Data Analysis
i) Plasma Concentration of Paracetamol and its Metabolites
Mean plasma concentrations of paracetamol and its sulphate and
glucuronide conjugates were plotted on a semilogarithmic graph
against time and Cmax, Tmax, AUC and th values were determined as
described in detail in Chapter III. The relative paracetamol bio¬
availability was calculated by dividing the 0-24 h area under the
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plasma paracetamol concentration-time curve after administration of
2.146 g paracetamol N-acetyl-D-L-methionate by the corresponding
plasma paracetamol area under the curve following administration of
1 g of paracetamol alone to the same healthy male subjects.
ii) Urinary Excretion of Paracetamol and its Metabolites
Each subject received 2.146 g of paracetamol N-acetyl-D-L-methionate
which if completely hydrolysed would yield 1 g of paracetamol. As
only paracetamol and its metabolites were measured in urine it was
the percentage of the paracetamol component of the dose (1 g) re¬
covered in urine in 24 h following administration of paracetamol N-
acetyl-D-L-methionate which was determined.
In addition the cumulative urinary recovery, fractional urinary
recovery in divided collections, urinary excretion rate, urinary
elimination half life and renal clearance of paracetamol and its
metabolites were calculated as described in detail in Chapter III.
iii) Statistical Analysis
Mean values +_ standard deviation (SD) are presented. The relation¬
ship between quantitative observations on each subject (bivariate
data) was determined by calculation of the correlation coefficient
(r). The correlation coefficient was tested for statistical signifi¬
cance using tabulated values (Geigy Scientific Tables, page 61).
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The Student t-test for paired data was used for statistical signifi¬
cance.
c) Results
i) Plasma Concentrations of Paracetamol N-acetyl-D-L-methionate
No measurable paracetamol N-acetyl-D-L-methionate was detected in any
of the plasma samples taken from the 4 subjects. The limit of detec¬
tion of plasma paracetamol N-acetyl-D-L-methionate was 0.1 pig.ml"1.
Experiments showed that 42 +_ 8% of the paracetamol N-acetyl-D-L-
methionate was hydrolysed in the time taken to process a spiked whole
blood sample (20 pig.ml"1; n = 4) and that a whole blood concentration
of 1 to 4 pig.ml"1 would be required for the detection of any paraceta¬
mol N-acetyl-D-L-methionate under these experimental conditions.
ii) Plasma Concentrations of Paracetamol and its Sulphate and
Glucuronide Conjugates
Mean plasma concentrations of paracetamol and its sulphate and glucu¬
ronide conjugates following oral administration of 2.146 g of para¬
cetamol N-acetyl-D-L-methionate in 10 healthy male subjects are shown
in Table 4.1 and Figure 4.1. Following administration of 2.146 g of
paracetamol N-acetyl-D-L-methionate, plasma concentrations of the
cysteine and mercapturic acid conjugates of paracetamol were below
the limit of detection. Individual values for peak concentration
(Cmax), time to reach peak concentration (Tmax) and apparent elimi-
180
TABLE 4.1 Mean Plasma Concentrations of Paracetamol and Its Sulphate and Glucuronlde
Conjugates in 10 Healthy Male Subjects Following Ingestion of 2.146 g of
Paracetamol N-Acetyl-D-L-methlonate
| T1 me After | P I asma Concentration (pig.ml"1)
| Ingestion [ Paracetamol | Paracetamol Sulphate |Paracetamol Glucuronide|
1 <h) 1
1 1
(Mean + SD) | (Mean + SD) |
1 1














| 2.0 +_ 0.7 |
1 |






| 2.7 _+ 0.9 |
1 |






| 3.1 _+ 1 .0 |
1 |






| 3.8 _+_ 1 .1 |
1 |






| 3.8 + 1.1 |
I i






| 3.5 _+ 1.1 |
I |












3.2 _+ 1 .0+
1 1
| 2.4 +_ 0.9 |
1 i














| 1 .4 _+ 0.7 |
I |






| 1 .2 _+ 0.5 |
I |






| 1.0 +_ 0.4 |
1 |














| 0.5 +_ 0.3 |
1 |






| 0.1 + 0.2 |
1 1
0.4 +_ 0.2 |
* = Mean of 9
+ = Significantly Increased compared to administration of paracetamol alone; P<0.05
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FIGURE 4.1 Mean Plasma Concentrations of Paracetamol and Its Sulphate and Glucuronide













nation half life are shown in Tables 4.2 and 4.3 respectively.
Plasma concentrations for each subject are shown in Appendices 4.1-
4.3.
Paracetamol
Plasma paracetamol concentrations fluctuated in most subjects prior
to reaching peak concentration. The mean individual peak plasma
paracetamol concentration after administration of the methionate
ester was significantly reduced (10.1 +_ 1.8 ug.mr1 compared to 20.0 +_
8.4 uO-mi"1 with paracetamol alone; t = 4.183, P<0.01) and delayed
(1.08 +_ 0.55 h compared to 0.35 _+ 0.17 h with paracetamol alone; t =
4.657, P<0.01). From 2-8 h plasma paracetamol concentrations de¬
clined linearly when plotted on a semi-logarithmic graph. The mean
elimination half life over this period was 2.3 +_ 0.3 h (range 1.9-
2.8) which was the same as that obtained after administration of
paracetamol alone to the same subjects. From 1.5-10 h after dosing
the mean plasma paracetamol concentrations with paracetamol N-acetyl-
D-L-methionate were significantly higher than those obtained after
administration of paracetamol. Too few data points were available to
accurately determine the paracetamol half life from 10-24 h.
Paracetamol Sulphate
Paracetamol sulphate was detected in plasma after 15 min in most
subjects. Compared with paracetamol alone, the mean individual time
to reach peak plasma paracetamol sulphate concentration was signifi¬
cantly delayed (1.90 + 0.61 h compared with 1.08 + 0.53 h; t = 3.587,
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TABLE 4.2 Peak Plasma Concentrations (Cmax) and Time to Reach Peak Plasma
Concentrations (Tmax) of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 10 Healthy Male Subjects Following Ingestion of 2.146 g
of Paracetamol N-Acetyl-D-L-methIonate
J Paracetamol Paracetamo SuIphate Paracetamol G Iucuron de |
! Subject j Cmax I Tmax Cmax Tmax Cmax I Tmax
| Number I tug.ml"1) I <h) (pg. ml 4) (h) (]ig. ml 4) I (h)
| 1
1






















































































































| + | + + + | ++




.08 + 0. 55 4.0 +_ 1 .0 1.90 _+ 0.61 9.2 _+ 2.4 |3
I
.00 +_ 0 .47 |
I I I I I I I I
I I I I I I I I
I I I I I I I I
I * I I I




.35 _+ 0. 17 3.5 +_ 0.7 1 .08 +_ 0.53 9.4 _+ 2.6 I2
I
.00 +_ 0 .44 |
* = Mean data obtained following Ingestion of 1 g of paracetamol
+ = Significantly different from paracetamol alone; P<0.02
++ = Significantly different from paracetamol alone; P<0.001
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TABLE 4.3 Apparent Plasma Elimination Half Life of Paracetamol and Its Sulphate and
Glucuronide Conjugates In 10 Healthy Male Subjects Following Ingestion of
2.146 g of Paracetamol N-Acetyl-D-L-methionate
| Subject | Apparent P I asma E I i mi nation Ha f Life (h)
















































































































| Mean + SD |
I I
I






.1 +_ 0.3 j
II I I I
II I I I
II I I I
I* I 1
| Mean + SD |
i i
2.3 + 0.3 |
I
3.2 + 0.4 | 3
1
.0 + 0.3 |
* = Mean data obtained following ingestion of 1 g of paracetamol
Half life calculated over: 2-8 h for paracetamol
3-8 h for paracetamol sulphate
5-12 h for paracetamol glucuronide
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P<G.G1), and the mean individual peak plasma paracetamol sulphate
concentration was significantly increased (3.5 + 0.7 pg.mT1 compared
with 4.G + 1.0 pg.ml"1; t = 2.313, P<G.02).
The mean paracetamol sulphate half life from 3-8 h was 3.1 + 0.5 h
(range 2.4-3.7) which was similar to that obtained after paracetamol
administration to the same subjects (3.2 +_ 0.4 h). Mean plasma con¬
centrations of paracetamol sulphate were lower than those of parace¬
tamol at all times.
Paracetamol Glucuronide
Plasma paracetamol glucuronide was detected in plasma in all subjects
from 15 min after administration of paracetamol N-acetyl-D-L-methion-
ate and paracetamol glucuronide concentrations rose above those of
paracetamol in most subjects after 2-3 h. The mean individual peak
plasma paracetamol glucuronide concentration was 9.2 + 2.4 pg.ml"1
(range 6.4-12.8) which was similar to that obtained after paracetamol
alone (9.4 + 2.6 yg.ml"1).
Compared to paracetamol, the mean individual time to reach the peak
plasma paracetamol glucuronide concentration following paracetamol N-
acetyl-D-L-methionate was significantly delayed (3.GG +_ 0.47 h com¬
pared with 2.00 +_ G.44 h; t = 6.034, P<0.001). The mean paracetamol
glucuronide half life from 5-12 h was 3.1 + 0.3 h (range 2.7-3.5)
which was similar to that obtained after paracetamol administration
(3.0 + 0.3 h).
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iii) Areas Under the Plasma Concentration-time Curves of Paracetamol
and its Sulphate and Glucuronide Conjugates
The individual areas under the plasma concentration time curves for
paracetamol and its sulphate and glucuronide conjugates following
administration of 1 g of paracetamol as (1) paracetamol and (2)
paracetamol N-acetyl-D-L-methionate are shown in Table 4.4
The mean areas under the plasma concentration-time curves following
administration of paracetamol N-acetyl-D-L-methionate for paraceta¬
mol, paracetamol sulphate and paracetamol glucuronide were 46.0 +_
9.2, 26.7 _+ 10.2 and 68.4 _+ 15.6 pig.h.ml"1 respectively. These values
did not differ significantly from those obtained following paraceta¬
mol administration to the same subjects (45.3 + 10.6, 22.4 _+ 5.1 and
65.0 +_ 15.9 pig.h.ml"1 respectively). The bioavailability of paraceta¬
mol after paracetamol N-acetyl-D-L-methionate administration was
therefore the same as after administration of paracetamol alone. The
mean relative paracetamol bioavailability was 102.7 _+ 9.5%.
iv) Urine Recovery of Paracetamol and its Sulphate, Glucuronide,
Cysteine and Mercapturic Acid Conjugates
The fraction of the paracetamol component of the dose (1 g) recovered
in urine in 24 h as paracetamol and its metabolites after adminis¬
tration of 2.146 g paracetamol N-acetyl-D-L-methionate, and the mean
cumulative urinary recovery of paracetamol and its metabolites fol¬
lowing administration of 1 g of paracetamol as (1) paracetamol and
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Table 4.4 Areas Under the Plasma Concentration-time Curves of Paracetamol and Its
Sulphate and Glucuronlde Conjugates In 10 Healthy Male Subjects Following
Ingestion of 1 g of Paracetamol as (1) Paracetamol (PARA) and (2)
Paracetamol N-Acetyl-D-L-methionate (PNAM)
Area Under the PI asma Concentration-time Curve 0-24 h (ug.h.ml"1) i
| Subject Paracetamol Paracetam Su I phate Paracetarol Glucuronide |
























21.0 71 .2 j 70.0 |















20.8 89.2 I 93.1 |







31.3 70.3 I "79.1 |































25.9 67.4 I 62.1 |







26.7 _+ 10.2 65.0 _+ 15.9 j68.4 _+ 15.6 |
188
(2) paracetamol N-acetyl-D-L-methionate are shown in Tables 4.5
4.6(i), (ii) and Figure 4.2 respectively. Individual urinary
excretion data are shown in Appendices 4.3-4.8.
The mean 24 h urinary recovery of paracetamol sulphate was signifi¬
cantly increased following paracetamol N-acetyl-D-L-methionate admin¬
istration (258.9 +_ 55.1 mg compared to 236.5 _+ 45.2 mg with paraceta¬
mol; t = 2.460, P<0.05). From 0-4 h, however, the mean cumulative
urinary recovery of paracetamol sulphate was not significantly dif¬
ferent from that obtained after paracetamol administration. The mean
urinary recoveries of paracetamol and its glucuronide, cysteine and
mercapturic acid conjugates after 24 h were not significantly differ¬
ent from those obtained with paracetamol.
The mean urinary recovery of paracetamol glucuronide over 24 h after
administration of paracetamol N-acetyl-D-L-methionate represented
497.3 +_ 64.9 mg (range 407-572). The recovery of this conjugate was
significantly reduced over the first 4 h (193.0 +_ 34.0 mg compared to
223.1 +_ 50.8 mg with paracetamol; t = 2.534, P<0.05).
Following paracetamol N-acetyl-D-L-methionate administration the mean
24 h urinary recovery of paracetamol represented 31.3 _+ 10.2 mg
(range 14-48). The mean 0-2 h urinary recovery was significantly
reduced (11.7 +_ 5.5 mg compared to 17.1 + 8.0 mg with paracetamol; t
= 3.028, P<0.02).
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TABLE 4.5 Percentage of the Paracetamol Component of the Dose (1 g) Recovered In
Urine as Paracetamol and its Sulphate, Glucuronide, Cysteine and
Mercapturlc Acid Conjugates in 24 h Following Ingestion of 2.146 g of
Paracetamol N-Acetyl-D-L-methlonate in 10 Healthy Male Subjects



















































43.5 3.9 1 5.7 9.6 91 .9 |
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* = Mean data obtained following Ingestion of 1 g of paracetamol
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TABLE 4.6(i ) Mean Cumulative Urinary Recovery of Paracetamol and Its Sulphate and
Glucuronide Metabolites In 10 Healthy Male Subjects Following Ingestion
of 1 g of Paracetamol as (1) Paracetamol and (2) Paracetamol N-Acetyl-
D-L-methionate
1 1 Mean Cumulative Urinary Recovery J
1 1 (mg + SD )
[ Col lection Period |
1 <h) 1 |Paracetamol N-Acetyl-|





1 0-2 | 17.1 + 8.0 | 11.7 +_ 5.5+ |
1 0-4 | 26.3 + 11.3 | 21 .4 _+ 7.4 |
1 0-6 | 31 .2 j+ 13.6 | 26.8 _+ 8.4 |
1 0-8 | 34.3 + 15.2 | 29.2 _+ 9.1 |
| 0-10 | 35.4 + 15.3 | 30.8 _+10.0 |
I 0-12 j 35.4 + 15.2 | 31 .5 _+_ 10.2 |
| 0-24 j
I I







I 0-2 | 56.3 ^20.8 | 54.2 +_ 14.8 |
I 0-4 | 1 12.8 + 25.1 | 118.8 +_ 24.7 |
I 0-6 | 152.5 +_ 33.6 | 163.4 _+37.9+ |
I 0-8 | 178.7 +^33.9 | 193.0 + 46.0+ |
| 0-10 | 195.6 + 34.9 j 214.4 +_ 45.7+ j
I 0-12 | 207.4 +_ 37.8 | 228.5 + 45.2+ |
| 0-24 |
i I
236.5 + 45.2 j 258.9
I





I 0-2 | 93.0 + 37.7 | 64.8 19.2+ |
I 0-4 | 223.1 +_50.8 | 193.0 j+_ 34.0+ |
I 0-6 | 323.4 + 60.9 | 294.7 _+ 56.1 |
I 0-8 | 392.5 +_ 52.6 | 361.4 +_ 64.3 |
| 0-10 | 432.8 +_ 52.7 | 409.6 +_54.1 |
1 0-12 | 459.0 _+ 53.2 | 442.3 +_ 54.2 |
j 0-24 j 497.9 + 67.6 | 497.3 _+ 64.9 |
I I I
+
= Significantly different from paracetamol alone; P<0.05
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TABLE 4.6(11) Mean Cumulative Urinary Recovery of Paracetamol Cysteine and Paracetamol
Mercapturic Acid In 10 Healthy Male Subjects Following Ingestion of 1 g
of Paracetamol as (1) Paracetamol and (2) Paracetamol N-Acetyl-D-L-
me+hlona+e
1 1 Mean Cumulative Urinary Recovery
1 1 (mg + SD)
! Col lection Period |
1 (h) 1 | Paracetamol N-Acety I- |





1 0-2 | 1 .8 +_ 1 .4 I 1 »2 j+ 1 .6 |
1 0-4 j 6.3 _+ 3.1 j 7.4 _+ 5.2 j
1 0-6 j 11 .8 _+ 6.2 | 14.4 _+ 9.6 |
1 0-8 | 16.6 _+ 8.0 j 19.6 1 3.1 j
1 0-10 j 19.0 +_ 9.3 j 24.3 _+ 15.2 j
1 0-12 | 20.4 _+ 10.1 | 26.9 _+ 16.3 |
I 0-24 j
I I







I 0-2 j 3.4 +_ 2.0 | 2.4 + 2.1 j
I 0-4 | 12.0 +_ 4.9 | 12.4 _+ 6.2 |
I 0-6 | 20.0 +_ 8.6 | 21 .9 _+ 1 0.5 j
I 0-8 | 25.2 1 9,7 j 28.1 +_ 1 3.6 |
| 0-10 | 28.2 +_ 10.6 j 32.7 _+ 15.1 j
1 0-12 j 30.0 +_ 11.1 | 35.4 _+ 15.6 j
I 0-24 |
I I




|Cysteine + Mercapturate |
I
I
I 0-2 | 5.2 +_ 3.2 | 3.6 _+ 3.6 |
I 0-4 | 18.3 _+ 7.9 | 19.8 j^n.3 |
I 0-6 | 31 .8 _+ 14.1 | 36.4 +19.7 |
I 0-8 | 41 .8 +_ 17.0 j 47.7 +_ 26.5 j
I 0-10 j 47.2 +_ 19.1 | 57.0 +_ 29.9 |
I 0-12 | 50.4 _+ 20.4 j 62.2 _+ 31 .5 j
I 0-24 | 56.4 +_ 24.9 | 68.1 _+37.5 |
I I 1
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FIGURE 4.2 Mean Cumulative Urinary Recovery of Paracetamol and Its Metabolites up to
24 h In 10 Healthy Subjects Following Ingestion of 1 g of Paracetamol as





















Urinary excretion of paracetamol cysteine and paracetamol mercapturic
acid following administration of paracetamol N-acetyl-D-L-methionate
was similar to that obtained after administration of paracetamol
alone to the same subjects. The mean combined 24 h urinary recovery
of these metabolites was 68.1 +_ 37.5 mg, with more mercapturic acid
conjugate than cysteine conjugate recovered in most subjects over
24 h. The mean 24 h urinary recovery of paracetamol cysteine and
paracetamol mercapturic acid was 29.5 +_ 19.3 mg (range 11-70) and
38.5 +_ 18.7 mg (range 19-73) respectively. Subject 1 had particu¬
larly high recoveries of paracetamol cysteine and mercapturic acid
conjugate in urine, representing 7.0 and 7.3% of the paracetamol
component of the dose respectively.
Following administration of paracetamol N-acetyl-D-L-methionate the
mean percentage of the paracetamol component of the dose (1 g) re¬
covered in urine after 6, 12 and 24 h represented 52.1, 76.5 and
85.5% respectively. These recoveries were similar to those obtained
after administration of 1 g of paracetamol alone (53.9, 75.9 and
82.6% respectively).
v) Fractional Excretion of Paracetamol and its Sulphate Glucuronide,
Cysteine and Mercapturic Acid Conjugates
The mean percentages of total paracetamol excreted in divided urine
collections as paracetamol and its metabolites following ingestion of
2.146 g of paracetamol N-acetyl-D-L-methionate in 10 healthy subjects
are shown in Table 4.7 and Figure 4.3. Individual data are shown in
Appendices 4.4-4.8.
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TABLE 4.7 Mean Percentage of Total Paracetamol Excreted in Divided Urine Collections
as Paracetamol and its Metabolites Following Ingestion of 2.146 g
Paracetamol N-Acetyl-D-L-me+hlona+e In 10 Healthy Male Subjects
Mean Proportion Excreted
(As Percentage of Total in Sample + SD







































































= Significantly different from paracetamol alone; PO.05
++
= Significantly different from paracetamol alone; P<0.001
Note: Paracetamol sulphate was significantly Increased and paracetamol
glucuronide significantly reduced
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FIGURE 4.3 Changes In the Mean Proportional Urinary Excretion of Paracetamol and Its
Sulphate, Glucuronide, Cysteine and Mercapturlc Acid Conjugates with Time
Following Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-roethlonate In
















The mean fractional excretion patterns of paracetamol and its meta¬
bolites following administration of paracetamol N-acetyl-D-L-methi-
onate were similar to those obtained with paracetamol in the same
subjects.
Paracetamol represented 9.2 + 4.1% of the total excreted over the
first 2 h and the fraction as the cysteine and mercapturic conjugates
increased to 5.8 + 3.5 and 5.9 + 2.6% respectively by 10 h. There¬
after the fractional excretion of paracetamol and these metabolites
declined.
The fraction excreted as paracetamol sulphate was significantly in¬
creased from C-2 h (40.2 + 4.7% compared to 32.9 + 6.6% with para¬
cetamol; t = 7.167, P<0.001) and 2-4 h (29.4 + 5.1% compared to 27.1
+ 4.7% with paracetamol; t = 4.518, P<0.01). From 6-12 h the fract¬
ion excreted as paracetamol sulphate remained relatively constant
representing approximately 26% of the total. This was similar to
that obtained after paracetamol administration.
The fraction of the total excreted as paracetamol glucuronide in each
divided urine collection was significantly reduced. From 0-2 h the
fraction excreted was 48.2 +_ 6.8% compared to 54.8 + 8.4% with para¬
cetamol (t = 4.972, P<0.001) and from 6-8 h, 61.1 + 8.8% compared to
63.7 + 7.8% (t = 2.930, P<0.02).
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vi) Urinary Excretion Rate of Paracetamol and its Sulphate,
Glucuronide, Cysteine and Mercapturic Acid Conjugates
The mean urinary excretion rates of paracetamol and its metabolites
in 10 healthy male subjects following ingestion of 2.146 g of para¬
cetamol N-acetyl-D-L-methionate are plotted semilogarithmically in
Figure 4.4. Individual excretion rates fluctuated as was observed
after paracetamol administration. Individual data are shown in
Appendices 4.4-4.8.
Paracetamol
The mean 0-2 h urinary excretion rate of paracetamol was signifi¬
cantly reduced after paracetamol N-acetyl-D-L-methionate admini¬
stration (5.9 +_ 2.8 mg.h"1 compared to 8.6 +_ 4.0 mg.h"1 with para¬
cetamol; t = 3.028, P<0.02). Thereafter the mean paracetamol
excretion rates were similar to those obtained after paracetamol
administration to the same healthy subjects.
Paracetamol Sulphate
The mean urinary excretion rate of paracetamol sulphate after
administration of paracetamol N-acetyl-D-L-methionate rose to 32.3 +_
7.6 mg.h"1 after 4 h and thereafter declined with a mean apparent
urinary elimination half life (n = 9) from 2-12 h of 3.3 _+ 0.5 h
(range 2.5-4.3). The mean sulphate excretion rate from 2-4 h was
32.3 + 7.6 mg.h"1 compared to 28.3 + 5.9 mg.h"1 with paracetamol (t =
198
FIGURE 4.4 Mean Urinary Excretion Rates of Paracetamol and Its Metabolites In 10
Healthy Male Subjects Following Ingestion of 2.146 g of Paracetamol N-











2.743, P<0.05) and from 4-6 h it was 22.3 _+ 7.0 mg.h"1 compared to
19.9 +_ 5.3 mg.h"1 with paracetamol (t = 2.343, P<0.05).
Paracetamol Glucuronide
The mean 0-2 h urinary excretion rate for paracetamol glucuronide was
significantly reduced after paracetamol N-acetyl-D-L-methionate ad¬
ministration (32.4 +_ 9.6 mg.h"1 compared to 46.5 +_ 18.8 mg.h"1 with
paracetamol; t = 3.562, P<0.01). Mean paracetamol glucuronide ex¬
cretion rates thereafter were similar to those obtained with para¬
cetamol .
The mean apparent urinary elimination half life (n = 9) from 2-12 h
for paracetamol glucuronide was 3.4 +_ 0.3 h (range 2.9-3.8) which was
similar to that obtained after administration of paracetamol alone to
the same subjects (3.1 +_ 0.4 h).
Paracetamol Cysteine and Mercapturic Acid
The mean urinary excretion rates of the cysteine and marcapturic acid
conjugates of paracetamol increased to 3.5 +_ 2.2 mg.h"1 from 4-6 h and
5.0 _+ 2.5 mg.h"1 from 2-4 h respectively. These rates were not sig¬
nificantly different from those obtained after paracetamol adminis¬
tration. The mean urinary excretion rate of paracetamol cysteine
after administration of paracetamol N-acetyl-D-L-methionate was sig¬
nificantly increased from 8-10 h (2.4 + 1.4 mg.h"1 compared to 1.2 +_
0.7 mg.h"1 with paracetamol; t = 3.785, P<0.01) and 10-12 h (1.3 +_
0.6 mg.h"1 compared to 0.8 +_ 0.6 mg.h"1 with paracetamol; t = 3.645,
P<0.01). Similar results were obtained for paracetamol mercapturate
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from 8-10 h (2.3 1.1 mg.h"1 compared to 1.6 _+ 0.6 mg.h"1 with parace¬
tamol; t = 4.015, P<0.01) and 10-12 h (1.3 _+ 0.5 mg.h"1 compared to
0.9 + 0.4 mg.h"1 with paracetamol; t = 2.594, P<0.05).
vii) Renal Clearances of Paracetamol and its Sulphate and Glucuronide
Conjugates
After administration of paracetamol N-acetyl-D-L-methionate, the mean
renal clearances of paracetamol, paracetamol sulphate and paracetamol
glucuronide from 0-8 h were 13.0 _+ 4.2 (range 8.8-18.1), 172.8 +_ 57.9
(range 98.6-292.9) and 129.1 +_ 29.1 ml.min"1 (range 78.9 _+ 175.7) re¬
spectively. These did not differ significantly from the renal clear¬
ances obtained after paracetamol administration to the same subjects
(15.2 + 7.0, 180.5 +_ 31.6 and 136.9 +_ 32.9 ml.min"1 respectively).
The 0-8 h renal clearance of paracetamol was positively correlated
with urine flow rate, but the relationship was not as strong as after
paracetamol administration. As with administration of paracetamol,
no such correlation existed for the sulphate and glucuronide conju¬
gates and there were no significant correlations between 0-8 h renal




Paracetamol N-acetyl-D-L-methionate is a prodrug in which paracetamol
is linked to N-acetyl-D-L-methionine by an ester bond. In stability
experiments (Chapter II, Section 3) the hydrolysis rate of para¬
cetamol N-acetyl-D-L-methionate increased with pH at 37°C. It is
therefore likely that the further paracetamol N-acetyl-D-L-methionate
passes down the gastro-intestinal tract prior to absorption the more
susceptible it will be to hydrolysis. Esterases present in the
intestine, liver and plasma contribute to the hydrolysis of orally
administered ester prodrugs (Williams, 1985). Paracetamol N-acetyl-
D-L-methionate was rapidly hydrolysed in plasma at 37°C (half life
0.4 h) and the rate of hydrolysis was even greater in whole blood at
37°C (Chapter II, Section 3). It is therefore probable that little,
if any, administered paracetamol N-acetyl-D-L-methionate remains
intact.
The inability to detect paracetamol N-acetyl-D-L-methionate in the
plasma of any of the healthy subjects is consistent with previous
reports. (SWRD Reports 304655, 1977; 305510, 1978). Paracetamol N-
acetyl-D-L-methionate hydrolysis was reduced but not prevented by
cooling of the blood samples. Whole blood concentrations of approxi¬
mately 1 pig.ml"1 would be required in order for any paracetamol N-
acetyl-D-L-methionate to be detected in plasma under the present
conditions.
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Individual plasma paracetamol concentrations fluctuated in most
subjects prior to reaching their peak values. In addition, following
administration of paracetamol N-acetyl-D-L-methionate the mean peak
plasma paracetamol concentration was only 50% of that obtained with
paracetamol alone and the mean time to reach its peak was delayed by
approximately 45 min. These results were consistent with other
studies in animals and man (SWRD Reports 305212; 305213; 305510,
1978). The delayed absorption of paracetamol may be explained by the
insolubility of paracetamol N-acetyl-D-L-methionate (see Appendix
1.2), however, it is not possible to ascertain whether the paraceta¬
mol N-acetyl-D-L-methionate is absorbed intact. Delay in paracetamol
absorption may in itself provide some degree of protection against
liver damage if paracetamol N-acetyl-D-L-methionate was taken in
overdosage, however, there may also be a delayed and reduced pharma¬
cological effect when taken in therapeutic doses. Because the
absorption of paracetamol was slow there was no obvious distribution
phase as observed after paracetamol administration.
The mean plasma paracetamol elimination half life from 2-8 h was 2.3
0.3 h which was the same as that obtained with paracetamol in the
same healthy subjects. Similarly, the mean area under the plasma
paracetamol concentration-time curve from 0-24 h was not significant¬
ly different from that obtained after paracetamol. This indicates
that although absorption was delayed and slow, the bioavailability of
paracetamol after paracetamol N-acetyl-D-L-methionate administration
was the same as after administration of paracetamol alone. The mean
relative paracetamol bioavailability was 103%.
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From 1.5 to 10 h mean plasma concentrations of paracetamol were
significantly higher than those obtained with paracetamol. No
pharmacodynamic studies following single oral administration of
paracetamol N-acetyl-D-L-methionate have been performed in man,
however, conflicting results have been obtained in animal models.
Compared to paracetamol, paracetamol N-acetyl-D-L-methionate had a
delayed onset of action but a longer dose dependent duration of
analgesia in rats using the Randal-Selitto test, whereas similar
analgesia and duration of effect for each compound was observed using
a mouse writhing test (SWRD Report 105032, 1978).
Following paracetamol N-acetyl-D-L-methionate administration the mean
24 h urinary recoveries of paracetamol and its glucuronide, cysteine
and mercapturic acid conjugates represented 3.1 + 1.0, 49.7 + 6.5,
3.0 + 1.9 and 3.9 + 1.9% of the paracetamol component of the dose
respectively. These were not significantly different from those
obtained following administration of paracetamol alone. The mean
24 h urinary recovery of paracetamol sulphate, was however, signifi¬
cantly increased, accounting for 259 + 55 mg compared to 237 _+ 45 mg
after paracetamol administration (P<0.05). No significant differ¬
ences in paracetamol metabolism have previously been reported
following paracetamol N-acetyl-D-L-methionate administration.
As observed after paracetamol administration, paracetamol sulphate
metabolism was initially a major metabolic route. The mean peak
plasma paracetamol sulphate concentration was delayed by approxi¬
mately 50 min due to the slower delivery rate of paracetamol, but the
mean peak plasma paracetamol sulphate concentration was significantly
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increased (4.0 +_ 1.0 iig.ml"1 compared to 3.5 +_ 0.7 pig.ml"1 with para¬
cetamol, P<0.02). Although the mean area under the plasma paraceta¬
mol sulphate concentration-time curve was greater than that obtained
after paracetamol administration to the same subjects, the difference
was not significant.
The mean paracetamol sulphate urinary excretion rate from 0-2 h was
similar to that obtained after paracetamol administration, but sul¬
phate conjugation was increased relative to the other routes of meta¬
bolism over this period. Thus the mean paracetamol and paracetamol
glucuronide urinary excretion rates from 0-2 h were significantly
reduced over this period because of delayed paracetamol absorption,
whereas the paracetamol sulphate excretion rate remained unaltered.
The mean urinary excretion rate of paracetamol sulphate was signifi¬
cantly increased from 2-6 h. In addition, the mean fractional urin¬
ary excretion of paracetamol sulphate was significantly increased
from 0-2 h following paracetamol N-acetyl-D-L-methionate administra¬
tion (40.2 +_ 4.7% compared to 32.9 +_ 6.6% with paracetamol; P<0.001).
It was also observed that the mean paracetamol sulphate excretion
rate over the first 4 h was not constant as was observed after admin¬
istration of paracetamol to the same subjects. These results suggest
that following paracetamol N-acetyl-D-L-methionate administration,
saturation of the sulphate pathway did not occur. This may be due to
methionine providing a source of inorganic sulphate and thus preven¬
ting its depletion, or alternatively the sulphate pathway may be less
readily saturated since paracetamol was absorbed more slowly.
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As with paracetamol sulphate, the mean peak plasma paracetamol
glucuronide concentration was delayed, but it was not significantly
different from that obtained after paracetamol administration. The
mean apparent plasma and urinary elimination half life values for
paracetamol sulphate and paracetamol glucuronide were also similar to
those following paracetamol administration to the same subjects. The
mean fractional urinary excretion of paracetamol glucuronide was
significantly reduced and the increase in sulphate conjugation was at
the expense of glucuronide conjugation. Previously it has been shown
that decreased sulphate conjugation was accompanied by a correspon¬
ding increase in glucuronide conjugation (Clements et al, 1984).
Paracetamol N-acetyl-D-L-methionate administered to mice at a dose
level equivalent to 400 nig.kg"1 of paracetamol caused less depletion
of hepatic glutathione than the equivalent paracetamol dose (Skoglund
et al, 1986). Although paracetamol N-acetyl-D-L-methionate might be
expected to increase the fraction of cysteine and mercapturic acid
conjugates produced, the plasma concentrations of these metabolites
were below the limit of detection and the mean 24 h urinary recov¬
eries of these metabolites were not significantly different from
those obtained following paracetamol administration. Again, the
appearance of the cysteine and mercapturic acid conjugates was
delayed relative to the other metabolites. The cysteine and mercap¬
turic acid conjugation of paracetamol was therefore not influenced
following administration of a therapeutic dose of paracetamol as the
N-acetyl-D-L-methionate ester.
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Following administration of paracetamol N-acetyl-D-L-methionate the
mean percentage of the paracetamol component of the dose recovered in
urine in 24 h was 85.5 + 6.1$, and absorption of paracetamol in this
form was essentially complete. In a previous study the mean total
24 h urinary recovery of paracetamol was less after paracetamol N-
acetyl-D-L-methionate administration (62$) than after paracetamol
administration (74$) to healthy subjects (SWRD Report 305510, 1978).
There was a wide range in the 24 h urinary recoveries of paracetamol
metabolites reflecting inter-individual differences in paracetamol
metabolism as reported previously (Caldwell et al, 1980; Clements
et al, 1984; Critchley et al, 1986). Subjects 4 and 7 who produced
less paracetamol glucuronide and more paracetamol sulphate, cysteine
and mercapturic acid conjugates than the other subjects after ad¬
ministration of 1 g of paracetamol produced a similar metabolic
profile after paracetamol N-acetyl-D-L-methionate administration.
The mean renal clearances of paracetamol and its sulphate and glucu¬
ronide conjugates were not significantly different from those obtain¬
ed after paracetamol administration to the same subjects. As before
these results were consistent with glomerular filtration and passive
reabsorption of paracetamol and active tubular secretion of the
sulphate and glucuronide conjugates (Prescott and Wright, 1973;
Duggin and Mudge, 1975).
The renal clearance of paracetamol sulphate is concentration depend¬
ent and the renal clearance decreases as the plasma concentration
increases (Clements et al, 1984; Morris and Levy, 1984). This trend
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was observed after paracetamol N-acetyl-D-L-methionate administra¬
tion, but the result was not statistically significant.
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e) Summary and Conclusion
Following administration of 1 g of paracetamol as paracetamol N-
acetyl-D-L-methionate to 10 healthy male subjects the overall dispo¬
sition of paracetamol was similar to that obtained after administra¬
tion of 1 g of paracetamol alone to the same subjects.
Paracetamol N-acetyl-D-L-methionate was rapidly hydrolysed in the
presence of ubiquitous esterases, and the peak plasma paracetamol
concentration was reduced and the appearance of paracetamol and its
metabolites delayed following administration of paracetamol N-acetyl-
D-L-methionate. The area under the plasma paracetamol concentration-
time curve and the total urinary recovery following administration of
paracetamol N-acetyl-D-L-methionate were similar to those obtained
after administration of paracetamol alone. The relative bioavail¬
ability of paracetamol was, therefore, the same and paracetamol
absorption essentially complete following administration of paraceta¬
mol N-acetyl-D-L-methionate.
The urinary recovery of paracetamol and thus the extent of paraceta¬
mol metabolism following administration of the N-acetyl-D-L-methion¬
ate ester of paracetamol were similar to those obtained after
administration of paracetamol alone. In particular the portion of
the paracetamol dose metabolised via the toxic intermediate to form
the cysteine and mercapturic acid conjugates of paracetamol was not
increased even although methionine is a glutathione precursor.
Sulphate conjugation was, however, significantly increased following
administration of paracetamol N-acetyl-D-L-methionate. Saturation of
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the sulphate pathway was observed after administration of paracetamol
alone and may have been prevented following administration of para¬
cetamol N-acetyl-D-L-methionate. This may be explained by methionine
providing a source of inorganic sulphate thus preventing its deple¬
tion or alternatively that the paracetamol sulphate pathway was less
readily saturated as paracetamol was released more slowly. The
increase in sulphate conjugation was at the expense of glucuronide
conjugation.
The elimination of paracetamol following administration of paraceta¬
mol N-acetyl-D-L-methionate was similar to that obtained after admin¬
istration of paracetamol alone and consistent with glomerular filtra¬
tion and passive reabsorption of paracetamol and active secretion of
the sulphate and glucuronide conjugates.
Mean data obtained from healthy subjects following administration of
1 g of paracetamol as (1) paracetamol and (2) paracetamol N-acetyl-D-
L-methionate are summarised in Table 4.8.
In conclusion, 2.146 g of paracetamol N-acetyl-D-L-methionate may
provide a safer form of paracetamol, however, its pharmacological
effectiveness may be reduced and delayed compared to paracetamol
alone when administered as a single therapeutic dose to healthy
subjects. Pameton (500 mg paracetamol + 250 mg D-L-methionine),
which is already commercially available is, however, less likely to
present this problem as the paracetamol component is probably rapidly
absorbed. Paracetamol N-acetyl-D-L-methionate is, however, tasteless
and, therefore, probably more palatable. In addition, paracetamol
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N-acetyl-D-L-methionate contains more D-L-methionine than the
equivalent paracetamol dose of Pameton. The efficacy of Pameton or
paracetamol N-acetyl-D-L-methionate in preventing human paracetamol
poisoning, however, remains to be established.
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CHAPTER V
Paracetamol Disposition in Patients with Impaired Renal Function
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PARACETAMOL DISPOSITION IN PATIENTS WITH IMPAIRED RENAL FUNCTION
a) Introduction
Most polar drugs and metabolites are dependent on renal excretion for
elimination. Therefore, in patients with renal failure, drug dispo¬
sition is abnormal. Protein binding is often decreased in patients
with renal disease which affects drug distribution (Gibaldi, 1977;
Reidenberg, 1977a) and drug metabolism may be normal, accelerated or
slowed in patients with renal failure (Reidenberg, 1977b). To pre¬
vent cumulation and toxicity, drugs predominantly excreted unchanged
in urine or metabolised to form active metabolites are usually admin¬
istered at a reduced dose to patients with renal failure (Drayer,
1977; Mawer, 1982). In order to be effective, however, drugs that
are metabolised by the liver to form inactive metabolites may require
to be administered to renal patients at the full normal dose. This
results in marked cumulation of metabolites which may account for the
unpredictable toxicity and adverse drug reactions often observed in
patients with renal impairment (Fabre and Balant, 1976; Stone and
Walle, 1980; Lieberman et al, 1985).
Paracetamol is often administered to patients with renal impairment,
and is predominantly metabolised by the liver to form inactive meta¬
bolites which are normally eliminated in the urine (see Chapter III).
It is generally assumed that these metabolites of paracetamol are
pharmacologically inactive but no information is available on this
point. The excretion rate of paracetamol sulphate and paracetamol
glucuronide is greatly reduced in patients with renal failure follow¬
ing paracetamol overdosage (Prescott and Wright, 1973), and the renal
excretion of paracetamol and its metabolites was delayed in
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proportion to the degree of renal impairment in patients with either
analgesic nephropathy or nephropathy due to other causes, following
administration of 650 mg of [1^C]-paracetamo1 (Thomas et al, 1980).
In anephric patients the elimination of paracetamol metabolites was
greatly impaired and haemodialysis was the major route for their
elimination (Oie et al_, 1975; Lowenthal et al, 1976). In this
chapter the disposition of 1 g of paracetamol administered to non-
dialysis and haemodialysis patients is investigated in more detail.
Healthy male subjects who received 1 g of paracetamol (Chapter III)
were used as the control group.
b) Methods
Patients
Eleven men and one woman with chronic renal impairment were studied.
Their mean age was 52 +_ 12 years and their body weight was 75 _+ 8 kg.
Seven had moderate to severe renal failure but were not being treated
with dialysis and 5 with more advanced disease were receiving long
term dialysis 2 or 3 times a week. Their clinical details are
summarised in Table 5.1. Informed consent was given by each patient
and the study was approved by the local Ethics Committee.
Drug Administration and Sampling
Patients attended the University Department of Clinical Pharmacology
or the Medical Renal Unit after fasting overnight and an in-dwelling
cannula was inserted into a forearm vein. Haemodialysis patients
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attended on an interdialysis day. Sachets containing 1 g of an
effervescent formulation of paracetamol were supplied by Sterling
Winthrop, Alnwick. Each patient received the contents of one sachet
orally in 200 ml of water. The patients remained recumbent for 3 h
and lunch and supper were allowed at 4 and 8 h respectively. Each
patient received meals appropriate to their condition (eg low
protein, controlled sodium or potassium intake). Fluid intake was
restricted in haemodialysis patients and non-dialysis patients
received 200 ml of water every 2 h for 12 h after administration of
the paracetamol.
5 ml venous blood samples were taken into heparinised tubes at 0,
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24 h.
The blood was centrifuged at 1400 x g for 10 min and the plasma
separated and stored at -20°C. Urine samples from non-dialysis
patients were collected immediately before drug administration and
then from 0-2, 2-4, 4-6, 6-8, 8-10, 10-12 and 12-24 h. The total
urine volume and pH were recorded and 50 ml aliquots were stored at
-20°C prior to analysis. Individual urine volumes and pH values are
shown in Appendix 5.11.
Drug Analysis
Plasma concentrations of paracetamol, paracetamol sulphate and
paracetamol glucuronide, and urinary concentrations of paracetamol,
paracetamol sulphate, paracetamol glucuronide, paracetamol cysteine
and paracetamol mercapturic acid were measured by HPLC as described
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in Chapter II, Section 1. Metabolite concentrations are expressed as
paracetamol equivalents. Electrochemical detection (Model LC - 4A,
Bioanalytical Systems Incorporated) was also used to detect low con¬
centrations and to increase selectivity of the assay for cysteine and
mercapturic acid conjugates of paracetamol in plasma. Significant
blank values were obtained in some patients and these were subtracted
to give corrected concentrations. Patient No. 07 had a high urinary
protein concentration and the paracetamol sulphate peak could not be
properly resolved. The amount of sulphate excreted was, therefore,
estimated from the relative areas under the plasma concentration-time
curves of the sulphate and glucuronide conjugates and the urinary
recovery of paracetamol glucuronide, assuming both metabolites had
the same renal clearance and volume of distribution.
DATA ANALYSIS
i) Plasma Concentrations of Paracetamol and its Metabolites
Mean plasma concentrations of paracetamol and its sulphate, glucur¬
onide, cysteine and mercapturic acid conjugates were plotted against
time on a semi logarithmic graph and individual peak plasma concentra¬
tions (Cmax) and times to reach peak concentration (Tmax) were deter¬
mined.
ii) Plasma Elimination Half Life
The plasma elimination half life for paracetamol and the apparent
plasma elimination half life for paracetamol sulphate and paracetamol
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glucuronide were determined: th = 0.301/slope. The slope was deter¬
mined by direct linear regression from semilogarithmic plots of
plasma concentration against time over the period 2-8 and 8-24 h for
paracetamol and 8-24 h for paracetamol sulphate and glucuronide.
Formal model dependent curve fitting and compartmental analysis was
not performed,
i ii) Area Under the Curve
The 0-24 h area under the plasma concentration-time curve was calcu¬
lated by the trapezoidal method for paracetamol and its sulphate and
glucuronide conjugates.
iv) Non-dialysis Patients - Recovery of Paracetamol and its
Metabolites in Urine
The percentage of the administered dose recovered in 24 h was deter¬
mined. In addition, the fractional urinary recoveries of paracetamol
and its metabolites in 24 h and in divided urine collections were
calculated. The cumulative urinary recoveries of paracetamol and its
metabolites were plotted against time.
v) Non-dialysis Patients - Renal Clearance
The 0-8 h renal clearances of paracetamol and its glucuronide and
sulphate conjugates and the 0-24 h renal clearances of paracetamol
cysteine and paracetamol mercapturic acid were calculated by dividing
the amount recovered in the urine by the corresponding area under the
plasma concentration-time curve. The area under the curve was calcu¬
lated by the trapezoidal method.
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vi) Statistical Analysis
Mean values _+ standard deviation (SD) are presented. The relation¬
ship between quantitative observations on each subject (bivariate
data) was determined by calculation of the correlation coefficient
(r) and this was tested for statistical significance using tabulated
values (Geigy Scientific Tables, page 61). Differences between means
were compared by the Mann-Whitney two sample rank test for statis¬
tical significance.
c) Results
i) Plasma Concentrations of Paracetamol and its Sulphate,
Glucuronide, Cysteine and Mercapturic Acid Conjugates
Mean plasma concentrations of paracetamol and its sulphate, glucur¬
onide, cysteine and mercapturic acid conjugates following oral admin¬
istration of 1 g of paracetamol to 7 non-dialysis and 5 haemodialysis
patients are shown in Table 5.2, Figure 5.1 and Table 5.3, Figure 5.2
respectively. Individual values for peak concentration (Cmax) and
time to reach peak concentration (Tmax), apparent elimination half
life and area under the plasma concentration-time curves for parace¬
tamol and its metabolites in non-dialysis patients are shown in
Tables 5.4, 5.6 and 5.7 respectively. Individual values for Cmax and
Tmax, and area under the plasma concentration-time curves for parace¬
tamol and its metabolites in haemodialysis patients are shown in
Tables 5.5 and 5.8 respectively. Plasma concentrations for each sub¬
ject are shown in Appendices 5.1-5.5.
220
TABLE 5.2 Mean Plasma Concentrations of Paracetamol and its Sulphate, Glucuronide,
Cysteine and Mercapturlc Acid Conjugates In 7 Non-dialysis Patients
Following Ingestion of 1 g of Paracetamol
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FIGURE 5.1 Mean Plasma Concentrations of Paracetamol and Its Sulphate, Glucuronide,
Cysteine and Mercapturlc Acid Conjugates In 7 Non-dlalysls Patients
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TABLE 5.3 Mean Plasma Concentrations of Paracetamol and Its Sulphate, Glucuronide,
Cysteine and Mercap+urlc Acid Conjugates in 5 Haemod i a I ysls Patients
Following Ingestion of 1 g of Paracetamol
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FIGURE 5.2 Mean Plasma Concentrations of Paracetamol and Its Sulphate, G1ucuronIde,
Cysteine and Mercapturlc Acid Conjugates In 5 Haemodla Iysis Patients















TABLE 5.4 Peak Plasma Concentrations (Cmax) and Time to Reach Peak Plasma
Concentrations (Tmax) of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 7 Non-dialysis Patients Following Ingestion of 1 g of
Paracetamol
| Paracetamol Paracetamol SuIphate Paracetamol Glucuronlde|
Patient | Cmax | Tmax Cmax Tmax Cmax [ Tmax j
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Mean + SD |20.0 + 8.4
1
10.35 +_ 0 .17 3.5 _+ 0.7 1 .08 _+ 0.53 9.4 _+ 2.6 12.00 _+ 0.441
* = Mean data obtained following administration of 1 g of paracetamol to 10 healthy
male subjects
+ = Significantly different from healthy subjects; P<0.001
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TABLE 5.5 Peak Plasma Concentrations (Cmax) and Time to Reach Peak Plasma
Concentrations (Tmax) of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 5 Haemodialysls Patients Following Ingestion of 1 g of
Paracetamol
I Paracetamol Paracetamol Su1phate Paracetamol Glucuron 1 de |
Patient | Cmax J Tmax Cmax Tmax Cmax | Tmax
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* I
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* = Mean data obtained following administration of 1 g of paracetamol to 10 healthy
male subjects
+ = Significantly different from healthy subjects; P<0-005
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TABLE 5.6 Apparent Plasma Elimination Half Life of Paracetamol and Its Sulphate and
Glucuronide Conjugates In 7 Non-dialysis Patients Following Ingestion of
1 g of Paracetamol
I Paracetamol Paracetamol Sulphate |Paracetamol Glucuronide|
| Patient l+i (2-8 h) |+i (8-24 h) ti (8-24 h) I ti (8-24 h) |
! Number I (h) (h) (h) I (h) |
I 01 I
1
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| Mean + SD 1 2
1
.5 _+ 0.3 111 .6 _+ 3.9 21 .1 +_ 15.4 1
1
29.1 32.3 |
I I I I I I
I I I I I I
I I I I I I
I* 1 1
| Mean + SD 1 2
1
.3 _+ 0.3 I 5 .4 _+ 2.4 3.2 +_ 0.4 1
1
3.0+0.3 |
* = Mean data obtained following administration of 1 g of paracetamol to healthy male
subjects. The paracetamol sulphate and glucuronide elimination half life was
calculated over 3-8 and 4-12 h respectively.
+ = Significantly different from healthy subjects; P<0.005
++ = Significantly different from healthy subjects; P0.001
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TABLE 5.7 Area Under the Plasma Concentration-time Curves of Paracetamol and Its
Sulphate and Glucuronide Conjugates In 7 Non-dialysis Patients Following
Ingestion of 1 g of Paracetamol
j Paracetamol Paracetamol Sulphate |Paracetamol Glucuron!de|
| Patient |AUC (0-24 h) |AUC (8-24 h) AUC (0-24 h) I AUC (0-24 h) |

























































| + | + ++ |++
|Mean + SD |62.5 + 13.6 | 14.7 + 5.3 231.9 + 108.3 | 431.4 + 157.4 |
i I I
1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
1* I I I
|Mean + SD 145-3 + 10.6
I
| 8.0 _+ 4.3 22.4 +_ 5.1 | 65.0 + 15.9 |
1 1
* = Mean data obtained following administration of 1 g of paracetamol to 10 healthy
male subjects
+ = Significantly different from healthy subjects; P<0.05
++ = Significantly different from healthy subjects; P<0.001
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TABLE 5.8 Area Under the Plasma Concentratlon-tlme Curve of Paracetamol and Its
Sulphate and Glucuronide Conjugates In 5 Haemodialysls Patients Following
Ingestion of 1 g of Paracetamol
i Paracetamol Paracetamol Sulphate |Paracetamol Glucuronlde|
| Patient |AUC (0-24 h) AUC (8-24 h) AUC (0-24 h) ] AUC (0-24 h) |
| Number | (yg.h.ml"1) (pg.h.mlH) (pg.h.ml4) | (pg.h.ml"1) !




j 09 | 39.6 - 399.8 | 831.7 |
1 |













|Mean + SD 155.7 _+ 18.8 17.0 _+ 1 .3 449.6 _+ 108.3 | 673.1 + 227.9 |
I I
I I I I I I
I I I I I I
I l I I I I
i* I |
|Mean + SD 145.3 _+ 10.6 8.0 _+ 4.3 22.4 +_ 5.1 | 65.0 + 15.9 |
1 1
* = Mean data obtained following administration of 1 g of paracetamol to 10 healthy
male subjects
+ = Significantly different from healthy subjects; P<0.02
++ = Significantly different from healthy subjects; P<0.005
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Paracetamol
Paracetamol absorption was rapid in renal patients and the mean
individual peak plasma paracetamol concentration in non-dialysis and
dialysis patients was 17.3 +_ 8.2 ug.ml"1 (range 7.8-30.3) and 18.7 +_
5.2 pig.ml"1 (range 15.3-27.9) respectively. The mean individual time
to reach peak paracetamol concentration was 0.54 +_ 0.44 h and 0.45 _+
0.32 h in non-dialysis and dialysis patients respectively. These
values were not significantly different from those obtained in
healthy male subjects which were 20.0 +_ 8.4 pg.ml"1 and 0.35 +_ 0.17 h
respectively. From 2-8 h mean plasma paracetamol concentrations
declined linearly when plotted on a semi logarithmic graph. The mean
plasma elimination half life over this period was similar in healthy
subjects, non-dialysis and dialysis patients (2.3 + 0.3, 2.5 +_ 0.3
and 2.1 _+ 0.4 h respectively). From 8-24 h the plasma paracetamol
concentrations declined more slowly in both groups of renal patients.
This was reflected in their combined mean plasma paracetamol elimi¬
nation half life over this period which was 9.2 _+ 4.8 h (range 5.3-
19.7) compared to 5.4 +_ 2.4 h in normal subjects; (P<0.002). The
mean area under the plasma paracetamol concentration-time curve from
8-24 h for both renal groups combined was significantly greater than
in normal subjects (13.4 +_ 6.2 pig.h.ml"1 compared to 8.0 +_ 4.3
pig. h.ml"1; P<0.005). The mean 0-24 h area under the plasma
paracetamol concentration-time curve was significantly increased in
renal patients compared to healthy subjects (59.7 +_ 15.5 pig.h.ml"1
compared to 45.3 + 10.6 pig.h.ml"1; P<0.05).
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Paracetamol Sulphate
The plasma concentrations of paracetamol sulphate rose and exceeded
those of the parent drug and were greatly elevated in patients with
renal impairment. In Patient Oil sulphate conjugation was the major
metabolic route. In non-dialysis and dialysis patients the mean
individual peak plasma paracetamol sulphate concentration was signi¬
ficantly increased, at 13.7 +_ 5.9 ug.mlH (range 9.4-26.9) and 20.7 +_
5.4 ug.ml"1 (range 16.4-30.1) respectively, compared to 3.5 pig.ml"1 in
normal subjects (P<0.005). The mean individual times to reach peak
plasma paracetamol sulphate concentration in non-dialysis and dialy¬
sis patients were delayed correspondingly (5.6 +_ 1.5 and 8.2 +_ 0.8 h
respectively, compared to 1.1 h in normal subjects; P<0.005). In the
patients with impaired renal function the elimination of paracetamol
sulphate was much slower and the mean elimination half life from 8-24
h in non-dialysis patients was significantly increased compared to
the mean elimination half life from 3-8 h in normal subjects (21.1 +_
15.4 h and 3.2 +_ 0.4 h respectively; PO.OOl). The elimination of
paracetamol sulphate in haemodialysis patients was negligible with no
appreciable fall in plasma concentration up to 24 h. There was gross
retention of paracetamol sulphate as reflected by the mean area under
the 0-24 h plasma paracetamol sulphate concentration-time curves for
non-dialysis and dialysis patients (231.9 _+ 108.3 and 449.6 +_ 108.3
jig.h.ml"1 respectively compared to 22.4 +_ 5.1 ug.h.ml4 in the healthy
male subjects; P<0.005). These differences represented a 10 and 20-
fold increase and in non-dialysis patients there was a significant
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correlation between plasma creatinine concentration and area under
the plasma paracetamol sulphate concentration-time curve (r = 0.84,
P<0.02).
Paracetamol Glucuronide
As with paracetamol sulphate, plasma concentrations of the glucuro¬
nide conjugate were grossly elevated in the patients with impaired
renal function. In the non-dialysis and dialysis patients the mean
individual peak plasma paracetamol glucuronide concentrations were
25.2 + 8.9 pig.ml"1 (range 18.8-42.6) and 30.6 +_ 8.1 pig.ml"1 (range
21.5-36.7), compared to 9.4 pig.ml"1 in normal subjects (P<0.005). The
mean individual times to reach peak paracetamol glucuronide concen¬
tration in non-dialysis and dialysis patients were significantly
delayed (6.3 +_ 1.6 and 15.0 _+ 8.4 h respectively, compared to 2.0 h
in normal subjects; P<0.005). The mean paracetamol glucuronide
elimination half life from 8-24 h in non-dialysis patients was 29.1 _+
32.3 h compared to 3.0 +_ 0.3 h over the period 4-12 h in normal sub¬
jects (PO.OOl). The elimination of paracetamol glucuronide in hae-
modialysis patients was negligible with no significant fall in plasma
concentrations up to 24 h. In the non-dialysis and dialysis patients
the mean area under the 0-24 h plasma paracetamol glucuronide concen¬
tration-time curves were 431.4 +_ 157.4 and 673.1 +_ 227.9 pig.h.ml"1
respectively compared to 65.0 +_ 15.9 pig.h.ml"1 in the healthy male
subjects (P<0.005). In the non-dialysis patients there was a signi¬
ficant correlation between the plasma creatinine concentration and
232
area under the plasma paracetamol glucuronide concentration-time
curve (r = 0.94; P<0.01).
Paracetamol Cysteine and Mercapturic Acid Conjugates
Plasma concentrations of paracetamol cysteine and mercapturic acid
could not be measured in healthy subjects and the concentrations in
the patients with renal failure were low. The plasma concentrations
of the cysteine conjugate were higher than those of the mercapturic
acid conjugate and in the non-dialysis patients both conjugates dis¬
appeared at similar rates. In haemodialysis patients the rate of
disappearance of each conjugate was slower than in the non-dialysis
patients and there was no significant fall in the plasma mercapturic
acid concentration up to 24 h.
i i) Renal Excretion of Paracetamol and its Metabolites in Non-
Dialysis Patients
Individual total recoveries and 24 h fractional urinary recoveries of
paracetamol and its metabolites following ingestion of 1 g of parace¬
tamol in 7 non-dialysis patients are shown in Table 5.9 and the mean
cumulative urinary recovery of paracetamol and its metabolites up to
24 h in Figure 5.3. The mean percentages of total drug excreted in
divided urine collections as paracetamol and its metabolites are
shown in Table 5.10 and Figure 5.4. Individual urinary excretion
data are shown in Appendices 5.5-5.10.
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TABLE 5.9 Twenty Four Hour Urinary Recovery and Fractional Urinary Recovery of
Paracetamol and Its Sulphate, Glucuronide, Cysteine and Mercapturlc Acid
Conjugates In 7 Non-dialysis Patients Following Ingestion of 1 g of
ParacetamoI
24 h Fractional Ur I nary Recovery (?)
|Patient
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* = Mean data obtained following Ingestion of 1 g of paracetamol to 10 healthy male
subjects
+ = Significantly different from healthy subjects; P<0.02
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FIGURE 5.5 Mean Cumulative Urinary Recovery of Paracetamol and Its Metabolites up to
24 h In 7 Non-dialysis Patients Following Ingestion of 1 g of Paracetamol
0 2 4 6 8 10 12 24
Time (h)
235
TABLE 5.10 Mean Percentage of Total Drug Excreted in Divided Urine Collections as
Paracetamol and its Metabolites Following Ingestion of 1 g of Paracetamol
in 7 Non-dialysis Patients
Mean Proportion Excreted (as Percentage of Tota in Sample) + SD |












|Mercaptur 1 c |
| Acid |























+ 5.8 | 59.7 +_ 6.3 3.3 _+ 1.3 1 3.4
I
_+ 1.9 |
| 6-8 0.7 + 1 .7 |+30.9
1
































+ = Significantly different from healthy subjects; P<0.05
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FIGURE 5.4 Changes In the Mean Proportional Urinary Excretion of Paracetamol and Its
Sulphate, Glucuronlde, Cysteine and Mercapturlc Acid Conjugates Following
Ingestion of 1 g of Paracetamol In 7 Non-dialysis Patients
Time (h)
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Urinary Recovery of Paracetamol and its Sulphate, Glucuronide,
Cysteine and Mercapturic Acid Conjugates
The mean 24 h urinary recovery of the administered dose was signifi¬
cantly reduced in the non-dialysis patients 55.5 + 17.8% of the dose
(range 30.5-88.5) compared to 82.6% of the dose in healthy subjects
(P<0.02). There was a significant negative correlation between the
plasma creatinine concentration and the total urinary recovery (r = -
0.77; P<0.05). The mean percentage of the dose recovered up to 24 h
in non-dialysis patients as paracetamol and its sulphate, glucuron-
ide, cysteine and mercapturic acid conjugates represented 1.4, 16.8,
34.9, 1.8 and 1.8% of the dose respectively.
Fractional Excretion of Paracetamol and Its Metabolites
The mean 24 h fractional urinary recovery of paracetamol and its
sulphate, glucuronide, cysteine and mercapturic acid conjugates in
the non-dialysis patients was 2.6 + 1.0, 30.8 +_ 6.2, 60.9 _+ 6.7, 3.0
+ 1.0 and 2.8 + 1.4% respectively which was similar to healthy
subjects. The fractional urinary excretion pattern of paracetamol
and its sulphate, gl ucuronide, cysteine and mercapturic acid
conjugates in each divided urine collection in non-dialysis patients
were generally similar to those in healthy subjects. The mean
fraction recovered as paracetamol from 0-4 h and as paracetamol
sulphate from 4-8 h however, were significantly increased and the
mean fraction as paracetamol glucuronide from 0-2 h significantly
reduced in non-dialysis patients. The mean fraction excreted as
paracetamol cysteine was greater than that as paracetamol mercapturic
acid from 6-24 h.
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Renal Clearances of Paracetamol and its Metabolites
The renal clearances of paracetamol and its sulphate and glucuronide
conjugates following ingestion of 1 g of paracetamol in non-dialysis
patients are shown in Table 5.11.
In non-dialysis patients the mean renal clearances of the sulphate
and glucuronide conjugates of paracetamol were greatly reduced com¬
pared to healthy subjects (15.6 _+ 8.1 and 15.5 +_ 7.1 ml.min"1 versus
180.5 +_ 31.6 and 136.9 +_ 32.0 ml.min"1 respectively; P<0.001) and
there were significant negative correlations with the plasma crea¬
tinine concentrations (r = -0.91 and -0.81; P<0.05). Although the
mean renal clearance of paracetamol was significantly reduced in non-
dialysis patients (4.2 _+ 2.0 ml.min"1 compared to 15.2 +_ 7.0 ml.min"1
in healthy subjects; P<0.002) it was not reduced to the same extent
as the sulphate and glucuronide conjugates and there were no signifi¬
cant correlations with the plasma creatinine or creatinine clearance.
As in normal subjects, the renal clearance of paracetamol correlated
with the urine flow rate in the non-dialysis patients (r = 0.76;
P<0.05) but no such correlation existed for the sulphate or glucuron¬
ide conjugates. There was no significant correlation between the
renal clearances of paracetamol and its sulphate and glucuronide con¬
jugates and the urinary pH.
The mean renal clearance of paracetamol cysteine and mercapturic acid
in the non-dialysis patients were 35 +_ 25 and 80 _+ 45 ml.min"1
respectively.
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TABLE 5.11 Renal Clearance of Paracetamol and Its Sulphate and Glucuronide Conjugates
In 7 Non-dialysis Patients Following Ingestion of 1 g of Paracetamol
| Patient | 0-8 h Renal Clearance (ml. min"1) |

















































































| 15.5 + 7.1 |
I I
I 1 1 1 i
II 1 1 1
II 1 1 1
1* 1






.5 + 31 .6
I I
| 136.9 + 32.0 |
1 1
* = Mean 0-8 h renal clearance data obtained following administration of 1 g of
paracetamol to 10 healthy male subjects
+ = Significantly different from healthy subjects; P<0.002
++ = Significantly different from healthy subjects; P<0.001
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d) Discussion
The absorption of paracetamol was normal in the patients with renal
failure, but the elimination of paracetamol metabolites and parace¬
tamol itself were impaired. The control group consisted of healthy
subjects who were younger than the renal patients and was, therefore,
not ideal. However, it is unlikely that the differences observed
between the groups could be explained by factors other than renal
disease. There was gross retention of the paracetamol sulphate and
glucuronide conjugates in the patients with renal failure. The mean
peak plasma concentrations, times to reach peak plasma concentra¬
tions, areas under the plasma concentration-time curves and apparent
elimination half life values for the paracetamol sulphate and
glucuronide conjugates were all increased compared to those in
healthy subjects. The abnormalities in all cases were greatest in
the haemodialysis patients. There was negligible elimination of the
sulphate and glucuronide conjugates of paracetamol in the haemodia¬
lysis patients and this was consistent with previous studies (Oie et
al, 1975; Lowenthal et al, 1976).
The plasma concentrations of the cysteine and mercapturic acid
conjugates in patients with impaired renal function were low and the
concentrations of the cysteine conjugate were higher than those of
the mercapturic acid conjugate. In the non-dialysis patients these
metabolites disappeared at similar rates. In the haemodialysis
patients elimination of the paracetamol mercapturic acid conjugate
was negligible but the paracetamol cysteine conjugate disappeared
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slowly after approximately 8 h, indicating removal by a route other
than urinary excretion.
Paracetamol was absorbed rapidly in the patients with renal failure
and from 2-8 h it disappeared from plasma at the same rate in healthy
subjects, non-dialysis and haemodialysis patients. From 8-24 h, how¬
ever, paracetamol disappeared from plasma more slowly in the renal
patients with a significant increase in the elimination half life and
area under the plasma paracetamol concentration-time curve over this
period compared to healthy subjects. This extended elimination phase
in the patients with impaired renal function may be explained by
slower release of residual parent compound from peripheral tissues
back to the circulation, or more likely enterohepatic circulation of
the paracetamol conjugates with regeneration of the parent drug.
Enterohepatic circulation has previously been implicated in the unex¬
pected impaired elimination of drugs such as oxazepam, diflunisal and
clofibric acid in patients with renal failure (Odar-Cederlof et al,
1977; Verbeek et al, 1979; Faed and McQueen, 1979). Like paraceta¬
mol, these drugs are predominantly metabolised to glucuronide conju¬
gates which in renal failure undergo enterohepatic circulation with
subsequent hydrolysis which releases the parent compound in the gut.
This is subsequently reabsorbed (Verbreek et al, 1981). Labile ester
glucuronide conjugates have usually been implicated in this mechan¬
ism, and esterases rather than glucuronidase are responsible for
hydrolysis (Meffin et al, 1983). However, paracetamol is metabolised
to the more stable ether glucuronide conjugate. Paracetamol glucur¬
onide is normally excreted into bile only to a limited extent in man
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(Jayasinghe et al, 1986) but with the very high concentrations which
occur in patients with renal failure hydrolysis of the glucuronide
conjugate could explain the elevated plasma paracetamol concentra¬
tions from 8-24 h. Biliary excretion of the cysteine conjugate is
only a minor route of elimination in man (Seigers et al^, 1984;
Jayasinghe et al_, 1986). In the haemodialysis patients the mean
plasma paracetamol cysteine concentrations declined from 8 h, which
coincided with the decrease in disappearance of paracetamol. It may
be, therefore, that the cysteine conjugate undergoes enterohepatic
circulation in the haemodialysis patients. Enterohepatic circulation
of paracetamol glutathione has been demonstrated in rats (Siegers et
al, 1983) but there is no evidence for this in man.
The residual plasma paracetamol concentrations observed in the pre¬
sent study were low and clinically insignificant. However, para¬
cetamol concentrations would probably be much higher with the gross
cumulation of metabolites which must occur in renal patients on long
term therapy. Multiple dose studies require to be performed
(Prescott et al, 1989).
In the non-dialysis patients the mean 24 h urinary recovery of the
administered dose was significantly reduced compared to healthy sub¬
jects but the fractional urinary recovery of paracetamol and its
metabolites was similar. The ability to metabolise paracetamol by
each pathway was, therefore, unaffected in the patients with chronic
renal failure. Similar results have been reported in patients with
either analgesic nephropathy or nephropathy due to other causes
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(Thomas et al, 1980). In particular, the recovery of the cysteine
and mercapturic acid conjugates was not increased in patients with
renal disease and this indicates that conversion to the toxic inter¬
mediate was not enhanced. The mechanism by which paracetamol induces
renal failure in overdosage is thought to be similar to the mechanism
described for the liver. In the kidney a 50% reduction in renal
gluthatione results in binding of the reactive intermediate to vital
renal macromolecules (Mitchell et al, 1977).
In the non-dialysis patients the mean plasma concentrations and the
mean total urinary recovery of paracetamol cysteine were greater than
those of the mercapturic acid conjugate. Although the mean frac¬
tional urinary recovery of these metabolites was not significantly
different from those obtained in healthy subjects, the urinary
recovery of the mercapturic acid conjugate is normally greater than
that of the cysteine conjugate in healthy subjects. It is possible
that acetylation of the paracetamol cysteine conjugate to form para¬
cetamol mercapturic acid is reduced in patients with renal failure.
In this context acetylation in patients with renal disease may be
normal or slowed (Reidenberg, 1977b).
In the non-dialysis patients the mean renal clearances of the cys¬
teine and mercapturic acid conjugates were greater than the glome¬
rular filtration rate. A possible explanation may be that the kidney
is capable of forming these metabolites from precursors (Jones et al,
1979; Ross et al, 1980; Newton et al, 1982). However, one patient on
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the present study was anephric and
turic acid conjugate concentrations
other patients.
the plasma cysteine and mercap-
were comparable to those in the
In the non-dialysis patients the renal clearances of paracetamol
sulphate and glucuronide were greatly reduced and were correlated
with the plasma creatinine concentration but not with urine flow rate
or pH. The renal clearance of paracetamol was also reduced in the
non-dialysis patients but not to the extent observed with the sul¬
phate and glucuronide conjugates. In addition, the renal clearance
of paracetamol was unrelated to plasma creatinine and urinary pH, but
was dependent on the urine flow rate. In healthy subjects parace¬
tamol is freely filtered at the glomerulus and then passively reab¬
sorbed, while the glucuronide and sulphate conjugates are actively
secreted by the renal tubule (Prescott and Wright, 1973; Duggin and
Mudge, 1975). The disproportionate decrease in the renal clearance
of the conjugates suggests that the capacity for active tubular
transport is reduced to a greater extent than passive reabsorption in
patients with chronic renal failure. In addition to tubular defects
caused by disease, the retention of endogenous organic anions may




The absorption, distribution, metabolism and elimination of parace¬
tamol were studied in 7 non-dialysis and 5 haemodialysis patients
with chronic renal failure after oral administration of an efferves¬
cent formulation of 1 g of paracetamol. Results were compared with
those obtained following oral administration of an effervescent for¬
mulation of 1 g of paracetamol to 10 healthy male subjects.
The absorption of paracetamol was normal in the patients with im¬
paired renal function but there was gross retention of paracetamol
metabolites and the late elimination of the parent compound was also
impaired. The retention of metabolites was greatest in haemodialysis
patients and their elimination in this group was negligible.
From 2-8 h paracetamol disappeared from plasma at the same rate in
healthy subjects and in both groups of patients with chronic renal
failure. However, paracetamol elimination was delayed from 8-24 h in
the renal failure patients. The cysteine and mercapturic acid conju¬
gates of paracetamol were present at low concentrations in plasma in
the patients with impaired renal function and both metabolites were
eliminated at similar rates in the non-dialysis patients. In the
haemodialysis patients elimination of paracetamol mercapturic acid
was negligible but the plasma paracetamol cysteine concentrations
gradually decreased over the period 8-24 h. The cysteine conjugate
may undergo limited enterohepatic circulation with the subsequent
reabsorption of the parent compound. Limited enterohepatic circu-
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lation of this and the other metabolites of paracetamol which were
present at elevated concentrations may therefore explain the delayed
paracetamol elimination phase.
In the non-dialysis patients the mean 24 h urinary recovery of the
administered dose was less than in healthy subjects. Paracetamol
metabolism, however, was not abnormal as the fractional urinary
recoveries of paracetamol and its metabolites in these patients and
healthy subjects were similar.
One haemodialysis patient was anephric and the plasma concentrations
of paracetamol and its metabolites were comparable to those of the
other haemodialysis patients. The contribution of the kidney to the
overall metabolism of paracetamol appears to be minimal.
The renal clearances of paracetamol and its sulphate and glucuronide
conjugates were reduced in the non-dialysis patients. The decreases
in the renal clearances of the conjugates were disproportionately
greater than those of the parent compound. The capacity for active
tubular transport appeared to be reduced to a greater extent than the
capacity for passive reabsorption.
In the present study only the disposition of a single dose of parace¬
tamol was investigated in patients with chronic renal failure. On
long term therapy, however, paracetamol concentrations would probably
be higher and there would be gross cummulation of metabolites.
Multiple dose studies require to be performed.
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CHAPTER VI
Paracetamol N-Acetyl-D-L-Methionate Disposition in
Patients with Impaired Renal Function
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PARACETAMOL N-ACETYL-D-L-METHIONATE DISPOSITION IN
PATIENTS WITH IMPAIRED RENAL FUNCTION
a) Introduction
The idea to incorporate methionine into paracetamol tablets to make
them safer if taken in overdosage was first suggested in 1975 (McLean
and Day). Using this concept, Sterling Winthrop combined paracetamol
with N-acetyl-D-L-methionine as the N-acetyl-D-L-methionine ester of
paracetamol. This tasteless compound hydrolyses to yield equimolar
quantities of paracetamol and methionine. Methionine is a gluta¬
thione precursor and is effective in preventing severe liver damage
and death after paracetamol overdosage (Crome et al, 1976; Hamlyn
et al, 1981; Vale et al, 1981).
After investigation of the disposition of the ester in healthy sub¬
jects (Chapter IV), it was administered to 7 non-dialysis and 5 hae-
modialysis patients with stable renal impairment.
The equivalent of 1 g of paracetamol was administered as 1) paraceta¬
mol and 2) paracetamol N-acetyl-D-L-methionate. At least one week
was allowed between each administration. This chapter describes the
disposition of paracetamol in patients with renal impairment follow¬
ing administration of paracetamol N-acetyl-D-L-methionate. Data
obtained from
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patients with renal failure who received 1 g of paracetamol alone
(Chapter V) were used for comparison.
b) Methods
Patients
The same 11 men and one woman with chronic renal impairment previous¬
ly described in Chapter V were entered onto the study. Their mean
age was 52 + 12 years and body weight 75 +_ 8 kg. Seven had moderate
to severe renal failure but were not being treated with dialysis and
5 with more advanced disease were receiving long term dialysis 2 or 3
times a week. Clinical details of these patients are summarised in
Table 5.1. Informed consent was given by each patient and the study
was approved by the local Ethics Committee.
Administration and Sampling
Patients attended the University Department of Clinical Pharmacology
or the Medical Renal Unit after fasting overnight, and an in-dwelling
cannula was inserted into a forearm vein. Haemodialysis patients
attended on an interdialysis day. Sachets containing 2.146 g of an
effervescent formulation of paracetamol N-acetyl-D-L-methionate
(equivalent to 1 g of paracetamol) were supplied by Sterling
Winthrop, Alnwick. Each patient received the contents of one sachet
orally in 200 ml of water. The patients remained recumbent for 3 h
and lunch and supper were allowed at 4 and 8 h respectively. Each
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patient received meals appropriate to their condition (eg low
protein, controlled sodium or potassium intake). Fluid intake was
restricted as necessary in haemodialysis patients and non dialysis
patients received 200 ml of water every 2 h up to 12 h.
5 ml venous blood samples were taken into heparinised tubes at 0,
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24 h.
The blood was centrifuged at 1400 x g for 10 min and the plasma
separated and stored at -20°C. Urine samples from non-dialysis
patients were collected immediately before drug administration and
from 0-2, 2-4, 4-6, 6-8, 8-10, 10-12 and 12-24 h after dosing. The
total urine volume and pH were recorded and 50 ml aliquots were
stored at -20°C prior to analysis. Individual urine volumes and pH
values are shown in Appendix 6.9.
Drug Analysis
Plasma concentrations of paracetamol, paracetamol sulphate and
paracetamol glucuronide and urinary concentrations of paracetamol,
paracetamol sulphate, paracetamol glucuronide, paracetamol cysteine
and paracetamol mercapturic acid were measured by HPLC as described
in Chapter II, Section 1. Significant blank values were obtained in
some patients and these were subtracted to give corrected concen¬
trations. Patient 07 had a high urinary protein concentration and
the paracetamol sulphate peak was poorly resolved. The amount of
sulphate excreted was therefore estimated from the relative areas
under the plasma concentration-time curves of the sulphate and glucu-
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ronide conjugates and the urinary recovery of paracetamol glucuron-
ide, assuming both metabolites had the same renal clearance and
volume of distribution.
Data Analysis
i) Plasma Concentrations of Paracetamol and its Metabolites
Mean plasma concentrations of paracetamol and its sulphate and
glucuronide conjugates were plotted on a semi logarithmic graph
against time and Cmax, Tmax, paracetamol th (2-8 h), paracetamol
sulphate and glucuronide th (8-24 h) and AUC (0-24 h) values were
determined as described in detail in Chapter III. The relative
paracetamol bioavailability was calculated by dividing the 0-24 h
area under the plasma paracetamol concentration-time curve after
administration of 2.146 g paracetamol N-acetyl-D-L-methionate by the
corresponding plasma paracetamol area under the curve following
administration of 1 g of paracetamol alone to the same renal failure
patient.
ii) Non Dialysis Patients - Urinary Excretion of Paracetamol and its
Metabolites
Each subject received 2.146 g of paracetamol N-acetyl-D-L-methionate
which, if completely hydrolysed would yield 1 g of paracetamol. As
only paracetamol and its metabolites were measured in urine, the per¬
centage of the paracetamol component of the dose (1 g) recovered in
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urine in 24 h following administration of paracetamol N-acetyl-D-L-
methionate was determined.
In addition, the fractional urinary recovery in 24 h and in each
divided urine collection, and the 0-8 h renal clearances of paraceta¬
mol and its sulphate and glucuronide conjugates were calculated as
described in Chapter III.
iii) Statistical Analysis
Mean values + standard deviation (SD) are presented. The relation¬
ship between quantitative observations on each subject (bivariate
data) was determined by calculation of the correlation coefficient
(r). The correlation coefficient was tested for statistical signifi¬
cance using tabulated values (Geigy Scientific Tables, P61). Differ¬
ences between means were compared by the Wilcoxon paired sample rank
test for statistical significance.
c) Results
i) Plasma Concentrations of Paracetamol and its Sulphate and
Glucuronide Conjugates
Mean plasma concentrations of paracetamol and its sulphate and
glucuronide conjugates following oral administration of 2.146 g of
paracetamol N-acetyl-D-L-methionate to 7 non dialysis and 5 haemo-
dialysis patients are shown in Table 6.1, Figure 6.1 and Table 6.2,
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TABLE 6.1 Mean Plasma Concentrations of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 7 Non-dialysis Patients Following Ingestion of 2.146 g of
Paracetamol N-Acetyl-D-L-methlonate
| Time After | Plasma Concentration (y.g.mI"1>
| Ingestion | Paracetamol | Paracetamol Sulphate |Paracetamol Glucuronide]
I I
I I
(Mean + SD) | (Mean + SD) |
I I






| 0.6 +_ 0.7 |
i i














| 5.0 +_ 1.9 |
I |






| 6.2 +_ 2.2 |
I |
4.9 +_ 2.6 |
1 1




| 8.2 j+ 2.8 |
1 |






| 9.2 +_ 3.2 |
I |






| 11 .0 +_ 4.2 |
1 i






| 12.1 +_ 4.1 |
1 |














| 12.5 5.1 |
I |






















j 11.9 + 6.2 |
1 |




1 .5 _+ 0.4
1 1
| 11.4 +_ 5.3 |
I |














| 6.5 + 4.2 |
1 1
12.4 +_ 7.0 j
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FIGURE 6.1 Mean Plasma Concentrations of Paracetamol and Its Sulphate and Glucuronide















TABLE 6.2 Mean Plasma Concentrations of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 5 Haemodlalysls Patients Following Ingestion of 2.146 g of
ParacetamoI N-AcetyI-D-L-meth1onate






| Paracetamol Sulphate |Paracetamol Glucurontde|







| 1 .8 +_ 2.0 |
I i
























4.1 +_ 1 .1 j
1 1




| 9.5 +_ 2.3 |
1 |






| 11.0 2.5 |
1 i














| 16.2 3.9 |
I i












1 .9 +_ 1.2
1 1
| 18.5 _+ 6.2 |
1 |






| 18.9 + 6.6 |
1 |














| 18.6 7.0 |
1 |






| 19.1 +_ 8.3 |
I i














| 17.0 + 8.4 |
I I
26.3 +_ 7.8 |
+
= Mean of 4
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Figure 6.2 respectively. Individual values for peak concentration
(Cmax) and time to reach peak concentration (Tmax), apparent elimin¬
ation half life and area under the plasma concentration-time curves
for paracetamol and its metabolites in non-dialysis patients are
shown in Table 6.3, 6.5 and 6.6 respectively. Individual values for
Cmax and Tmax, and area under the plasma concentration-time curves
for paracetamol and its metabolites in haemodialysis patients are
shown in Tables 6.4 and 6.7 respectively. Plasma concentrations for
each subject are shown in Appendices 6.1-6.3.
Paracetamol
Following administration of 2.146 g of paracetamol N-acetyl-D-L-
methionate the mean plasma paracetamol profiles were similar in the
non-dialysis and dialysis patients, and in most patients plasma para¬
cetamol concentration fluctuated prior to reaching peak concentra¬
tion. The mean individual peak plasma paracetamol concentration
for the non-dialysis and dialysis patients combined following admin¬
istration of paracetamol N-acetyl-D-L-methionate was significantly
reduced (10.2 + 2.1 pg.ml"1 compared to 17.9 + 6.9 pig.ml"1; P<0.005)
and delayed (1.31 + 0.82 h compared to 0.50 + 0.38 h; P<0.01) com¬
pared to that obtained following administration of 1 g of paracetamol
alone to the same patients with impaired renal function. From 2-8 h
plasma paracetamol concentrations declined linearly when plotted on a
semi logarithmic graph and the mean plasma paracetamol elimination
half life values over this period in the non-dialysis and dialysis
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FIGURE 6.2 Mean Plasma Concentrations of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 5 Haeroodialysis Patients Following Ingestion of 2.146 g of
ParacetamoI N-AcetyI-D-L-methionate
0.1 H 1 1 1 1 1 —-i 1
0 2 4 6 8 10 12 24
Time (h)
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TABLE 6.5 Peak Plasma Concentrations (Cmax) and Time to Reach Peak Plasma
Concentrations (Tmax) of Paracetamol and its Sulphate and Glucuronide
Conjugates in 7 Non-dialysis Patients Following Ingestion of 2.146 g
of Paracetamol N-Acetyl-D-L-methionate
i Paracetamol Paracetamo Su I phate Paracetamol Glucuronide|
Subject J Cmax | Tmax Cmax Tmax Cmax | Tmax j











































































| + | + i 1
Mean + SD 110.8 + 2.4
I
O-+I00 .83 13.5 _+ 6.0 6.14 +2.12 23.3 _+ 8.7 |7.29 + 1 -501
1 1
I I I I I I I
I I I I I I I
I I I I I I I
* I I 1 1




.44 13.7 + 5.9 5.57 +_ 1 .51 25.2 + 8.9 16.29 + 1 .60 |
1 1
* = Mean data obtained following ingestion of 1 g of paracetamol to the same 7 non-
dialysis patients
+ = Significantly different from renal failure patients administered 1 g of
paracetamol; P<0.005
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TABLE 6.4 Peak Plasma Concentrations (Croax) and Time to Reach Peak Plasma
Concentrations (Tmax) of Paracetamol and Its Sulphate and Glucuronlde
Conjugates In 5 Haemodia Iysis Patients Following Ingestion of 2.146 g
of Paracetamol N-Acetyl-D-L-methlonate
i Paracetamol Paracetamo SuIphate Paracetamol Glucuronide |
Subject | Cmax | Tmax Cmax Tmax Cmax \ Tmax |
























































| + | + I I




.87 20.3 +_ 7.5 8.00 +_ 3.16 26.8 +_ 7.4 117-60 + 8.88 |
1 1
I I I I I I I
I I I I I I I
I I I I I I I
* I I 1 1




.32 20.7 _+ 5.4 00 roo i+ o 00 -t* 30.6 +_ 8.1 115.00 + 8.43|
1 1
* = Mean data obtained following ingestion of 1 g of paracetamol to the same 5
haemodlalysls patients
+ = Significantly different from renal failure patients administered 1 g of
paracetamol; P<0.005
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TABLE 6.5 Apparent Plasma Elimination Half Life of Paracetamol and Its Sulphate and
Glucuronide Conjugates In 7 Non-dialysis Patients Following Ingestion of
2.146 g of Paracetamol N-Acetyl-D-L-methlonate





j ti (8-24 h)
! (h)







































































| 22.2 + 20.5
1
1 1
| 28.5 + 30.7 |
1 1
II 1 1 1
II 1 1 1
II 1 1 1
1 * 1




| 21.1 + 15.4
1
1 1
| 29.1 + 32.3 |
I i
* = Mean data obtained following administration of 1 g of paracetamol to the same 7
non-dialysis patients
= CaIcuIated over 4-8 h
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TABLE 6.6 Area Under the Plasma Concentration-time Curves for Paracetamol and Its
Sulphate and Glucuronide Conjugates In 7 Non-dialysis Patients Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methlonate
| Patient | Area Under the P asma Concentration-time Curve 0-24 h (vig.h.ml"1) |





































































| 231.2 + 107.7
1
1 1
| 394.3 + 143.4 |
I I
II 1 1 1
II 1 1 1
II 1 1 1
1 * i




| 231.9 + 108.3
1
I I
| 431.4 + 157.4 |
I I
* = Mean data obtained following administration of 1 g of paracetamol to the same 7
non-dialysis patients
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TABLE 6.7 Area Under the Plasma Concentration-time Curves for Paracetamol and its
Sulphate and Glucuronide Conjugates In 5 Haemod!a IysIs Patients Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methlonate
| Patient | Area Under the Plasma Concentration-time Curve 0-24 h (pg.h.ml"1) 1




































| Mean + SD |
1
44.8 + 13.8 | 418.4 + 155.4
1
1 1
| 574.6 + 175.7 |
1 1
II I I I
II I I I
II I I I
I * I 1 1 I
| Mean + SD | 55.7 + 18.8 | 449.6 + 108.3
1
| 673.1 + 227.9 |
1 1
* = Mean data obtained following administration of 1 g of paracetamol to the same 5
haemodialysis patients
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patients were 2.9 +_ 0.5 h (range 2.3-3.5) and 2.0 +_ 0.3 h (range 1.5-
2.4) respectively. These values were not significantly different
from those obtained following administration of 1 g of paracetamol
alone (2.5 +_ 0.3 and 2.1 _+ 0.4 h respectively).
In both the non-dialysis patients and dialysis patients the plasma
paracetamol concentrations declined more slowly from 10-24 h but too
few data points were available to accurately determine the plasma
elimination half life over this period. The mean 0-24 h areas under
the plasma paracetamol concentration-time curve following
administration of paracetamol N-acetyl-D-L-methionate were 63.3 +_
13.4 pig.h.ml"1 (range 45.4-81.1) and 44.8 +_ 13.8 pig.h.ml"1 (range 30.8-
59.7) in non-dialysis and dialysis patients respectively. These
values were not significantly different from those obtained after
administration of paracetamol alone to the same patients which were
62.5 +_ 13.6 and 55.7 + 18.8 pig.h.ml"1 respectively.
The bioavailability of paracetamol after administration of paraceta¬
mol N-acetyl-D-L-methionate was therefore similar to that obtained
after administration of 1 g of paracetamol alone to the same renal
failure patients. The mean relative paracetamol bioavailability for
both groups of renal patients combined following administration of
paracetamol N-acetyl-D-L-methionate was 94.4 +_ 16.3%.
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Paracetamol Sulphate
Mean plasma concentrations of paracetamol sulphate following adminis¬
tration of 2.146 g paracetamol N-acetyl-D-L-methionate were similar
to those obtained after administration of 1 g of paracetamol to the
same patients with impaired renal function. None of the pharmacoki¬
netic variables for plasma paracetamol sulphate following adminis¬
tration of paracetamol N-acetyl-D-L-methionate were significantly
different from those obtained with paracetamol alone.
Following administration of paracetamol N-acetyl-D-L-methionate to
renal failure patients, plasma concentrations of paracetamol sulphate
were greatly elevated and exceeded those of the parent compound. In
Patient Oil sulphate conjugation appeared to be the major metabolic
route. In the non-dialysis and dialysis patients following adminis¬
tration of paracetamol N-acetyl-D-L-methionate, the mean individual
peak plasma paracetamol sulphate concentrations were 13.5 +_ 6.0
pig.ml"1 (range 9.7-26.5) and 20.3 +_ 7.5 pig.ml"1 (range 14.4-33.2)
respectively, and the mean individual times to reach peak plasma
paracetamol sulphate concentration were 6.14 +_ 2.12 h (range 4-10)
and 8.00 +_ 3.16 h (range 4-12) respectively. From 8-24 h the mean
plasma paracetamol sulphate apparent elimination half life in non-
daialysis patients following administraion of paracetamol N-acetyl-D-
L-methionate was 22.2 +_ 20.5 h (range 11.0-67.6) compared to 21.2 +_
15.4 h obtained after administration of 1 g of paracetamol to the
same patients. The elimination of paracetamol sulphate in haemo-
dialysis patients was negligible after administration of paracetamol
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N-acetyl-D-L-methionate. The mean areas under the plasma paracetamol
sulphate concentration-time curves in non-dialysis and dialysis
patients following administration of paracetamol N-acetyl-D-L-methi¬
onate were 231.2 +_ 107.7 pig.h.ml"1 (range 127-462) and 418.4 +_ 155.4
pig.h.ml"1 (range 233-659) respectively. In the non-dialysis patients
there was a significant correlation between plasma creatinine concen¬
tration and the area under the plasma paracetamol sulphate concen¬
tration-time curve (r = 0.82; P<0.05).
Paracetamol Glucuronide
As with paracetamol sulphate, none of the kinetic variables relating
to paracetamol glucuronide following administration of 2.146 g para¬
cetamol N-acetyl-D-L-methionate were significantly different from
those obtained after administration of 1 g of paracetamol in the same
patients.
In the non-dialysis and dialysis patients following administration of
paracetamol N-acetyl-D-L-methionate, the mean individual peak plasma
paracetamol glucuronide concentrations were 23.3 +_ 8.7 pig.ml"1 (range
14.7-40.5) and 26.8 +_ 7.4 pig.ml"1 (range 17.5-37.9) respectively, and
the mean individual times to reach peak paracetamol glucuronide con¬
centrations were 7.29 +_ 1.50 h (range 5-9) and 17.60 +_ 8.88 h (range
6-24) respectively. From 8-24 h the mean plasma paracetamol glucu¬
ronide apparent elimination half life in non-dialysis patients fol¬
lowing administration of paracetamol N-acetyl-D-L-methionate was 28.5
+ 30.7 h (range 10.0-96.7) compared to 29.1 + 32.3 h obtained after
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administration of 1 g of paracetamol to the same patients. The
elimination of paracetamol glucuronide in haemodialysis patients was
negligible after administration of paracetamol N-acetyl-D-L-methi-
onate. The mean areas under the plasma paracetamol glucuronide con¬
centration-time curves in non-dialysis and dialysis patients follow¬
ing administration of paracetamol N-acetyl-D-L-methionate were 394.3
+_ 143.4 pig.h.ml"1 (range 246-687) and 574.6 +_ 175.7 pig.h.ml"1 (range
342-764) respectively. In the non-dialysis patients there was a
significant correlation between plasma creatinine concentration and
the area under the plasma paracetamol glucuronide concentration-time
curve (r = 0.90; P<0.01).
ii) Renal Excretion of Paracetamol and its Metabolites in the Non-
dialysis Patients
Individual total recoveries of the paracetamol component of the dose
(1 g) and 24 h fractional urinary recoveries of paracetamol and its
metabolites following ingestion of 2.146 g paracetamol N-acetyl-D-L-
methionate in the 7 non-dialysis patients are shown in Table 6.8.
The mean percentages of total paracetamol excreted in divided urine
collections as paracetamol and its metabolites are shown in Table 6.9
and Figure 6.3. Individual urinary excretion data are shown in
Appendices 6.4-6.8.
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TABLE 6.8 Twenty Four Hour Urinary Recovery of the Paracetamol Component of the Dose
(1 g) and Fractional Urinary Recovery of Paracetamol and its Sulphate,
Glucuronlde, Cysteine and Mercapturlc Acid Conjugates In 7 Non-dialysis
Patients Following Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-
methionate
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* = Mean data obtained following ingestion of 1 g of paracetamol to the same 7 non-
dialysis patients
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TABLE 6.9 Mean Percentage of Total Paracetamol Excreted In Divided Urine Collection
as Paracetamol and Its Metabolites Following Ingestion of 2.146 g of
Paracetamol N-Acetyl-D-L-methlonate in 7 Non-dialysis Patients
|TI me After
Mean Proportion Excreted (as Percentage of Total in Samplel + SD |
|1ngestlon









| 0-2 25.2 _+ 12.5 36.8 + 10.0 38.3 + 9.6 2.1 +_ 1 .3 i 1 -3 j+ 1 .5 |
| 2-4 7.5 +_ 5.0 35.4 + 7.3 52.5 + 6.5 2.7 +_ 1 .5 | 3.0 _+ 2.5 |
| 4-6 1 .9 + 2.2 34.8 + 6.9 56.1 + 6.4 3.5 + 1 .6 | 4.0 _+ 3.1 |
| 6-8 0.7 + 1.6 33.8 + 7.0 57.7 _+ 7.9 4.0 _+ 1 .6 | 4.0 + 2.6 |
| 8-10 - 33.0 + 6.1 59.1 +_ 6.7 4.0 + 1 .3 | 4.0 +_ 2.4 |
| 10-12 - 33.1 +_ 6.7 59.3 _+ 7.1 3.9 + 1 .5 | 3.8 +_ 2.1 |
| 12-24 - 32.0 + 5.9 62.2 _+ 6.9 2.8 +_ 1 .5 | 3.0 + 1.4 |
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FIGURE 6.3 Changes In the Mean Proportional Urinary Excretion of Paracetamol and Its
Sulphate, Glucuronide, Cysteine and Mercapturlc Acid Conjugates Following
Ingestion of 2.146 g of Paracetamol N-AcetyI-D-L-methlonate In 7 Non-
dial ysls Patients
i 1 1 1 1 1 V 1
0 2 4 6 8 10 12 24
Time (h)
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Urinary Recovery of Paracetamol and Its Sulphate, Glucuronide,
Cysteine and Mercapturic Acid Conjugates
The mean 24 h urinary recovery of the paracetamol component of the
administered dose (1 g) after administration of 2.146 g paracetamol
N-acetyl-D-L-methionate was 56.8 _+ 13.4% (range 32.2-70.4) which was
similar to that obtained after administration of 1 g of paracetamol
alone (55.5 + 17.8%) to the same non-dialysis patients. There was a
significant negative correlation with plasma creatinine concentration
and total urinary recovery (r = -0.80; P<0.05). The mean percentage
of the paracetamol component of the dose recovered up to 24 h follow¬
ing administration of paracetamol N-acetyl-D-L-methionate in the non-
dialysis patients as paracetamol and its sulphate, glucuronide, cys¬
teine and mercapturic acid conjugates was 1.2, 18.9, 33.0, 1.9 and
1.9% respectively. These values were similar to those obtained after
administration of paracetamol alone to the same non-dialysis
patients (1.4, 16.8, 34.9, 1.8 and 1.8% respectively).
Fractional Excretion of Paracetamol and its Metabolites
The mean 24 h fractional urinary recovery of paracetamol and its
sulphate, glucuronide, cysteine and mercapturic acid conjugates in
non-dialysis patients following administration of paracetamol N-
acetyl-D-L-methionate were 2.2 + 0.8, 33.2 + 6.3, 58.1 + 6.3, 3.4 +
1.2 and 3.4 + 2.1% respectively. These values were not significantly
different from those obtained after administration of 1 g of para¬
cetamol to the same non-dialysis patients. The mean fractional
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urinary excretion pattern of paracetamol and its metabolites in each
divided urine collection in non-dialysis patients following adminis¬
tration of paracetamol N-acetyl-D-L-methionate was also not signifi¬
cantly different from that obtained in the same patients following
administration of paracetamol alone.
Renal Clearances of Paracetamol and its Sulphate and Glucuronide
Metabolites
The renal clearances of paracetamol and its sulphate and glucuronide
conjugates following ingestion of 2.146 g paracetamol N-acetyl-D-L-
methionate in non-dialysis patients are shown in Table 6.10.
Following administration of paracetamol N-acetyl-D-L-methionate the
mean renal clearances of paracetamol and its sulphate and glucuronide
conjugates were 4.4 +_ 1.5, 16.6 +_ 6.7 and 16.7 _+ 6.5 ml.min"1 respect¬
ively. These values were similar to those obtained after adminis¬
tration of 1 g of paracetamol to the same non-dialysis patients.
There was a significant correlation with plasma creatinine concen¬
tration and paracetamol sulphate and glucuronide renal clearances
(r = -0.94 and -0.81; P<0.05) but no such relationship existed for
the paracetamol. Paracetamol renal clearance correlated with urine
flow rate (r = 0.84; P<0.05) but not with urinary pH. The renal
clearances of paracetamol sulphate and glucuronide did not correlate
with either urine flow rate or urinary pH following administration of
paracetamol N-acetyl-D-L-methionate to non-dialysis patients.
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TABLE 6.10 Renal Clearance of Paracetamol and Its Sulphate and Glucuronide
Conjugates In 7 Non-dialysis Patients Following Ingestion of
2.146 g of Paracetamol N-Acetyl-D-L-methIonate
| Patient | 0-8 h Renal Clearance (ml • min"1) |


































































| Mean + SD |
1 _ _ 1
4.4 +_ 1 .5
1
| 16.6 + 6.7
1
1 1
| 16.7 + 6.5 |
1 1
I I 1 1 1
II 1 1 1
II 1 1 1
1 * 1




| 15.6 + 8.1
I
1 1
| 15.5 + 7.1 |
1 1
* = Mean 0-8 h renal clearance data obtained following administration of 1 g of
paracetamol to the same non-dialysis patients
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d) Discussion
The absorption of paracetamol appeared to be similar in the non-
dialysis and dialysis patients following administration of 2.146 g
paracetamol N-acetyl-D-L-methionate (equivalent to 1 g of paraceta¬
mol). However, the mean of the individual peak plasma paracetamol
concentration was reduced and delayed by approximately 50 min com¬
pared to that obtained after administration of 1 g of paracetamol
alone in the same renal failure patients. These results were con¬
sistent with the delayed absorption of paracetamol observed in
healthy subjects following administration of paracetamol N-acetyl-D-
L-methionate (SWRD Report 305510, 1978; Chapter IV of this thesis).
Orally administered ester prodrugs are particularly susceptible to
hydrolysis by esterases present in the intestine, liver and plasma
(Williams, 1985). It is therefore likely that, as in healthy sub¬
jects, paracetamol N-acetyl-D-L-methionate is rapidly hydrolysed in
patients with chronic renal failure. The delayed appearance of para¬
cetamol may be explained by slow absorption because of the relative
insolubility of paracetamol N-acetyl-D-L-methionate. It is not known
whether the methionine ester of paracetamol is absorbed intact.
Following administration of paracetamol N-acetyl-D-L-methionate in
patients with chronic renal failure, plasma paracetamol concentra¬
tions declined from 2-8 h at similar rates to those observed after
administration of paracetamol alone in the same patients with renal
failure. In addition, as was observed after administration of para¬
cetamol alone, there was an extended phase of paracetamol elimination
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from 10-24 h. The slower elimination of paracetamol during this
period can probably be explained by enterohepatic circulation of
paracetamol conjugates which are present at high concentrations in
patients with chronic renal failure. These may be excreted to a
limited extent into bile with subsequent hydrolysis releasing para¬
cetamol back into the gut which is then reabsorbed. This mechanism
has been described for drugs such as oxazepam, diflunisal and clofi-
bric acid in patients with chronic renal failure (Odar-Cederlof et
al, 1977; Faed and McQueen, 1979; Verbeek et al, 1979). Although the
residual plasma paracetamol concentrations were relatively low, con¬
centrations much higher are likely in patients with chronic renal
failure receiving long term therapy.
Following administration of paracetamol N-acetyl-D-L-methionate the
mean 0-24 h areas under the plasma paracetamol concentration-time
curves in non-dialysis and dialysis patient were not significantly
different from those obtained after administration of paracetamol
alone to the same renal failure patients. This indicates that al¬
though absorption was delayed and slow, the bioavailability of para¬
cetamol after administration of paracetamol N-acetyl-D-L-methionate
was similar to that obtained after administration of paracetamol
alone in patients with chronic renal failure. Similar findings were
observed in healthy subjects (Chapter IV).
As observed after administration of paracetamol alone, there was
gross retention of paracetamol sulphate and glucuronide conjugates
following administration of paracetamol N-acetyl-D-L-methionate in
patients with chronic renal failure. Plasma concentrations of these
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conjugates in the non-dialysis and dialysis patients were similar to
those obtained after administration of paracetamol alone in the same
patients. The elimination of the sulphate and glucuronide conjugates
in the haemodialysis patients was negligible following administration
of paracetamol N-acetyl-D-L-methionate.
In the non-dialysis patients the mean 24 h urinary recovery of the
paracetamol component of the dose was not significantly different
from that obtained after administration of 1 g of paracetamol alone
to the same patients. Similarly, the mean 24 h fractional urinary
recoveries of paracetamol and its metabolites were not altered. The
ability to metabolise paracetamol in this form was therefore unaf¬
fected in patients with chronic renal failure. In particular, even
although methionine is a glutathione precursor, the cysteine and
mercapturic acid conjugation of paracetamol was not influenced fol¬
lowing administration of paracetamol N-acetyl-D-L-methionate in non-
dialysis patients. As observed in the same patients following ad¬
ministration of paracetamol alone, the urinary recovery of the
cysteine conjugate was higher than that of the mercapturic acid
conjugate in 4 of the 7 non-dialysis patients following adminis¬
tration of paracetamol N-acetyl-D-L-methionate indicating that the
ability to acetylate paracetamol cysteine may be reduced in these
patients. Acetylation in patients with renal disease may be normal
or slowed (Reidenber 1977b).
In healthy subjects there was a small but significant increase in the
sulphation of paracetamol following administration of paracetamol
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N-acetyl-D-L-methionate compared to that obtained after adminis¬
tration of paracetamol alone to the same subjects (Chater IV). The
paracetamol sulphate pathway is susceptible to dose dependent satu¬
ration (Prescott, 1984) and is dependent on the availability of
inorganic sulphate (Levy, 1986). In the non-dialysis patients,
however there was no indication that sulphate conjugation of para¬
cetamol was significantly increased following administration of para¬
cetamol N-acetyl-D-L-methionate compared to paracetamol alone. It is
possible that unlike the findings in healthy subjects, the sulphate
conjugation pathway was not saturated following administration of
paracetamol in the non-dialysis patients. Inorganic sulphate is pre¬
dominantly eliminated by renal excretion (Cocchetto and Levy, 1981)
and it is retained in patients with chronic renal failure (Freeman
and Richards, 1979). Saturation of sulphate conjugation is probably
less likely in patients with chronic renal failure.
Following administration of paracetamol N-acetyl-D-L-methionate in
non-dialysis patients, the mean renal clearances of paracetamol and
its sulphate and glucuronide conjugates were not significantly dif¬
ferent from those obtained after administration of paracetamol alone
to the same patients. As with paracetamol, the results obtained
after administration of paracetamol N-acetyl-D-L-methionate to non-
dialysis patients were consistent with glomerular filtration and
passive reabsorption of paracetamol and active tubular secretion of
the sulphate and glucuronide conjugates. Similarly, the capacity for
active tubular transport seemed to be reduced to a greater extent
than the capacity for passive reabsorption.
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e) Summary and Conclusion
Following administration of 1 g of paracetamol as paracetamol N-
acetyl-D-L-methionate (2.146 g) to 7 non-dialysis and 5 haemodialysis
patients with chronic renal failure the overall disposition of para¬
cetamol was similar to that obtained after administration of 1 g of
paracetamol to the same patients.
Compared to paracetamol alone the appearance of paracetamol was
delayed and the peak plasma paracetamol concentration was reduced
following administration of paracetamol N-acetyl-D-L-methionate.
These findings were consistent with those in healthy subjects. All
other pharmacokinetic variables obtained following administration of
paracetamol N-acetyl-D-L-methionate were not significantly different
from those in the same renal failure patients following adminis¬
tration of paracetamol alone. Therefore the relative bioavail¬
ability, metabolism and elimination of paracetamol administered as
the N-acetyl-D-L-methionine ester were not altered in patients with
chronic renal failure. In particular, the production of the cysteine
and mercapturic acid conjugates were not increased even although
methionine is a glutathione precursor. In contrast to the findings
in healthy subjects, the sulphation of paracetamol was not increased
after administration of paracetamol N-acetyl-D-L-methionate in
patients with chronic renal failure. Inorganic sulphate is retained
in patients with chronic renal failure and this may account for the
absence of saturation of sulphate conjugation following adminis¬
tration of paracetamol alone.
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Mean data obtained in patients with chronic renal failure following
administration of 1 g of paracetamol as 1) paracetamol and 2) para¬
cetamol N-acetyl-D-L-methionate are summarised in Tables 6.11 and
6.12.
In conclusion 2.146 g paracetamol N-acetyl-D-L-methionate may provide
a safer form of paracetamol, however when administered as a single
therapeutic dose to patients with chronic renal failure the pharmaco¬
logical response may be reduced and delayed compared to the equiva¬
lent paracetamol dose. This is less likely to occur with Pameton
(500 mg paracetamol + 250 mg D-L-methionine) which is already avail¬
able commercially. Paracetamol N-acetyl-D-L-methionate does, how¬
ever, offer a tasteless formulation which yields paracetamol and
methionine in equimolar quantities. The effectiveness of Pameton and
paracetamol N-acetyl-D-L-methionate in preventing paracetamol
toxicity remains to be established.
On long term administration of paracetamol N-acetyl-D-L-methionate to
patients with chronic renal failure plasma paracetamol concentrations
would probably be higher than those described in the present study
and there would be gross cumulation of paracetamol metabolites. In
addition the consequences of long term administration of N-acetyl-D-
L-methionine to patients with chronic renal failure is not known and
multiple dose studies should be performed.

















































































































































































































++ =Halflifecalculatedover5-12h * =Significantlyd fferentfrompara etamoladministeredth lthysubj cts;P<0.05
**=Significantlyd fferentfromparacet moladministeredtths mre afailurt e s;P<0.05


















































































































































Paracetamol [acetaminophen, N-acetyl-p-aminophenol, 4-hydroxyacetani-
lide, N-(4-hydroxyphenyl) acetamide] is a non-prescription analgesic
and antipyretic agent.





Soluble in: 70 parts water, 7 parts alcohol, 13 parts acetone,
40 parts glycerol, 9 parts propylene glycol, 50
parts chloroform and 10 parts methyl alcohol.
Insoluble in: Ether, pentane and benzene.
283
APPENDIX 1.1 (continued)
Stability: At pH 6.0 at 25°C, an aqueous paracetamol solution
has a half life of approximately 22 years.
Degradation to acetic acid and p-aminophenol is
accelerated by acidic or alkaline conditions
(Koshy and Lach, 1961). Paracetamol metabolites
in urine stored at -20°C were observed to be










Paracetamol N-acetyl-D-L-methionate (p-acetamidophenyl, 2-carbamoyl,
4-methylthiobutanoate; SUR 2647).
Description: White tasteless powder with a characteristic odour
derived from the N-acetyl-D-L-methionine.
Molecular Weight: 324.4.
Mel ting Point: 184-186°C.
Soluble in: 100 parts methanol, 350 parts ethanol, 300 parts
acetone and 600 parts chloroform.
Insoluble in: Water.
Stability: See Chapter II, Section 3.
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APPENDIX 2.1
Calculation of Factor (F) from Standards
From the standard regression line the concentration in test samples
can be determined. From the regression equation: y = mx + c
ie ratio = slope x concentration + intercept
Therefore: concentration = ratio x 1
slope
The factor (F) represents the reciprocal of the slope of the
regression line for the standards, ie concentration = ratio x F.
Therefore: F = concentration
ratio
(F) can therefore be calculated from the standards as follows. The
example given is that for the plasma paracetamol assay.
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APPENDIX 2.1 (continued)
Paracetamol Peak Area Mean Ratio
Concentration Peak Area Ratio for +_
(pig.ml"1) Ratio 25 pig.ml"1 CVT
25 1.017 1.017
25 1.015 1.015
5 0.204 (x 5) 1.020
5 0.202 (x 5) 1.010
F = concentration = 25 = 24.62
rati0 1.016
1.016 + 0.4%
These principles were applied to all established assays used during
this work. The following mean values for F were obtained over the






Period of Time 1
(Months) 1
1 Plasma Paracetamol 1 5 and 25 24.61 + 2.2 12 I
1 Urinary Paracetamol ! 1000 1.970 + 0.071 12 !
1 Plasma Paracetamol 1
1 N-acetyl-D-L- 1
I Methionate 1
5 and 25 9.733 + 0.205 9 1
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APPENDIX 3.1
Individual Plasma Paracetamol Concentrations In 10 Healthy
Male Subjects Following Ingestion of 1 g of Paracetamol
PIasma Paracetamol Concentration (yg.ml
| Time Subj ect Number
| (h) 1 2 | 3 4 I 5 6 1 7 1 8 1 9 10 |





















































































2.3 | 1 .7
1 1
1 1 »6 1
1 |
2.2 3'7 1




1.6 | 1 .3
1 1
1 1 »1 I
1 |
1 .5 2.0 |








1 .0 1.9 |








0.7 1 .8 j








0.6 1 .2 |








0.5 1 .2 |



















Individual Plasma Paracetamol Sulphate Concentrations In 10 Healthy
Male Subjects Following Ingestion of 1 g of Paracetamol
Results expressed as paracetamol equivalents
Plasma Paracetamol Sulphate Concentration (pg.ml"1)
| Time | Subject Number
I lh> I 1 | 2 1 3 | 4 I 3 | 6 1 7 | 8 I 9 I 10 |







0.0 | 0.0 | 0.0 j 0.0 |







2.9 | 2.1 | 2.1 j 1 .4 |







3.4 | 4.0 | 3.1 j 2.6 j







3."7 j 4.5 j 3.1 j 2.6 |







4.0 j 4.5 | 3.0 j 2.9 j







3.8 j 4.5 | 2.8 | 3.4 |







3.3 j 3.8 | 2.5 j 2.1 |







3.2 j 3.4 | 2.3 | 2.5 |







2.4 j 2.1 | 1 .7 j 2.1 j







2.0 | 1 .9 | 1 .2 | 2.0 |
1 6 1 1.0 | 1.1 | I'4 i 1 .9
I I





1.5 | 1.6 | 1 .0 i 1.3 |
I 7 1 0.9 j 1.0 | 0.8 | 1.4
1 1





1.3 | 1.3 | 0.9 j 1.2 j







1.1 j 1.0 | 0.6 | 1 .1 |







0.9 j 1.1 | 0.8 j 0.9 |







- j 0.8 | 0.8 | 1.0 1







- | 0.6 | 0.6 j 1.2 |







- | - | - | 0.4 |
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APPENDIX 3.3
Individual Plasma Paracetamol Glucuronide Concentrations In 10 Healthy
Male Subjects Following Ingestion of 1 g of Paracetamol
Results expressed as paracetamol equivalents
Plasma Paracetamol Glucuronide Concentration (pig.ml"1)
| Ti me | Subject Number
| (h) | 1 2 3 | 4 5 j 5 1 7 8 I 9 I 10 I







0.0 0.0 j 0.0 | 0.0 |
I 0.25 | 1 .7 2.5 2.7 j 0.3
1 1





1 .2 1 .8 | 1 .6 | 1 -7 I







2.6 4.9 | 4.9 | 3.8 j







4.0 8.4 | 7.2 | 5.2 j







5.0 9.8 | 8.4 j 7.1 |







5.5 13.0 | 8.9 | 8.5 |
I 2 j 6.9 9.7 11.1 | 5.8
1 1





00•in 12.3 | 9.3 | 9.0 |







5.7 12.2 | 9.1 | 8.5 |







4.5 10.0 j 7.0 | 7.4 |







3.7 7.6 | 5.2 | 6.0 |







3.1 5.9 | 4.7 | 5.0 |







2.4 5.5 | 3.5 | 3.9 |







2.2 3.7 | 2.6 | 3.0 j







2.0 3.0 | 2.4 | 2.5 |






1 .7 2.8 | 1 -7 1 2.1 |
I 12 | 0.7 - 1.1 | 1 .0
1 1





0.7 1.5 | 0.8 | 1.5 |







- - | 0.6 | 0.3 |
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APPENDIX 3.4
Urinary Recovery of Paracetamol In Each Sample Following
Ingestion of 1 g of Paracetamol in 10 Healthy Male Subjects
| Time
| (h)
Urinary Recovery of Paracetamol (mg)
Subject Number

































































































Urinary Recovery of Paracetamol Sulphate In Each Sample Following
Ingestion of 1 g of Paracetamol in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol Sulphate (mg)
| Time Subject Number







































51 .0 63.1 |












31 .0 43.8 j






















































Urinary Recovery of Paracetamol Glucuronlde In Each Sample Following
Ingestion of 1 g of Paracetamol in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol Glucuronlde (mg)
j Time Subj ect Number
| (h) | 1 I 2 | 3 1 4 I 5 6 I 7 I 8 I 9 | 10 |










































Urinary Recovery of Paracetamol Cysteine in Each Sample Following
Ingestion of 1 g of Paracetamol in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol Cysteine (mg)
| Time I Subject Number
I <h> i 1 | 2 I 3 | 4 1 5 | 6 I 7 | 8 I 9 1 10 |















0.0 1 0.0 |












1.6 j 2.6 |















3.2 j 6.0 j















2.5 | 5.2 j















1.5 j 1.8 j















0.8 | 2.1 j















- | 1.3 |











- | 2.1 j
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APPENDIX 3.8
Urinary Recovery of Paracetamol Mercapturlc Acid in Each Sample Following
Ingestion of 1 g of Paracetamol in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol Mercapturi c Acid (mg)
| Time Subj ect Number
| Ch) 1 2 I 3 4 1 5 6 1 7 | 8 1 9 1 10 |











0.0 | 0.0 |










4.9 | 3.5 |











9.8 | 9.1 |











7.5 | 7.2 |











3.6 | 2.2 |











2.0 j 2.3 |











1.4 | 1 .8 |









4.6 | 2.1 |
APPENDIX3.9
















































































































































































































































































































Individual Plasma Paracetamol Concentrations in 10 Healthy
Male Subjects Following Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methlonate
| Time
| (h)
Plasma Paracetamol Concentration (ng.ml"1)
Subject Number
1 2 1 3 4 I 3 1 o | 7 1 8 1 9 10 |

































































































































1 1 *5 I
I i
2.9 3'2 I









1 1 -1 1
i i
1.6 2.6 |











1 .0 2.1 |

















































Individual Plasma Paracetamol Sulphate Concentrations In 10 Healthy
Male Subjects Following Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methlonate
Results expressed as paracetamol equivalents
| T1 me
| (h)
Plasma Paracetamol Sulphate Concentration (pg. ml "*)
Subject Number
1 | 2 I 3 | 4 I 5 I 8 1 7 | 8 | 9 1 10 |










0.0 | 0.0 | 0.0 |
| 0.25 - | 1 .3 | 0.2 j 1 .2
I I







2.0 | 0.4 | 1 .1 j










2.8 | 1.9 | 2.2 |










3.5 | 2.2 | 2.6 |










4.1 j 2.4 j 3.6 |










4.9 3.5 | 3.8 |










5.0 3.1 | 4.0 j









4.2 | 2.2 | 3.2 |










3.7 1 .9 | 2.6 |
I 5 1.3 | 2.0 | 2.5 | 4.5
1 1








2.8 | 1 .5 | 2.2 |
I 6 0.7 | 1 .6 j 2.0 | 3.6
I I








2.2 | 1 .4 | 1 .8 |
| 7 0.6 | 1 .1 | 1 .4 | 3.0
I I








1 .8 | 0.8 | 1 .5 j










1 .5 | 0.8 | 1 .2 |










1 .1 | 1 .0 | 1 .0 j









1 .0 | 0.9 | 0.8 j








0.8 | 0.8 | 0.5 |







- | 0.2 | - |
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APPENDIX 4.3
Individual Plasma Paracetamol Glucuronide Concentrations in 10 Healthy
Male Subjects Following Ingestion of 2.146 g of Paracetamol N-AcetyI-D-L-methionate
Results expressed as paracetamol equivalents
| T1 me |
1 (h) |
PIasma Paracetamol Giucuronide Concentration (pg.ml"1)
Subject Number












0.0 0.0 j 0.0 | 0.0 |











1 .0 0.9 j 0.3 | 0.5 |











2.1 2.5 | 1 .4 | 1 .6 |











1.9 4.4 | 2.7 | 2.5 |











3.1 6.5 | 3.9 | 4.2 j











4.4 10.0 | 6.5 | 5.7 j











5.3 11.9 | 7.9 | 7.3 j











6.9 12.5 | 8.1 | 1.9 |











5.4 10.8 | 8.0 | 7.3 |











5.3 9.0 | 6.3 | 6.8 j











3.8 7.2 | 4.6 j 5.1 j











3.3 6.0 j 3.7 j 4.0 |











2.7 4.7 | 2.9 | 3.2 |











2.3 3.5 | 2.4 | 2.5 |











1.9 2.9 | 2.0 | 2.2 |










1.7 2.1 | 1.3 j 1 .4 |











0.7 0.2 | 0.2 j 0.2 |
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APPENDIX 4.4
Urinary Recovery of Paracetamol in Each Sample Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methionate In 10 Healthy Male Subjects
| Time
| (h)
Urinary Recovery of Paracetamol (mg)
Subj ect Number
1 2 3 4 I 5 | 6 I 7 1 8 9 10 |























































































Urinary Recovery of Paracetamol Sulphate In Each Sample Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methlonate in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol Sulphate (mg)
| Time Subject Number











































































































Urinary Recovery of Paracetamol Glucuronlde in Each Sample Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methionate in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol Glucuronide (mg)
[ Time Subject Number
| (h) | 1 I 2 | 3 4 1 5 I 6 | 7 I 8 1 9 1 10 |










































Urinary Recovery of Paracetamol Cysteine in Each Sample Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methionate in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
| Ti me
| (h)
Urinary Recovery of Paracetamol Cysteine (mg)
Subject Number
1 | 2 | 3 4 I 5 I 6 | 7 | 8 | 9 I 10 |















0.0 j 0.0 I













- | - I















3.5 | 5.1 |















3.5 | 4.7 |















2.0 | 4.0 |













1 .2 j 4.2 |














0.6 | 2.5 |









- | - | 0.4 j
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APPENDIX 4.8
Urinary Recovery of Paracetamol Mercapturic Acid in Each Sample Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methionate in 10 Healthy Male Subjects
Results expressed as paracetamol equivalents
| TI me
| (h)
Urinary Recovery of Paracetamol Mercapturic Acid (mg)
Subj ect Number
1 2 1 3 4 I 5 6 1 7 | 8 1 9 10 |






























































1 .3 2.8 j


















































































































































































































































































































Individual Plasma Paracetamol Concentrations in 7 Non-dialysis and
5 Dialysis Patients Following Ingestion of 1 g of Paracetamol
| Time
| (h)
Plasma Paracetamol Concentration (yg.ml"1)
Patient Number
Non- dialysis Dia 1ys s
1 01 1 02 03 04 1 05 | 06 l 07 i 08 1 09 1 010 1 011 | 012 |

























































































































































































Individual Plasma Paracetamol Sulphate Concentrations in 7 Non-dialysis and
5 Dialysis Patients Following Ingestion of 1 g of Paracetamol
Results expressed as paracetamol equivalents
| Time
| (h)
Plasma Paracetamol Sulphate Concentration (jig.ml"1)
Patient Number
Non-dialysis Dialysis
01 02 1 03 | 04 05 | 06 07 08 09 010 011 012 |








0.0 0.0 0.0 0.0 0.0 0.0 |







3.3 4.0 2.2 6.4 - 6.0 j








6.0 9.0 5.2 9.1 6.8 8.4 j








6.0 11.2 6.8 9.9 10.4 9.0 [








7.4 12.8 7.8 10.6 12.5 9.7 [








7.8 13.1 11.8 12.3 15.2 10.9 |








8.2 16.2 13.1 13.5 18.4 11.8 |








8.9 17.5 15.0 14.9 21.9 13.0 [








9.7 18.4 16.2 15.9 23.9 13.9 [








10.0 16.9 16.6 17.4 24.4 15.5 |








10.4 19.5 17.8 17.5 27.9 15.3 |








10.8 20.4 17.9 17.4 29.8 15.3 [








10.4 19.5 18.9 17.9 28.0 15.3 |








10.4 19.6 18.9 17.3 30.1 16.4 |








9.7 19.6 18.9 16.9 28.6 16.4 |








9.3 17.6 18.9 16.9 28.1 15.9 j








8.4 13.5 16.0 15.1 27.6 15.7 |
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APPENDIX 5.3
Individual Plasma Paracetamol Glucuronide Concentrations In 7 Non-dialysis and
5 Dialysis Patients Following Ingestion of 1 g of Paracetamol. Predose Values were
Subtracted to Give Corrected Concentrations
Results expressed as paracetamol equivalents
| Time
| (h)
Plasma Paracetamol Glucuronide Concentration (ug.ml*)
Patient Number
Non-■dial ysis Dia Iys i s
I 01 | 02 1 03 04 | 05 | 06 1 07 | 08 | 09 | 010 011 1 012 |




2.2 | 1 .9 |




- | 1.3 |




- I 4-4 I




2.8 I 7-3 I




3.9 I 9.6 |




5.9 11 3.3 j



















15.2 j 25.1 |














18.4 j 25.8 |



















21 .5 j 28.8 |
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APPENDIX 5.4
Individual Plasma Paracetamol Cysteine Concentrations in 7 Non-dialysis
and 5 Dialysis Patients Following ingestion of 1 g of Paracetamol.
Predose Values were Subtracted to Give Corrected Concentrations
Results expressed as paracetamol equivalents
T i me
(h)
Plasma Paracetamol Cysteine Concentration (pg.ml-1)
Patient Number
Non-dialysis
01 02 03 04 05 06 07
Dialysis





































































































































































































Individual Plasma Paracetamol Mercap+urlc Acid Concentrations In 7 Non-dialysis
and 5 Dialysis Patients Following Ingestion of 1 g of Paracetamol.
Predose Values were Subtracted to Give Corrected Concentrations
Results expressed as paracetamol equivalents
| Time
j (h)
PIasma Paracetamol Mercapturlc Acid Concentration (pg.ml"1)
Patient Number
Non-dlalys s Dialysis




















- | - j 0.021 - 1 - 1
1
1







- | - 1 0.02 j 0.04 j - |
1
1








- | - | 0.021 0.031 - 1
1
1








- | - | 0.02] 0.06] - |
1
- | 0.04 j






























































































































































Urinary Recovery of Paracetamol In Each Sample Following
Ingestion of 1 g of Paracetamol in 7 Non-dialysis Patients
Urinary Recovery of Paracetamo (mg)
T i me Patient Number































































































+ = IncompIete coI Iection
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APPENDIX 5.7
Urinary Recovery of Paracetamol Sulphate in Each Sample Following
Ingestion of 1 g of Paracetamol in 7 Non-dialysis Patients
Results expressed as paracetamol equivalents
| Time
j (h)
Urinary Recovery of Paracetamol Sulphate (mg)
Patient Number
01 02 03 04 05 | 06 07 |















| 4-6 24.7 19.3 21 .7 | 26.8 29.7+|
I
12.6 7.7 j















| 12-24 55.7 58.3 43.0 |113.6 15.7+|
1
50.0 37.3 |
+ = Incomplete collection
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APPENDIX 5.8
Urinary Recovery of Paracetamol Glucuronlde In Each Sample Following
Ingestion of 1 g of Paracetamol In 7 Non-dialysis Patients
Results expressed as paracetamol equivalents
| Time
| (h)
|UrInar y Recovery of Paracetamol Glucuronide (mg)|
Patient Number
I 01 | 02 1 03 | 04 05 06 I 07 |




0.0 0.0 I o.o |




18.1 11.0 I 5.7 |




49.8 28.9 I 17.7 j




45.4+ 28.7 | 18.0 j




44.3 37.0 1 23.1 j




51 .2 14.2 I 21.4 |




43.2 47.2 I 24.4 j




20.5+ 124.1 |101.9 |
+ = Incomplete collection
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APPENDIX 5.9
Urinary Recovery of Paracetamol Cysteine In Each Sample Following
Ingestion of 1 g of Paracetamol In 7 Non-dialysls Patients
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol Cysteine (mg) |
| Time Patient Number
| (h) 01 | 02 | 03 | 04 | 05 | 06 | 07 |










0.0 | 0.0 |









0.4 | - j










1.2 | 0.3 j









1 .6 | 0.4 |










2.1 j 0.5 j










0.9 | 0.6 |










2.7 j 0.5 j









6.7 | 2.0 |
+ = Incomplete collection
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APPENDIX 5.10
Urinary Recovery of Paracetamol Mercapturic Acid In Each Sample Following
Ingestion of 1 g of Paracetamol in 7 Non-dialysis Patients
Results expressed as paracetamol equivalents
TI me
Urinary Recovery of Paracetamol
Mercapturic Acid (mg)
I <h) I Patient Number
01 02 1 03 | 04 | 05 | 06 | 07 |










0.0 | 0.0 |









0.1 | - j
I 2-4 I 5.7 1 .3
1 1








0.7 | - |









1 .1 | - |










1 .4 | - |










0.6 j - |










1 .9 | - |









5.0 | - |
+ = Incomplete collection
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APPENDIX 5.11
Individual Urine Volumes and pH in 7 Non-dialysis Patients
Following Ingestion of 1 g of Paracetamol
I Patient Number
| T1 me I 01 02 03 04 05 06 07 |
| (h) | Vol |








(ml ) | pH
Vol |
(ml ) | pH
Vol |














































































































































































Individual Plasma Paracetamol Concentrations in 7 Non-dialysis and 5 Dialysis
Patients Following Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-Methlonate.
Predose Values were Subtracted to Give Corrected Concentrations
| Time
| (h)
Plasma Paracetamol Concentration (jig.ml"1)
Patient Number
Non- dia Iysis Dia Iysis
I 01 | 02 03 04 | 05 | 06 07 08 09 | 010 | 01 1 | 012 |




0.0 I o-° i




3.8 I 4'6 I
j 0.5 112.1 112.3 7.3 6.4 | 6.9 j 1 2.7 4.7 7.5 7.1
1 1
1 7 »2 1
1 |
7.8 I 6.7 j




8.2 | "7.8 |




8.2 I 9-1 I




8.8 j 10.6 |









9.5 1 7»1 I




7.6 | 5.0 j




4.6 I 3.6 |
1 6 j 2.4 1 3.9 2.6 2.0 | 4.3 | 4.0 3.9 - 1 .7
1 1
| 1 .9 |
1 |
3.1 I 2.8 j
| 7 I 1 -9 | 3.6 2.3 1.5 1 3.4 I 3.4 3.8 - 1 .2
1 1
| 1 .2 |
I |
2.3 I 2*3 I




1 .7 | 1 .8 j




1 .2 | 1 .4 |
1 1° | 1 .0 1 2*1 1 .4 1 .1 | 2.0 I 1 -4 1 .8 - 0.6
I I
I |
1 .0 j 1.3 |
I 12 j 0.7 | 1 .6 1 .0 1 .0 1 I-4 | 1.2 1.4 - -
I I
I |
0.7 | 1.2 |
I 24 | 0.6 j 0.7 0.6 0.6 | 0.5 | 0.6 0.7 - 0.2
I I
! |
0.7 I °-7 I
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APPENDIX 6.2
Individual Plasma Paracetamol Sulphate Concentrations In 7 Non-dialysis and 5 Dialysis
Patients Following Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-Methlonate.
Predose Values were Subtracted to Give Corrected Concentrations
Results expressed as paracetamol equivalents
| Time
| (h)
PIasma Paracetamol Sulphate Concentration (yg.ml"*)
Patient Number
Non-dl al ys 1 s Dialysis
01 | 02 1 03 1 04 | 05 | 06 I 07 j 08 | 09 | 010 01 1 1 012 |















0.0 I 0-0 I









1 - 1 1 '7 | 2.9
1
1
- I 4.6 I















6.8 I 5.6 |







| 4.5 I 9-1
1




8.2 I 6.5 |











1 3.7 j 7.6 | 6.6 1 4.3
1
10.9 I 7*1 I















12.0 I 9 *2 |



























1 7 -5 j 1 4.3 115.0 1 9*3
1
17.5 111.8 |















21 .6 113.9 |















27.9 11 5.5 |


















































































































Individual Plasma Paracetamol Glucuronlde Concentrations In 7 Non-dialysis and
5 Dialysis Patients Following Ingestion of 2.146 g of Paracetamol N-AcetyI-D-L-
Methionate. Predose Values were Subtracted to Give Corrected Concentrations
Results expressed as paracetamol equivalents
| Time
1 (h)
Plasma Paracetamol Glucuronlde Concentration (pg.ml ■*•)
Patient Number
Non-dialys1s Dialysls
1 01 | 02 1 03 | 04 | 05 | 06 1 07 | 08 | 09 I 010 | 011 | 012 |




0.0 I o-o I
j 0.25 | 0.9 | 0.4 j 0.1 | - | - | 0.5 j 1 .0 | 0.3 | 2.0
1 1
1 |
- I 0.7 |




- | 1.5 j




- I 2.6 |
| 1 j 10.0 | 4.6 I 3.2 1 4«1 | 3.0 | 6.7 1 2 '1 j 4.0 j 5.6
1 1
1 4 *3 |
1 |
2.5 I 4 «3 j




3.5 I 7 *5 |


































15.5 j 26.1 |









17.5 j 25 .5 |












Urinary Recovery of Paracetamol in Each Sample Following Ingestion of 2.146 g of
Paracetamol N-Acetyl-D-L-methlonate In 7 Non-dialysis Patients
| Time |
I < h) |
Urinary Recovery of Paracetamol (mg)
Patient Number





1 1 1 1
Trace| - | 0.0 | 0.0 |
1 1 1 1
0.0 |




1 1 1 1
4.4 | - | 7.6 | 9.7 |
1 1 1 1
4.8 |





5.6 | - | 7.5 | 6.1 |
I 1 I 1
- |




1 1 1 1
3.1 | - | - | - |
1 1 1 1
- |




! 1 1 1
i i i I
- |




i i i i
- |
| 10-12 | -
1
1
1 1 1 1
i i i i
- |
| 12-24 | -
1
1
1 1 1 1




Urinary Recovery of Paracetamol Sulphate in Each Sample Following Ingestion of 2.146 g
of Paracetamol N-Acetyl-D-L-methionate In 7 Non-dialysis Patients
Results expressed as paracetamol equivalents
Urinary Recovery of Paracetamol SuIphate (mg) |
| Time Patient Number
| (h) 01 02 03 | 04 | 05 | 06 07 |










































Urinary Recovery of Paracetamol Glucuronide In Each Sarrple Following Ingestion of
2.146 g of Paracetamol N-Acetyl-D-L-methionate in 7 Non-dialysis Patients
Results expressed as paracetamol equivalents
|Urinary Recovery of Paracetamol Glucuronide (mg)|
| TI me 1 Patient Number
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APPENDIX 6.7
Urinary Recovery of Paracetamol Cysteine in Each Sample Following Ingestion of 2.146 g
of Paracetamol N-Acetyl-D-L-methionate in 7 Non-dialysis Patients
Results expressed as paracetamol equivalents
| Ti me
j (h)
Urinary Recovery of Paracetamol Cysteine (mg) |
Patient Number
01 | 02 03 | 04 | 05 | 06 07 I
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Urinary Recovery of Paracetamol Mercapturlc Acid In Each Sample Following Ingestion of
2.146 g of Paracetamol N-Acetyl-D-L-methlonate in 7 Non-dialysis Patients
Results expressed as paracetamol equivalents
| T1 me |
Urinary Recovery of Paracetamol
Mercapturic Acid (mg)
| (h) | Patient Number
01 02 I 03 | 04 | 05 | 06 | 07 |
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APPENDIX 6.9
Individual Urine Volumes and pH in 7 Non-dialysis Patients Following
Ingestion of 2.146 g of Paracetamol N-Acetyl-D-L-methlonate
I Patient Number
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Summary. The disposition of paracetamol following
an oral dose of 1.0 g was compared in 10 healthy vol¬
unteers, 7 patients with moderate chronic renal
failure and 6 patients with end stage renal failure on
maintenance haemodialysis.
Paracetamol absorption was normal in the pa¬
tients with renal failure. The mean plasma half-life of
paracetamol from 2 to 8 h was similar in the 3 groups
(2.1 to 2.3 h) but from 8 to 24 h it disappeared much
more slowly in the renal failure patients (half-life
11.7 compared with 4.9 h in the healthy volunteers).
Plasma concentrations of paracetamol glucuronide
and sulphate conjugates were greatly increased in
the patients with moderate renal failure and the
mean plasma half-lives were 30.5 and 21.8 h respec¬
tively compared with about 3 h in the healthy volun¬
teers. Plasma concentrations of these metabolites
were even higher in the dialysis patients and there
was no significant fall over 24 h. The cysteine and
mercapturic acid conjugates of paracetamol could
only be measured in plasma in the patients with
renal failure and concentrations were very low.
The fractional urinary recovery of paracetamol
and its glucuronide, sulphate, cysteine and mercap-
■turic acid conjugates was similar in healthy volun¬
teers and patients with moderate renal failure. The
=mean renal clearances of paracetamol and its glucu-
=ronide and sulphate conjugates in the healthy volun¬
teers and patients with moderate renal failure were
15.7, 137 and 172, and 5.9, 14.5 and 14.8 ml/min re¬
spectively. In the latter patients the mean renal clear¬
ances of the cysteine and mercapturic acid con¬
jugates were much greater at 35.4 and 80.2 ml/min.
iln the patients with moderate renal failure the
AUC's of the glucuronide and sulphate conjugates
■were related to the plasma creatinine and there were
significant negative correlations with the renal clear¬
ances of these metabolites and total urinary re¬
covery. Marked cumulation of the polar glucuronide
and sulphate conjugates of paracetamol would seem
inevitable in patients with renal failure and the par¬
ent drug is apparently regenerated to a limited extent
from retained metabolites.
Keywords: paracetamol, renal failure; drug disposi¬
tion, polar metabolites, cumulation, pharmacokinet¬
ics
The disposition of drugs is often abnormal in pa¬
tients with chronic renal failure [1-3], and those
which are excreted largely unchanged by the kidney
or converted to active metabolites are usually given
to patients with renal failure in reduced dosage to
avoid cumulation and toxicity [4, 5], However, drugs
which are primarily inactivated by metabolism in the
liver are often continued in full dosage and in such
circumstances marked cumulation of their polar me¬
tabolites is inevitable unless there are alternative
routes of elimination. Under normal conditions
these metabolites may be inactive but at the remark¬
ably high concentrations which must be achieved
during chronic therapy in patients with renal failure
their biological effects are unknown. Such patients
are particularly susceptible to adverse drug reactions
and in some cases unsuspected toxicity may be
caused by cumulation of drug metabolites [6, 7].
Paracetamol (acetaminophen) is one of the most
commonly used drugs and about 90% of a thera¬
peutic dose is normally excreted in the urine in 24 h
as glucuronide, sulphate and glutathione-derived
conjugates [8]. The excretion rate of the glucuronide
and sulphate conjugates is markedly reduced in pa¬
tients with renal failure following paracetamol over¬
dosage [9] while in patients with end-stage renal
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Table 1. Clinical details of patients with renal failure
Patient Weight Age Diagnosis Hb Albumin ALT Bili¬ Alk Creatinine Creatinine Drugs
(kg) (years)/
Sex






1 76.4 46/M CF 16.3 44 17 14 40 334 17 AT
2 77.4 57/M AG, RA 11.9 39 13 4 114 440 23 NF
3 85.3 43/M PK 12.1 47 20 8 67 484 22 MT, BD, PZ
4 83.6 49-'M DB. HT 10.3 41 12 5 % 442 19 MT, NF, PZ, IN
5 68.4 46/M CG 7.6 44 18 5 89 946 HD AT, NF
6 79.5 33/M CG, AN 7.2 45 24 4 128 1127 HD
7 74.5 70/M CG, NE 10.3 23 16 3 119 727 9 NF, MZ, BU
8 64.9 65/M GP 5.5 40 13 4 74 752 HD
9 61 48/F PK 10.7 46 15 3 56 879 5 NF, QD, SB
10 83.1 65/M PK, HT 11.3 43 14 11 59 378 17 NF, MT
11 76.9 39/M CF 6.9 45 22 5 51 760 HD
12 64.7 62/M RA, AM 7.4 37 11 6 46 641 HD MT, BP
13 65.7 60/F CF 4.8 39 12 4 60 1175 HD
HD = Haemodialysis, CF= Chronic renal failure of unknown aetiology, AG = Analgesic nephropathy, AN = Anephric, AM = Amyloido¬
sis, NE = Nephrotic syndrome, CG = Chronic glomerulonephritis, DB=Diabetes, GP= Goodpasture's syndrome, HT= Hypertension,
PK = Polycystic kidneys, RA = Rheumatoid arthritis. AT= Atenolol, BD= Bendrofluazide, BP= Buprenorphine, BU = Bumetanide,
IN = Insulin. MT= Metoprolol. MZ = Metolazone, NF= Nifedipine, PZ = Prazosin, QD =Quinidine, SB = Salbutamol
failure the elimination of these metabolites is greatly
impaired and haemodialysis appears to be the major
route for their removal from the body [10,11], We re¬
port detailed studies of the disposition and kinetics
of paracetamol and its polar metabolites in patients
with moderate to severe impairment of renal func¬
tion.
the next 3 h and received 200 ml ofwater every 2 h up
to 12 h. The usual diet was resumed 4 h after dosing.
Blood was sampled at frequent intervals for 24 h and
except in the haemodialysis patients (who produced
little or no urine), divided urine collections were made
over the same period. In the latter patients the study
was carried out on a day preceding dialysis.
Methods, Patients and Subjects
Eleven men and 2 women with chronic renal impair¬
ment were studied. Their mean age was 53 (11) years
and their body weight was 74 (8) kg. Seven had
moderate to severe renal failure but were not being
treated with dialysis, and 6 with more advanced dis¬
ease were receiving long-term haemodialysis 2 or
3 times a week. Their clinical details are summarized
in Table 1. Ten healthy male volunteers with a mean
age of 29 (7) years and body weight 72 (11) kg served
as controls. They did not take drugs regularly or
smoke and they denied excessive regular consump¬
tion of ethanol. Physical examination was normal as
were liver function tests, haemoglobin and plasma
urea and creatinine concentrations estimated by
standard automated methods. The study was ap¬
proved by the local Ethics Committee and all pa¬
tients and volunteers gave informed consent.
Drug Analysis
Paracetamol and its glucuronide, sulphate, cysteine
and mercapturic acid conjugates in plasma and urine
were assayed by high performance liquid chroma¬
tography using UV detection. Electrochemical detec¬
tion was also used for low concentrations ofparaceta¬
mol and cysteine and mercapturic acid conjugates in
the presence of potentially interfering peaks [12].
Variable blank values were obtained in some patients
with renal failure and these were subtracted to give
corrected concentrations. In Patient 7 paracetamol
sulphate could not be measured in urine because of
interference. The amount excreted was therefore esti¬
mated from the relative areas under the plasma con¬
centration time curves of the glucuronide and sul¬
phate conjugates and the urinary recovery of
glucuronide assuming that both metabolites had the
same renal clearance and volume of distribution.
Drug Administration and Sampling
After an overnight fast, the patients and volunteers
took 1.0 g ofsoluble paracetamol in 200 ml ofwater at
approximately 08.30 h. They remained recumbent for
Data Analysis
The plasma half-life (ti/2) of paracetamol and its me¬
tabolites was determined from the log-linear phases of
the concentration-time curves by weighted linear re-
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Time (h)
Fig.l. Mean plasma concentrations of paracetamol and its glucu-
ronide and sulphate conjugates in 10 healthy volunteers following
an oral dose of 1.0 g
gression and the area under the curve (AUC) was esti¬
mated by the trapezoidal method. Renal clearance in
the healthy volunteers and patients with moderate
renal failure was calculated by dividing the amount re¬
covered in the urine by the corresponding AUC. The
"SIPHAR"' modeling and parameter estimation pro-
=gramme was used for compartmental and model-in-
dependent analysis of the plasma paracetamol and
■metabolite concentration data. To obtain the volumes
of distribution (V) of the glucuronide and sulphate
-conjugates in the patients with moderate renal failure,
■the "dose" of conjugate was taken as the amount
■formed from the administered dose of paracetamol
<1.0 g x the fractional 24-h urinary recovery of the me¬
tabolite). Vz was calculated as total clearance/!) and
"Vss as the product of the clearance and mean residence
■time. It was assumed that the absorption of paraceta-
■mol was complete and that there was no extra-renal
■loss of the conjugates.
Results are given as means (SD) and metabolite
concentrations are expressed as paracetamol equi¬
valents. Differences between means were compared
+>y the Mann-Whitney test or non-parametric anal¬
1 Centres d'Etudes et de Recherches en Statistiques et Informati-
.que Medicaies, Creteil, Cedex-France
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Time (h)
Fig. 2. Mean plasma concentrations of paracetamol and its glucu¬
ronide and sulphate conjugates in 7 patients with moderate renal
failure following an oral dose of 1.0 g




Paracetamol was rapidly absorbed in the healthy
volunteers and renal failure patients with mean peak
plasma concentrations of 20.0 and 17.9mg-l_1 oc-
curing on average at 0.35 and 0.5 h respectively after
administration. The mean plasma half-life from 2 to
8 h was similar in the volunteers, patients with
moderate renal failure and dialysis patients (2.2 (0.3),
2.3 (0.5) and 2.1 (0.4) h). However, after 8 h there
were significant differences between the groups
(Figs. 1-3). Paracetamol continued to disappear
rapidly from 8 to 24 h in the healthy volunteers with
a mean half-life of 4.9 (2.1) h while low levels persist¬
ed in the renal patients and the corresponding half-
life in both renal groups combined was 11.7 (5.2) h
(p= <0.001). As a result, the total AUC for parace¬
tamol was greater in the renal patients than in the
healthy volunteers (Table 2) and there was a highly
significant difference in the area from 8 to 24 h
(12.4 compared with 6.7 mg ■ 1 ~1 • h, p = < 0.005).
359





Fig. 3. Mean plasma concentrations of paracetamol and its glucu-
ronide and sulphate conjugates in 6 patients with end-stage renal
failure on maintenance haemodialysis following an oral dose of
1.0 g
Table 2. Mean plasma half-life (h) from 8 to 24 h and area under
the plasma concentration-time curve (AUC, mg • 1 ~1 • h) from 0 to
24 h for paracetamol and its glucuronide and sulphate conjugates





tt/2 AUC t,/2 AUC tl/2 AUC
Healthy




patients 11.0(5.3) 63 (12) 30.5 (40.7) 431 (157) 21.8(15.2) 232 (108)
Dialysis
patients 12.7(5.5) 57(15) - 671 (204) - 438 (101)
a 4 to 12 h
Table 3. Mean maximum plasma concentration (Cmax, mg-1-1)
of paracetamol and its glucuronide and sulphate conjugates, and
the time to peak concentrations (tmax, h) in healthy volunteers and













patients 17.3 (8.2) 0.54(0.44) 25.2(8.9) 6.0(1.6) 13.7 (5.9) 5.6(1.5)
Dialvsis
patients 18.6(4.7) 0.46(0.29) 31.4(7.4) 13.8(8.5) 20.8 (6.5) 8.3 (1.2)
Plasma Concentrations ofParacetamol Conjugates
The plasma concentrations of the glucuronide and
sulphate conjugates of paracetamol were greatly
elevated in the patients with moderate renal failure,
and were even greater in the dialysis patients
(Figs. 1-3). There were corresponding highly signifi¬
cant increases in the mean AUC with more than 10-
and 20-fold increases for glucuronide and sulphate
respectively in the dialysis patients (Table 2). The
mean peak plasma concentrations of glucuronide
and sulphate (Cmax) and the time to reach peak con¬
centrations (tmax) were significantly increased in the
renal patients with the greatest increase in those on
dialysis (Table 3).
The elimination of the glucuronide and sulphate
conjugates was very slow in the patients with moder¬
ate renal failure and the mean plasma half-lives were
30.5 and 21.8 h compared with 2.9 and 3.5 h respec¬
tively in the healthy volunteers (p= <0.001,
Table 2). There was gross retention of these metabo¬
lites in the dialysis patients with no significant fall in
concentrations up to 24 h (Fig.3). In the patients
with moderate renal failure there were significant
correlations between the plasma creatinine concen¬
tration and the AUCs of the glucuronide and sul¬
phate conjugates (r = 0.91 and 0.84, p= <0.02).
The cysteine and mercapturic acid conjugates
could not be measured in plasma in the healthy vol¬
unteers and concentrations were low in the patients
with renal failure. Cysteine conjugate concentrations
were consistently higher than those of the mercap¬
turic acid conjugate and it disappeared slowly in
both groups of renal patients. In the dialysis patients
there was no significant fall in plasma mercapturic
acid conjugate concentrations up to 24 h (Fig. 4).
Renal Excretion ofParacetamol and Metabolites
In the healthy volunteers a mean of 82.5% of the ad¬
ministered dose of paracetamol was recovered in the
urine in 24 h. The mean recovery in the patients with
moderate renal failure was 56.9% (range 30-86%)
and there was a significant negative correlation with
the plasma creatinine concentration (r=—0.77,
p = <0.05). There were no important differences be¬
tween the groups in respect of the fractional urinary
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In the patients with moderate renal failure the
renal clearances of the glucuronide and sulphate
conjugates were greatly reduced (mean 14.5 and
14.8 ml • min~1 versus 137 and 172 ml ■ min-1 respec¬
tively in the healthy volunteers), and were inversely
related to the plasma creatinine concentration
(r = —0.87 and —0.84, p— <0.02). In contrast, the
decrease in renal clearance of unchanged paraceta¬
mol in these patients ws proportionately much small¬
er (Table 5) and there was no significant correlation
with plasma creatinine or creatinine clearance. As
expected, the renal clearance of paracetamol was
correlated with the urine flow rate (r = 0.96,
p= <0.01) and there was no such relationship with
the glucuronide and sulphate conjugates.
The renal clearances of the cysteine and mercap-
turic acid conjugates in the patients with moderate
renal failure were surprisingly high (Table 5) and
greatly exceeded the creatinine clearance in every
case.
Distribution Volumes of the Glucuronide and
Sulphate Conjugates
The volumes of distribution of the glucuronide and
sulphate conjugates were similar. The respective
mean values for Vz and Vss were 0.24 (0.05), 0.28
(0.04), 0.27 (0.06) and 0.29 (0.06) 1-kg"1.
Discussion
The absorption of paracetamol appeared to be nor¬
mal in the patients with renal failure but there were
major abnormalities in other aspects of its disposi-
Table 4. Mean 24-h urinary recovery of paracetamol and its major metabolites in healthy volunteers and patients with moderate renal
failure
Fractional urinary recovery %
Paracetamol Glucuronide Sulphate Cysteine Mercapturate % of dose
conjugate conjugate conjugate conjugate recovered
in 24 h
Fiealthy volunteers 4.1 (1.4) 60.7 (7.5) 28.1 (5.1) 3.0(1.7) 4.1 (1.7) 82.5 (6.1)
Moderate renal
failure patients 2.4(1.1) 61.0(6.8) 30.8 (6.1) 3.0 (0.9) 2.8(1.4) 56.9(17.1)
Table 5. Renal clearance (ml ■ min ') of paracetamol and its conjugates in healthy volunteers and patients with moderate renal failure
Paracetamol Glucuronide Sulphate Cysteine Mercapturic 24-h urine
conjugate conjugate conjugate acid conjugate volume (I)
Fiealthy volunteers 15.7 (6.0) 137 (31) 172 (39) _ _ 1.81 (0.69)
Moderate renal
failure patients 5.9 (2.5) 14.5 (6.6) 14.8(7.6) 35.4 (45) 80.2 (45) 2.08 (0.64)
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tion. Not only were the glucuronide and sulphate
conjugates retained as expected, but the elimination
of paracetamol itself was also impaired. The rate at
which it disappeared from the plasma during the
first 8 h was virtually identical in the healthy volun¬
teers and patients with renal failure but in the latter
low concentrations persisted after this time and the
half-life from 8 to 24 h was greatly prolonged. The
healthy volunteers were younger than the renal pa¬
tients and thus not ideal controls, but it is most un¬
likely that these differences could be related to fac¬
tors other than renal disease.
After rapid oral absorption or bolus intravenous
administration, paracetamol normally disappears
from the plasma in 3 distinct phases. Distribution is
largely complete in 1 to 1.5 h, and the log-linear de¬
cline from 2 to about 8 h is normally used to calcu¬
late the elimination half-life of the drug. However,
after 8 h there is a third phase of slower disappear-
Fig.4. Mean plasma concentrations of cysteine and mercapturic
acid conjugates of paracetamol following an oral dose of 1.0 g in
7 patients with moderate renal failure not on dialysis and 6 pa¬
tients on regular haemodialysis
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ance in which the half-life is increased to 4 to 5 h
[13]. This late elimination phase was greatly ex¬
tended in the patients with renal disease and
possible rate-limiting mechanisms include slow
transfer of residual drug from peripheral tissues
back to the circulation and augmented enterohe-
patic circulation of paracetamol conjugates with re¬
generation of the parent drug. The latter is more
likely since similar unexpected impairment of elimi¬
nation of drugs such as oxazepam, diflunisal and
clofibric acid has been described in patients with
chronic renal failure [14-16]. Like paracetamol,
these drugs are extensively metabolized by glucu-
ronide conjugation. In patients with renal failure
there may be enterohepatic circulation of the re¬
tained glucuronide conjugates with regeneration of
the parent drug by hydrolysis and subsequent reab-
sorption [3]. This effect is probably greatest with
drugs which form labile ester glucuronides [17].
Paracetamol is converted to a more stable ether glu¬
curonide which is normally excreted into bile to
only a limited extent [18]. Although the residual
plasma concentrations of paracetamol observed in
the present single dose study were low and clinically
insignificant, higher concentrations might be ex¬
pected with the extensive cumulation of conjugates
which would occur during long-term treatment in
patients with severe renal failure.
The overall metabolic fate of paracetamol in the
patients with moderate renal failure and the healthy
volunteers was similar as judged by the fractional
urinary recovery of the drug and its major metabo¬
lites. In particular, the recovery of glutathione-
derived conjugates was not increased and there was
no evidence of enhanced conversion to potentially
toxic metabolites. In the patients with moderate
renal failure the renal clearances of paracetamol
glucuronide and sulphate were greatly reduced and
correlated with the plasma creatinine concentration.
In contrast, the renal clearance of unchanged
paracetamol was unrelated to the plasma creatinine
and in proportion it was reduced much less than the
renal clearances of the conjugates. Indeed, the mean
renal clearance of paracetamol was within the nor¬
mal range of 5 to 20ml-min~1, and as in healthy
subjects its clearance (but not those of the glucu¬
ronide and sulphate conjugates) was dependent on
the urine flow rate [8]. The polar glucuronide and
sulphate conjugates are excreted primarily by active
tubular secretion but the renal clearance of parace¬
tamol depends on glomerular filtration with exten¬
sive passive tubular reabsorption [9, 19]. The strik¬
ingly disproportionate decrease in the clearance of
the conjugates implies much greater reduction in
the capacity for active tubular transport than for
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passive reabsorption. It is also possible that compe¬
tition or saturation of tubular transport by retained
endogenous anions contributes to the very low
clearance of the conjugates in patients with renal
failure.
Plasma concentrations of the cysteine and mer-
capturic acid conjugates were very low and the dis¬
appearance of the former in the haemodialysis pa¬
tients indicates a route of elimination other than
renal excretion. In the patients with moderate renal
failure the renal clearances of both metabolites were
considerably greater than the glomerular filtration
rate, raising the possibility of their formation from
precursors in the kidney. The findings are consistent
with renal acetylation of cysteine to form the mer-
capturic acid conjugate. The volumes of distribution
of the individual glucuronide and sulphate con¬
jugates of paracetamol have not been reported pre¬
viously. Similar values of about 0.27 ml-kg-1 were
obtained for both conjugates in the patients with
moderate renal failure, and these are of the same
order as reported previously for the two metabolites
combined [9, 11].
The glucuronide and sulphate conjugates of
paracetamol appear to be eliminated almost entirely
by renal excretion, and marked cumulation would
occur with continued use of the drug in patients with
renal failure. Predictions based on the clearance of
these metabolites by haemodialysis [10] indicate that
the average maximum plasma concentrations of glu¬
curonide and sulphate conjugates would exceed 500
and 400mg-l_1 respectively during regular therapy
with 1 g of paracetamol 4 times daily in patients with
end stage renal disease on twice weekly maintenance
haemodialysis. Further studies with multiple doses
should be carried out in patients with renal disease
and similar cumulation may be expected with other
drugs that are extensively converted to polar me¬
tabolites which depend on renal excretion for their
removal from the body.
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